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Abstract 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, encoded by Hsd11b1) is an 
enzyme that predominantly converts inactive glucocorticoids (cortisone in human 
and most mammals, 11dehydro-corticosterone in mice and rats) into their active 
forms (cortisol and corticosterone, respectively). Thus 11β-HSD1 amplifies intra-
cellular levels of glucocorticoids. Studies in globally 11β-HSD1 deficient mice have 
revealed changes in glucocorticoid-regulated physiological and pathological 
processes, including metabolism, aging, arthritis and angiogenesis. The function of 
macrophages, which play an important role in inflammation, is also altered. For 
example, 11β-HSD1 deficiency in macrophages causes a delay in their acquisition of 
phagocytic capacity.  To dissect the role of macrophage 11β-HSD1 in angiogenesis, 
arthritis and obesity, both in vitro macrophage stimulation and in vivo functional 
assays in macrophage-specific 11β-HSD1 knockout mice, were conducted. 
Thioglycollate-elicited peritoneal macrophages from globally 11β-HSD1 deficient 
and control C57BL/6 mice were used for in vitro studies. In M1/M2 macrophage 
polarisation experiments, 11β-HSD1 deficient macrophages showed increased 
expression of mRNAs encoding pro-inflammatory factors upon lipopolysaccharide 
and interferon-ϒ treatment and decreased expression of pro-resolution genes with 
interleukin-4 stimulation. However, at cytokine or protein levels, there was little 
difference between the genotypes except for decrease IL12 p40 levels in 11β-HSD1 
deficient macrophages. Hypoxic stress failed to show differences between genotypes 
in hypoxia-regulated gene expression. These data do not support a strong role for 
macrophage 11β-HSD1 in inflammation regulation, nor in response to hypoxia, at 
least when measured in vitro. The discrepancy between transcriptional and 
translational responses is currently unexplained, but may reflect altered post-
transcriptional activity.  
To investigate the role of macrophage 11β-HSD1 in vivo, macrophage-specific 
Hsd11b1 knockout mice, LysM-Cre Hsd11b1
flox/flox 
(MKO) mice and Hsd11b1
flox/flox 
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littermate controls were generated. In MKO mice, 11β-HSD1 protein levels and 
enzyme activity were reduced by >80% in resident peritoneal macrophages. However, 
11β-HSD1 protein and enzyme activity levels were unchanged or only modestly 
reduced in thioglycocollate-elicited peritoneal neutrophils, monocytes/macrophages, 
or in bone marrow-derived macrophages, despite >80% decrease in Hsd11b1 mRNA 
levels in these cells. A relatively long half-life of 11β-HSD1 protein compared to that 
of circulating myeloid cells may underlie this mismatch between transcriptional and 
translational expression. Furthermore, following 12 days of inflammatory arthritis 
induced by K/BxN serum transfer, the reduction in 11β-HSD1 protein levels in 
circulating neutrophils of MKO mice is consistently around 50%, which corroborates 
the above explanation.  
MKO mice and littermate controls were subjected to inflammatory models which 
may involve resident macrophages. First, to address the role of 11β-HSD1 in 
macrophages in angiogenesis, sponge implants were inserted subcutaneously into the 
flanks of adult male mice and harvested after 21 days. Chalkley counting on 
hematoxylin and eosin stained sponge sections showed significantly increased 
angiogenesis in MKO mice (scores: 5.2±1.0 versus 4.3±0.7; p<0.05, n=9-11). Cdh5 
expression (encoding VE-cadherin, a marker of endothelial cells) was higher in 
sponges from MKO mice (relative expression: 1.5±0.9 versus 0.8±0.6; p<0.05), as 
was Il1b (encoding IL-1 beta, a marker of inflammation, relative expression: 6.5±6.4 
versus 1.5±0.9; p<0.05). Vegfa mRNA (encoding vascular endothelial growth factor 
alpha) was unchanged, with a trend for higher Angpt1 (encoding angiopoietin 1, 
p=0.09) expression levels in the MKO group. These results suggest that lack of 11β-
HSD1 in resident macrophages increases their pro-angiogenic activity, independently 
of VEGF-.   
The K/BxN serum transfer model of arthritis was used to investigate the role of 
macrophage 11β-HSD1 in arthritis. Adult male MKO and control mice received a 
single i.p. injection of 125μl K/BxN serum per mouse, followed by 21 days of 
clinical scoring to assess joint inflammation. The onset of inflammation (d1-8) was 
similar between MKO and control mice, but MKO mice exhibited greater clinical 
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inflammation scores in the resolution phase of arthritis (d13-21; area-under-the-curve: 
86.6±14.7 versus 60.1±13.4; p<0.005), indistinguishable from globally 11β-HSD1-
deficient mice. Hematoxylin and eosin staining revealed pronounced fibroplasia 
predominantly in the supporting mesenchyme associated with the tenosynovium, 
with new bone and blood vessel formation. These results suggest that macrophage 
11β-HSD1 deficiency is fully accountable for the worse arthritis resolution 
phenotype in the globally 11β-HSD1 deficient mice, but not the earlier onset of 
inflammation with global 11β-HSD1 deficiency. 
Macrophage activation states are closely linked with adipose insulin sensitivity. 
Globally 11β-HSD1 deficient mice are protected from high fat diet induced insulin 
resistance and adipose tissue hypoxia and fibrosis. To study the effect of macrophage 
11β-HSD1 deficiency on insulin sensitivity, adult male MKO and control mice were 
given a 14 week high fat diet, which typically causes insulin resistance in control but 
not globally 11β-HSD1 KO mice. The level of fibrosis in subcutaneous adipose 
tissues was reduced as indicated by quantification of picrosirius red staining of 
collagen, though GTT data so far does not support protection from insulin resistance 
in MKO mice.  
In summary, in vitro macrophage polarisation experiments do not support a strong 
role of 11β-HSD in M1/M2 macrophage polarisations or response to hypoxia. 
However, MKO mice reveal, for the first time, an important in vivo role of 
macrophage 11β-HSD1 to promote angiogenesis and facilitate resolution of K/BxN 
serum transfer induced arthritis. Modulation of fibrosis is context dependent. 
Reduced adipose fibrosis may be one of the mechanisms that improve insulin 
sensitivity. Meanwhile, these findings suggest caution regarding the potential side 
effects of 11β-HSD1 inhibitors in treating metabolic disease in patients with 
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Chapter 1: Introduction  1 
Chapter 1:  Introduction 
Cortisone, a natural but intrinsically inert glucocorticoid was discovered in the 
middle of the 20
th
 century and is one of the most useful drugs to suppress 
inflammation. However, its efficacy was subsequently revealed to be dependent on 
an enzyme called 11β-hydroxysteroid dehydrogenase type 1,which converts the inert 
cortisone into active cortisol (reviewed by (Chapman, Holmes et al. 2013)). More 
than half a century later, glucocorticoids remain one of the most widely prescribed 
anti-inflammatory drugs and efforts to elucidate the anti-inflammatory mechanisms 
continues, including studies on the role of endogenous glucocorticoids. The theme of 
this thesis is to dissect the role of reactivation of endogenous glucocorticoids by 11β-
hydroxysteroid dehydrogenase type 1 in macrophages, in modulating inflammation 
development. 
 
1.1 Inflammation and tissue homeostasis 
1.1.1 Inflammation and immune cells 
Inflammation was described by Cornelius Celsus in as early as the 1
st
 century AD in 
his treatise De medicina. The four cardinal signs of inflammation were described as: 
rubor et tumor cum calore et dolore (redness and swelling with heat and pain; 
reviewed by (Medzhitov 2010)). In the 19
th
 century, with only a microscope to study 
inflammatory tissues, Julius Cohnheim observed vasodilation, leakage of plasma, 
and migration of leukocytes out of blood vessels and into the surrounding tissues 
(reviewed by (Majno 2004)). Functio laesa (disturbance of function), was added as 
the fifth cardinal sign by Rudolph Virchow in 1858 (reviewed by (Majno 1975)). 
According to the duration of the symptoms, inflammation can be classified into acute 
and chronic forms. Acute inflammation usually resolves within days to weeks, with 
restoration of normal tissue function, while chronic inflammation, such as 
rheumatoid arthritis, causes long lasting damage to tissues (reviewed by (Ryan and 
Majno 1977; Medzhitov 2010)).  
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The modern study of inflammatory mechanisms began in the late 19th century; 
Robert Koch and Louis Pasteur introduced the germ theory of diseases to explain a 
major cause of inflammation. Later, Elie Metchnikoff discovered that some blood 
cells, macrophages and microphages (neutrophils) are able to phagocytose micro-
organisms, a beneficial aspect  of inflammation (reviewed by (Tauber 2003)). 
Phagocytes are found in both plants and vertebrates as the ‘first line’ cells of host 
defence and are appreciated as innate immune cells. Emil von Behring and 
Shibasaburo Kitasato discovered serum therapy against diphtheria and tetanus toxins 
in 1890, which led to early development of the humoral immunity theory (reviewed 
by (Medzhitov 2010)). Serum antibodies were found to be produced by B cells with 
the help of T cells in the middle of the 20th century. B and T cells are adaptive 
immune cells, found only in vertebrates.  
Humoral immunity explained the long lasting immunity against some infections. But 
the puzzle of how innate immune cells were linked with adaptive immune cells was 
not solved until the 1990s. Bruce A. Beutler and Jules A. Hoffmann discovered toll-
like receptors (TLRs) and uncovered their roles in the recognition of micro-organism 
components. At a similar time, Ralph M. Steinman discovered the ability of dendritic 
cells to present antigens to T cells. Their works was honoured by the 2011 Nobel 
Prize in Physiology or Medicine (2011). The hemogenesis of immune cells is 














Figure 1-1 Hemogenesis of bone marrow derived immune cells.  
‘White blood cells’ are immune cells, which are generated along the myeloid and lymphoid 
lineages in the bone marrow. Macrophages and neutrophils are the main innate myeloid cells 
and T and B cells are the main adaptive lymphoid cells. Image 
Hematopoiesis_(human)_diagram.png by A. Rad was obtained from Wikimedia Commons 
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1.1.2 Different types of inflammatory response  
Ruslan Medzhitov proposed that inflammation comprises four components: 
inflammatory inducers, sensors in immune cells, the inflammatory mediators 
produced by immune cells and the affected target tissues (Medzhitov 2010) 
(inflammation resolution was not included). Different inflammatory inducers trigger 
different inflammatory responses. Bacterial products such as lipopolysaccharide 
(LPS) are sensed by TLR4 on macrophages, which then produce inflammatory 
cytokines, such as tumour necrosis factor (TNF) alpha, interleukin (IL) -1, IL-6 and 
chemokines. These products can directly induce blood vasodilation and elicit 
neutrophils, as well as induce liver production of acute phase reaction proteins, such 
as C-reactive protein. Viral infection induces production of type-I interferons (IFN-α, 
IFN-β) in infected cells, whereas parasitic worms induce mast cells and basophils to 
produce histamine, IL-4, IL-5, and IL-13.  
The signalling in sterile inflammation, such as tissue injury, is less understood. Dead 
cell products, such as ATP, high-mobility group box 1 (HMGB1), DNA, heat shock 
proteins, etc., may be the inflammatory inducer (reviewed by (Chen and Nunez 2010; 
Medzhitov 2010; Shen, Kreisel et al. 2013)). Inflammasome activation to generate Il-
1β revealed by genetic studies in humans is one of the most intensively studied 
pathological signalling pathways and it plays an important role in lots of clinical 
autoinflammatory diseases, such as  familial cold autoinflammatory syndrome, 
Muckle-Wells syndrome, neonatal-onset multisystem inflammatory disease 
(reviewed by (Masters, Simon et al. 2009)). 
According to the patterns of lymphokine production, two types of murine helper T 
cell clones were reported in 1986 (Mosmann, Cherwinski et al. 1986).  The different 
populations of helper T cells were later found during in vivo studies. In viral 
infection, Th1 cells are induced to exert cellular cytolytic activity by production of 
inflammatory cytokines, like TNF-α and IFN. In parasitic infection, Th2 cells 
produce IL-4, 5, and 13, to stimulate B cell generation of immunoglobulin (Ig) G and 
IgE. Th2 responses are linked to the allergy response (reviewed by (Constant and 
Bottomly 1997)). Similar to Th1/Th2, there is the M1/M2 macrophage nomenclature 
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based on in vitro experiments, though macrophages in vivo are highly heterogeneous 
and frequently do not confine to the M1/M2 classifications (detailed description in 
Section 1.2.2). 
Like the sterile inflammation mentioned above, the inflammatory inducers are not 
always clear for in vivo inflammatory models. Models used in the studies described 
in this thesis will be briefly discussed below. Thioglycollate induced sterile 
peritonitis is often used to elicit large quantities of myeloid cells, especially 
macrophages. The sensor for thioglycollate remains elusive. In this model, 
neutrophils are first recruited and their number peaks between 4-24h, followed by 
accumulation of macrophages peaking on day 3 or 4 (Van Furth, Diesselhoff-den 
Dulk et al. 1973). The macrophage peak accumulation is dissociated from the peak 
production of inflammatory mediators on day 1 (Lam, Harris et al. 2013).  
High fat or high cholesterol diet feeding is usually conceived to be associated with 
development of low-grade inflammation. Again, there is no clear pathway that 
describes how lipid or cholesterol induces immune cell activation and whether the 
inflammation is dominated by hepatocytes and adipocytes or the infiltrating immune 
cells needs further clarification. Microarray of cholesterol loaded macrophages (foam 
cells) surprisingly showed decreased inflammatory gene expression profiles (Spann, 
Garmire et al. 2012). The primary inflammatory response to lipid may come from 
adipocytes, which could recognize lipid by TLR4 and secrete inflammatory 
cytokines in response (Pal, Dasgupta et al. 2012).  
In the K/BxN serum transfer model of inflammatory arthritis, the serum anti-glucose-
6-phosphate isomerase (anti-G6PI) antibody forms immune complexes when injected 
into naïve mice and the immune complexes are sensed by FcϒIIIR receptor in 
myeloid cells (Binstadt, Patel et al. 2006). A subsequent lipid-cytokine-chemokine 
cascade leads to accumulation of neutrophils, and the arthritis resolution is likely to 
be dependent on macrophage clearance of apoptotic neutrophils (Elliott, Van Ziffle 
et al. 2011; Sadik and Luster 2012).  
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1.1.3 Inflammation resolution, angiogenesis and fibrosis in 
the tissue repair process  
The beneficial side of inflammation to clear debris and infection was first 
appreciated by Metchnikoff in his discovery of macrophage (Metchnikoff 1892). 
However, in the other side of the inflammation ‘coin’, tissue damage usually happens 
as a ‘trade-off’. For example, reactive oxygen species generated by neutrophils can 
induce DNA damage (van Berlo, Wessels et al. 2010). Chronic low-grade 
inflammation without a clear (but possibly persistent) stimulus accompanies a large 
number of diseases, including atherosclerosis, obesity, type 2 diabetes mellitus and 
Alzheimer’s disease (reviewed by (Nathan and Ding 2010; Aguzzi, Barres et al. 
2013; Odegaard and Chawla 2013; Swirski and Nahrendorf 2013; Tabas and Glass 
2013)). To restore normal tissue homeostasis, effective inflammation resolution is 
required, the mechanism of which is still poorly understood. Cytokines IL-4, IL-10, 
transforming growth factor beta (TGF-β), endogenous glucocorticoids and lipoxins 
are able to suppress inflammation (reviewed by (McMahon and Godson 2004; 
Medzhitov 2010)). Accumulating evidence suggests that apoptotic cells induce an 
anti-inflammatory response (Fadok, Bratton et al. 1998; Ren, Xie et al. 2008; Miles, 
Heaney et al. 2012). 
Angiogenesis and fibrosis are usually induced by inflammatory tissue damage, which 
may further perpetuate inflammation development. Both angiogenesis and fibrosis 
occur in response to hypoxic conditions in tissue injury, under control of the 
transcription factors, hypoxia induced factors (HIFs). To facilitate tissue repair, HIFs 
upregulate expression of metabolic proteins (GLUT-1), soluble growth factors (TGF-
β and vascular endothelial growth factor (VEGF)) and extracellular matrix 
components (type I collagen and fibronectin) (reviewed by (Walshe and D'Amore 
2008; Lokmic, Musyoka et al. 2012)). 
Angiogenesis is a process of new capillary formation from pre-existing vessels. In 
this process, inflammatory cells secrete pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor, angiopoietins, 
TNF-α, nitrogen oxide (NO) and IL-1β, to stimulate endothelial cell mitosis and 
migration (Costa, Incio et al. 2007). It can be beneficial to restore tissue 
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homoeostasis, for example providing oxygen and nutrition by re-vascularisation in 
ischemic areas.  However, it is deleterious and facilitates inflammation development 
in other situations, such as promotion of synovitis in rheumatoid arthritis (Szekanecz, 
Besenyei et al. 2010).  
To repair the injury caused by inflammation and maintain tissue integrity, cytokines 
such as TGF-β activate fibroblasts and transform them into smooth muscle actin 
positive (SMA+) myofibroblasts, which then secret collagens to maintain tissue 
intactness (Lee and Kalluri 2010). After tissue repair, these myofibroblasts usually 
become apoptotic (Wynn and Ramalingam 2012). Persistence of myofibroblasts in 
tissues can lead to fibrosis. In addition, activated fibroblasts were shown to play an 
important role in supporting inflammation development, by secreting inflammatory 
cytokines, like IL-6 and IFNs (reviewed by (Flavell, Hou et al. 2008). The source of 
myofibroblasts remains unclear and has been mainly attributed to bone marrow 
derived fibrocytes and endothelial-mesenchymal transition (Hinz and Gabbiani 
2010). However, a number of fate mapping studies have suggested that local vessel 











Chapter 1: Introduction  8 
1.2 Macrophages  
1.2.1 Macrophage origin and differentiation 
As the first discovered immune cells, macrophages have been extensively studied for 
over 100 years. They can be broadly divided into tissue-resident macrophages and 
infiltrating inflammatory macrophages. The former group includes liver Kupffer 
cells, brain microglia, lung alveolar macrophages, peritoneal macrophages, splenic 
red pulp macrophages and bone marrow resident macrophages. Tissue resident 
macrophages are conceived to be sentinels for tissue patrolling to clear cell debris 
and sense tissue injury (Soehnlein and Lindbom 2010). Infiltrating macrophages 
arise in pathological situations. They differentiate from blood monocytes, and 
accumulated evidence has shown that classical monocytes (also known as 
“inflammatory” or Ly6C
hi 
monocytes) are the source of infiltrating macrophages 
found in pathological settings, such as in cancer, atherosclerosis, and metabolic 
diseases (reviewed by (Hashimoto, Chow et al. 2013)).  
The origin of tissue resident macrophages has been debated. Until recently, it was 
though that they originated from bone marrow derived Ly6C
low 
‘patrolling’ 
monocytes, amid suggestions of a different origin. For example, resident peritoneal 
macrophage density is normal in mice lacking C-C chemokine receptor type 2 
(CCR2, the receptor for the monocyte chemo-attractant protein (MCP)1), despite 
defects in monocyte infiltration of these mice (Kuziel, Morgan et al. 1997). Tissue 
resident macrophages in mice have recently been revealed to derive from the yolk 
sac during embryo development, and they are maintained independently of 
hematopoietic stem cells (Schulz, Perdiguero et al. 2012). Tissue resident 
macrophages can divide in response to Th2 inflammation (Jenkins, Ruckerl et al. 
2011), in contradiction to the paradigm that macrophages are terminally 
differentiated cells that cannot divide. Gene array analysis of tissue resident 
macrophages shows heterogeneous gene expression signatures in different 
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1.2.2 Classic and alternative macrophage polarizations  
Similar to the Th1/Th2 nomenclature, classically activated macrophages (M1) and 
alternatively activated macrophages (M2) were defined by Siamon Gordon during in 
vitro experiments with bone marrow derived macrophages (reviewed by (Mantovani, 
Sica et al. 2005)). M1 macrophages, usually activated by IFN-γ and/or LPS, are 
mainly microbicidal, characterized by high production of inflammatory cytokines 
and chemokines (such as IL-1, IL-6, TNF-α, IFN-ϒ and CCL2), as well as reactive 
oxygen species and NO. M2 macrophages, in contrast, are induced by Th2 cell 
products like IL-4, IL-13, IL-10 or apoptotic cells or glucocorticoids, with high 
expression levels of YM1, FIZZ1 and arginase 1 (reviewed by (Varin and Gordon 
2009)). They are associated with resolution of inflammation, angiogenesis and 
fibrosis (reviewed by (Gordon and Martinez 2010)). The M1/M2 polarisation scheme 
is summarized in Figure 1-2.  
Based on in vitro experiments, M2 macrophages can be sub-divided into 3 
categories: IL-4/13-stimulated M2a cells, IL-1R+TLR-stimulated M2b cells and 
glucocorticoid-activated M2c cells (reviewed by (Mantovani, Sica et al. 2004)). 
Different to M2a and M2c, there is also a high inflammatory response in M2b cells, 
in addition to the common anti-inflammatory features of M2 macrophages 
(Mantovani, Sica et al. 2004). Actually, monocyte-derived macrophages are very 
plastic to stimuli during in vitro experiments and exhibit high differentiation 
heterogeneity. It is further proposed that macrophage polarisation state is best 
described as in a full spectrum (Mosser and Edwards 2008; Geissmann, Gordon et al. 
2010; Gordon 2012). 
It should be noted that the M1/M2 macrophage nomenclature does not correspond to 
the classifications of recruited and tissue resident macrophages. Macrophage 
polarisation experiments are usually carried out in monocyte derived macrophages, 
while tissue resident macrophages are generally shown to be important for 
inflammation resolution. For example, 12/15 lipoxygenase which is enriched in 
peritoneal resident, but not recruited macrophages, generates pro-resolution lipoxins 
that mediate phagocytosis of apoptotic neutrophils (Uderhardt, Herrmann et al. 
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2012). Even for bone marrow derived macrophages, so far, there is no direct in vivo 
evidence to separate the two distinct populations of macrophages which regulate 
different physiological processes. Heterogeneous macrophage gene expression 
profiles (a mixture of both M1 and M2) are found during either wound repair or 
tissue fibrosis (Duffield, Forbes et al. 2005; Daley, Brancato et al. 2010; Novak and 





Figure 1-2 Classical (M1) and alternative (M2) Macrophage polarisation.  
The respective stimuli to induce M1/M2 polarisations are shown at the top of the picture, 
with related transcription factors in the middle, and characteristic products/markers at the 
bottom of the picture. Adapted from (Lawrence and Natoli 2011). 
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1.2.3 Macrophages in tissue repair 
Inflammation is accompanied by tissue remodelling, such as angiogenesis and 
fibrosis, as introduced in section 1.1.3. So far, of all the immune cells, macrophages 
are considered the main regulators of tissue remodelling. In physiological situations, 
macrophages are essential to many tissue developmental processes, such as bone 
morphogenesis, ductal branching, neuronal patterning and vascular patterning 
(reviewed by (Pollard 2009; Wynn, Chawla et al. 2013)). Macrophages are also 
extensively and actively involved in pathological situations as introduced below. 
The interest of macrophages in situations of pathological angiogenesis probably 
stems from observations of tumour associated macrophages in supporting tumour 
growth and metastasis (Sunderkotter, Steinbrink et al. 1994; Lin, Li et al. 2006). 





promote angiogenesis (De Palma, Venneri et al. 2005). TIE2 is the angiopoietin 
receptor and NRP1 is a receptor for specific class 3 semaphorins and VEGF isoforms 
(Kawamura, Li et al. 2008). The presence of this subset of macrophages was later 
described in healthy mouse blood and developing embryos (Pucci, Venneri et al. 
2009).  Their role is to stimulate fusion of activated endothelial tip cells to form new 
circuits from existing blood vessel networks (Fantin, Vieira et al. 2010). Apart from 
tumour angiogenesis, they are also important for angiogenesis in ischaemic situations 
(Patel, Smith et al. 2013). In an in vitro angiogenesis model of aortic ring assay, 
macrophages play a non-redundant role, as they are ‘rich sources’ of pro-angiogenic 
factors such as TNF-α, IL-6, IL-1, VEGFα and angiopoiten 1. (Ligresti, Aplin et al. 
2011). But macrophages are also able to suppress angiogenesis, mediated through the 
Wnt-Flt1 pathway to inhibit VEGF signalling (Stefater, Lewkowich et al. 2011). 
The important role of macrophages in fibrosis during tissue repair was recognised as 
early as the 1970s. Depletion of monocytes/macrophages, with combined systemic 
glucocorticoid and local anti-macrophage serum treatment, impaired wounding 
healing with delayed fibroblast recruitment and activation (Leibovich and Ross 
1975). From separate studies of liver fibrosis and wound healing in CD11b-DTR and 
LysM-Cre/iDTR mice, where macrophages can be specifically depleted by 
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administration of diphtheria toxin, macrophages were shown to promote fibrosis 
development and wound healing (Duffield, Forbes et al. 2005; Goren, Allmann et al. 
2009; Lucas, Waisman et al. 2010). The functions of macrophages in fibrosis include 
phagocytosis of cell debris, secretion of TGF-β and platelet derived growth factor 
(PDGF) to activate mesenchymal stem cells, expression of arginase activity to 
generate proline for collagen synthesis, as well as production of matrix 
metalloproteinase (MMPs) to degrade extracellular matrix in tissue remodelling 
(Wynn and Barron 2010). 
It is of note that there are also suggestions that lack of resident macrophages and 
recruiting neutrophils doesn’t impair wound healing, with normal wound healing in 
myeloid cell deficient PU.1
-/- 
mice on antibiotics (Martin, D'Souza et al. 2003). Thus, 
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1.3 Glucocorticoids  
1.3.1 History of glucocorticoid discovery 
In the 1930s, Dr Tadeus Reichstein in Switzerland first isolated 25 steroid 
compounds from the adrenal cortex and shared the results with Dr Edward Kendall at 
the Mayo Clinic in the United States. After chromatographic separation of the 
steroids, Dr. Kendall decided to characterise 5 of the compounds named A-E, the 
chemical structures of which were published simultaneously and independently by 
him and Drs. Reichstein and Pfiffner (Mason, Myers et al. 1936; Reichstein 1936; 
Wintersteiner and Pfiffner 1936). These compounds were later revealed as the 
following chemicals: Kendall's compound A, 11-dehydrocorticosterone; Kendall's 
compound B (Reichstein's substance H), corticosterone; Kendall's compound C 
(Reichstein's substance C), 5α-pregnane-3α,11β,17α,21-tetrol-20-one; Kendall's 
compound D (Reichstein's substance A), 5α-pregnane-3β,11β,17α,20β,21-pentol; 
Kendall's compound E (Reichstein's substance F), cortisone, and Kendall's 
compound F (Reichstein's substance M) is cortisol. 
Dr. Philip Hench at the Mayo Clinic, who had been long interested in the observation 
of an adrenal hormone ‘X’, likely to relieve rheumatoid arthritis (RA), pioneered the 
use of the newly discovered ‘E’ (cortisone) in RA patients. The first patient, Mrs 
Gardner, a 29 year old woman with severe RA, was injected with compound E on 
21st of September 1948 and showed a ‘miraculous’ cure (Hench, Slocumb et al. 
1950; Slocumb, Polley et al. 1950). Dr Philip Hench received the Nobel Prize in 
1950 for this clinical application, together with Dr. Tadeus Reichstein and Edward 
Kendall.  
Since then, a variety of synthetic glucocorticoids (GCs), have gained widespread use 
in the treatment of various inflammatory diseases, including hydrocortisone (cortisol, 
a natural GC) (Peterson and Murray 1952), prednisone (Oliveto 1959), prednisolone 
(Arthur 1958), methylprednisolone (Sebek and Spero 1959), triamcinolone (Seymour 
and Allen 1957), betamethasone (David, Wendler et al. 1962), dexamethasone 
(Georges, Roland et al. 1961), fluodrocortisone (Spero, Magerlein et al. 1958), 
fluticasone (H, M et al. 1982) and budesonide (Brattsand, Af Ekenstam et al. 1975) 
 
Chapter 1: Introduction  14 
including RA, asthma and autoimmune diseases such as systemic lupus 
erythematosus (reviewed by (Joanny 2011)).  
 
1.3.2 Physiological regulation of endogenous glucocorticoids  
Endogenous GCs are synthesised and secreted from the zona fasciculata-reticularis 
of the adrenal cortex, under the control of hypothalamic-pituitary-adrenocortical 
(HPA) axis activity. Integration of numerous neural and humoral signals by the 
hypothalamus leads to release of corticotrophin-releasing hormone (CRH) and 
arginine vasopressin (AVP) from the hypothalamic paraventicular nucleus (PVN) 
into the portal vessels, to reach the anterior pituitary gland. This triggers ACTH 
release and production of its precursor pro-opiomelanocortin (POMC). Following 
release of ACTH into the circulation, it reaches the adrenal cortex and binds with 
melanocortin receptor type 2 to stimulate GC synthesis (reviewed by (McEwen, 
Biron et al. 1997)). The HPA axis is negatively regulated by circulating GC, which 
reduces CRH and ACTH secretion from the hypothalamus and anterior pituitary 
gland, respectively (reviewed by (Gomez, De Kloet et al. 1998)).  
There is a circadian rhythm in the secretion of GCs, with a peak in the morning and 
nadir in the evening in humans, opposite to that in nocturnally active mammals, such 
as mice (reviewed by (Dickmeis 2009)). GCs are secreted in a pulsatile manner, and 
this is determined to be in an hourly pattern in rats, with alternating phases of 
activation and inhibition, accompanied by shuttle of glucocorticoid receptor (GR) 
between nucleus and cytoplasm (Lightman, Wiles et al. 2008). 
In the circulation, in addition to weak binding to albumin, more than 90% 
cortisol/corticosterone is bound to corticosteroid binding globulin (CBG), which is a 
glycoprotein secreted by the liver with poor affinity for inert forms of GCs and 
aldosterone (Funder, Feldman et al. 1973).  CBG is a substrate of the elastase 
released from inflammatory neutrophils and after cleavage, CBG releases more than 
80% of the bound GC (Hammond, Smith et al. 1990) and this may act as GC ‘local’ 
delivery mechanism by inflammatory neutrophils. CBG binding with GC is an 
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important control of GC availability, as only free GC can diffuse through the lipid 
membrane of cells. In CBG deficient mice, total corticosterone levels were reduced 
by 50% but with a 10-fold increase in the free fraction of the hormone (Petersen, 
Andreassen et al. 2006). However, GCs are also subject to trafficking by cell 
membrane GC transporters such as multidrug resistance protein 1 (MDR1, ABCB1) 
and ABCG1, which can export GCs out of cells and may actively regulate 
intracellular levels of GC (Webster and Carlstedt-Duke 2002; Nieuwenhuis, Luth et 
al. 2009).   
 
1.3.3 GCs in inflammation 
Synthetic GCs have been widely used to treat inflammatory diseases since their 
initial success in RA patients, but the role of endogenous GCs in inflammation has 
been less studied. Early evidence supporting a role for endogenous GCs to suppress 
inflammation includes the higher mortality rate in adrenalectomised mice or mice 
treated with the glucocorticoid receptor (GR) antagonist RU486, upon challenge with 
endotoxin treatment or infection (Bertini, Bianchi et al. 1988; Hawes, Rock et al. 
1992). Higher lethality was also observed in macrophage-specific GR knockout mice 
in response to LPS stimulation (Bhattacharyya, Brown et al. 2007) and in T cell 
specific GR knockout mice in response to parasite infection  (Kugler, Mittelstadt et 
al. 2013).  
In contrast, the effects of synthetic GCs have been well documented. They have 
many effects on immune cells during inflammation. Generally, GCs modulate 
immune cell functions by decreasing activation and promoting differentiation of pro-
resolution phenotypes (summarized in Figure 1-3). GCs promote neutrophilia by 
increasing neutrophil mobilization from the bone marrow and reducing neutrophil 
extravasation from blood vessels by down-regulating adherence molecule expression 
on endothelial cells (Mishler and Emerson 1977; Jilma, Voltmann et al. 1997; Jilma, 
Stohlawetz et al. 1998). GCs also delay neutrophil apoptosis, in contrast to the 
apoptosis-inducing effects in most other immune cells such as eosinophils, mast cells 
and T lymphocytes (Cox 1995; Meagher, Cousin et al. 1996; Saffar, Ashdown et al. 
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2011). GCs suppress pro-inflammatory gene expression in macrophages, induce an 
anti-inflammatory M2 polarization of blood monocytes (Ehrchen, Steinmuller et al. 
2007) and increase the phagocytosic ability of macrophages (Giles, Ross et al. 2001). 
Mast cell degranulation is decreased by GCs, which is linked to the anti-allergic 
effect of GCs (Zhou, Liu et al. 2008). GCs also suppress dendritic cell functions, 
such as migration, differentiation and antigen presentation (Moser, De Smedt et al. 
1995). In terms of the effect of GCs on adaptive immune cells, GCs decrease Th1 
and promote Th2 development (Ashwell, Lu et al. 2000). Decreased IgG production 
from B cells by GC treatment was reported, but this is still debated (Baschant, Lane 
et al. 2012).  
To dissect the main effective immune cells for the anti-inflammatory effects of GCs, 
tissue specific GR knockout mice have been used in inflammatory models. This has 
revealed that the effective immune cell populations for inflammation suppression by 
GC are context dependent. While T cell GR is found to be important for GC in 
experimental autoimmune encephalomyelitis and collagen induced arthritis, myeloid 
cell GR is important for GC suppression of inflammation in a contact skin allergy 
model (Tuckermann, Kleiman et al. 2007; Wust, van den Brandt et al. 2008; 
Baschant, Frappart et al. 2011). Pharmacological targeting of GC to myeloid cells 
showed strong anti-inflammatory effects compared to systemic orally administrated 
GC, which confirmed the importance of GC action in myeloid cells (Metselaar, van 
den Berg et al. 2004; Ulmansky, Turjeman et al. 2012). Because inflammation 
models used in this thesis predominantly involve myeloid cells, more information 
about GCs and macrophages is introduced below.  
Although the effects of GCs are generally known to be anti-inflammatory, it is 
reported that low dose GC (0.1nM corticosterone) can increase inflammatory 
responses in macrophages ((Lim, Muller et al. 2007)). Anti-inflammatory effect of 
GCs on macrophages during TLR4 mediated inflammatory response is specifically 
dependent on inhibition of p38 MAPK, but not PI3K/Akt, ERK, or JNK 
(Bhattacharyya, Brown et al. 2007). Another function of GC related to inflammation 
resolution is augmentation of macrophage phagocytosis, associated with high levels 
of active Rac and partially mediated through an IL-10–dependent induction of the 
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Gas6/MerTK pathway (Giles, Ross et al. 2001; Zizzo, Hilliard et al. 2012). 
Macrophage migration inhibitory factor is an endogenous factor counteracting anti-
inflammatory effects of GC, inhibition of which may potentate anti-inflammatory 
actions of GC (reviewed (Flaster, Bernhagen et al. 2007)). 
 
 
Figure 1-3 Effects of GCs on immune cells.  
GCs modulate both innate and adaptive immune cell activity, usually shifting them from 
activated to pro-resolution states to restore homeostasis. Please refer to the above text for 
detailed description. Adapted from 2 publications (Perretti and D'Acquisto 2009; Baschant, 
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1.3.4 GCs in metabolism 
As suggested by the name glucocorticoid (glucose-corticoid), GCs are important in 
energy metabolism. Although GCs can stimulate insulin secretion from pancreas 
during feeding, their main function is to counteract the anabolic effect of insulin. 
Insulin stimulates fast uptake and non-oxidative metabolism of glucose in liver, 
muscle and adipose tissue, and simultaneously inhibits glycogenolysis and 
gluconeogenesis during feeding. In contrast, in stress, such as pro-longed fasting or 
exercise, GCs increase lipolysis in skeletal muscle and adipose tissue, reduce glucose 
uptake in muscle and fat and increase gluconeogenesis in the liver to increase blood 
glucose levels (reviewed by (Vegiopoulos and Herzig 2007)).  
The importance of GC in metabolism is evident in conditions of either GC deficiency 
or excess: Addison’s disease and Cushing’s syndrome, respectively. In Addison’s 
disease (caused by autoimmunity against the adrenal cortex, inherited GC synthesis 
deficiency or pituitary disease), impaired GC action leads to chronic fatigue, weight 
loss and hypoglycemia. In Cushing’s syndrome (caused by pituitary adenomas, 
ectopic ACTH-producing tumours or long term administration of synthetic GCs), 
excess GC action causes central obesity, reduced skeletal muscle mass, 
hyperglycemia, dyslipidemia, hypertension, hepatic steatosis and insulin resistance 
(reviewed by (Rose, Vegiopoulos et al. 2010)). 
In the liver, during stress situations, GCs increase expression of key enzymes in 
gluconeogenesis such as phosphoenolpyruvate carboxykinase (PEPCK) (Friedman, 
Yun et al. 1993). Mice specifically deficient of hepatocyte GR exhibit profound 
hypoglycemia after prolonged fasting (Opherk, Tronche et al. 2004). GCs also 
increase serum VLDL-triglyceride (TG) levels and hepatic lipid accumulation, 
probably due to down-regulation of genes involved in hepatic TG lipolysis and β-
oxidation of fatty acids, as well as an up-regulation of fatty acid uptake and storage 
(reviewed by (Macfarlane, Forbes et al. 2008)).  
GCs are suggested to play different roles in white adipose tissue from different 
depots. This is reflected in the fat redistribution characterisation of Cushing’s 
syndrome, with about a 2- and 5-fold increase in abdominal subcutaneous and 
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visceral fat, respectively but with reduced limb subcutaneous adipose tissue 
(Mayosmith, Hayes et al. 1989). During in vitro experiments, it was shown that GCs 
cause lipolysis in subcutaneous adipose tissues by inducing hormone-sensitive lipase 
and reducing lipoprotein lipase activity, whereas in visceral adipose tissue, GCs 
promote pre-adipocyte differentiation and induce lipogenic gene expression 
(Gaillard, Wabitsch et al. 1991; Slavin, Ong et al. 1994).  
In muscle and adipose tissue, GCs blunt insulin-stimulated glucose uptake, insulin 
signalling, GLUT4 translocation and glycogen synthase activation (Buren, Lai et al. 
2008). In the muscle, GCs are implicated in muscle protein degradation by induction 
of the muscle-specific ubiquitin E3 ligase, Murf1, and inhibition of protein synthesis 
by inducing an mTORC1 inhibitor protein REDD1 (reviewed by (Rose, Vegiopoulos 
et al. 2010). 
 
1.3.5 Receptors for glucocorticoids, GR and MR 
Soon after the success in treating RA with cortisone in 1950s, it was found that there 
are 2 receptors for endogenous GCs, now known as glucocorticoid receptor (GR, the 
type II GC receptor) and mineralocorticoid receptor (MR, the type I GC receptor). 
MR is ancestral to GR (Bridgham, Carroll et al. 2006). GR and MR show 90% 
identity in their DNA binding domains and 56% identity in the ligand binding 
domains (Arriza, Weinberger et al. 1987). In terms of ligand binding, MR has about 
10-fold higher affinity than GR for GCs (Reul, Gesing et al. 2000). MR expression is 
confined to classical aldosterone target tissues, such as the kidney, colon, and 
salivary glands, and is modestly expressed in vascular tissues, adipocytes and 
specific immune cell populations including macrophages. In contrast, GR expression 
occurs at higher levels and in a wider range of tissues (reviewed by (Chapman, 
Holmes et al. 2013)). Activated GR and MR exert different functions. For example, 
GR and MR mediate opposing actions on the survival of hippocampal granule cells, 
partly explained by opposite changes in the ratios of pro- and anti-apoptotic gene 
expression (Almeida, Conde et al. 2000). In macrophages, while activation of GR 
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induces anti-inflammatory M2c macrophages, activation of MR promotes 
inflammatory M1 macrophage polarization (Usher, Duan et al. 2010). 
Like MR (NR3C2), GR (NR3C1) belongs to the nuclear receptor superfamily. In 
humans, the GR gene is on chromosome 5 (Gehring et al., 1985) and comprises 9 
exons, spread over ~124kb. The protein structure can be divided into an N-terminal 
transactivation domain (containing activation function 1, AF1, similar to all nuclear 
receptors), a DNA binding domain, a hinge region and a C-terminal ligand binding 
domain (containing AF2, similar to all nuclear receptors). There are a number of GR 
mRNA splice variants (GR-α, β, ϒ) arising from alternative splicing and there are 
different translational start sites of GR α. Thus, there is a complex group of GR 
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Figure 1-4 Schematic representation of the human GR gene structure, GR mRNA and 
GR protein structure. 
(A) There are 9 exons in the GR gene. (B) Transcriptional splice variance in exon 9 
generates GRα and GRβ (GRϒ not depicted in the figure). (C) From different translational 
start sites, GRα is translated into GRA and GRB (translational forms GRC1-3 and GRD1-3 
(Revollo and Cidlowski 2009) not depicted in the figure). (D) Full length GR protein can be 
divided into 4 domains: N-terminal transactivation region (NTD), a pair of zinc-finger motifs 
comprising the DNA binding domains (DBD), the hinge region (HR) and the C-terminal 
ligand binding domain (LBD). AF1 and AF2 are in the NTD and LBD respectively. 
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1.3.6 Genetic regulation by GR 
GC action can be divided into genomic effects (requiring binding of GR to DNA, 
resulting in changes of gene transcription) and non-genomic effects (occurring at the 
cell membrane, within minutes of GC administration, too rapidly to be attributed to 
effects on gene transcription). The underlying mechanism of the latter is still poorly 
understood, with a plausible role for GR (Perretti and D'Acquisto 2009). It is 
reported that around 2% of the genome is transcriptionally controlled by GCs 
(Reddy, Pauli et al. 2009). 
In the absence of ligand, GR is normally retained in an inactive state by a complex 
containing chaperone proteins, including heat shock protein (HSP) -70 and HSP-90 
(reviewed by (Muzumdar, Tasic et al. 2007)). Following binding of GC, the ligand-
receptor complex dissociates from the HSP complex and translocates into the 
nucleus. The outcome is transactivation or transrepression, with the mechanism of 
the latter still under debate as described below. 
It has been generally conceived that the anti-inflammatory effects of GCs are 
dependent on transrepression while the adverse metabolic effects of GCs arise from 
transactivation of metabolic genes. However, recent evidence has shown that there 
are a number of GC activated genes encoding anti-inflammatory factors, such as IL-
10, β-adrenergic receptor, IL-1-receptor antagonist, tristetraprolin, dual-specificity 
protein phosphatase 1 (DUSP1) and annexin A1 (reviewed by (Clark 2007; 
Vandevyver, Dejager et al. 2013)). Tristetraprolin can reduce inflammatory 
signalling post-transcriptionally by aiding degradation of inflammatory mRNAs with 
adenosine and uridine rich elements in the 3’ UTR region. These elements are also 
found in many genes repressed by GCs (Carrick, Lai et al. 2004; Ishmael, Fang et al. 
2008). DUSP1, also known as mitogen-activated protein kinase (MAKP) 
phosphatase 1, dephosphorylates and inactivates MAPKs (such as LPS activated p38, 
JNK and ERK), which negatively controls inflammation. DUSP1 induction by GC 
(Tchen, Martins et al. 2010) controls a subset of inflammatory gene expression, 
evidenced by impaired anti-inflammatory effect of GCs, worse experimental arthritis 
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in DUSP1 knockout mice (Abraham, Lawrence et al. 2006; Vattakuzhi, Abraham et 
al. 2012). 
Similar to other nuclear receptors, the AF1 and AF2 regions of GR, where 
phosphorylation and recruitment of other co-factors such as p160, CBP/p300, RNA 
Pol II, SRC1, SRA RNA occur, are important to control GR activity (Freedman 
1999; Leo and Chen 2000). More and more co-factors are revealed to cross-talk with 
GR including histone H3 lysine-9 methyltransferase G9a and the mediator 
component MED14 (Bittencourt, Wu et al. 2012; Bolt, Stossi et al. 2013). More 
specifically to GR, dimerization of the DBD has been extensively studied and 
suggested to be crucial for GR function, supporting stable GR-DNA complex 
formation as described below. Mutation of AF1, AF2 or the GR dimerization 
interface in the DBD all affects GR-DNA binding, but the binding affinity is not 
found to be linked to control of gene regulation (Meijsing, Pufall et al. 2009).   
It used to be thought that transactivation and transrepression can be dissociated by 
mutation of the GR dimerization interface in the DBD. In this theory, transactivation 
was through homodimers of GR binding to glucocorticoid response elements (GRE, 
consensus: 5-GGT ACA NNN TGT TCT-3) in the cis-regulatory regions of target 
genes, while transrepression was mediated by direct GR and DNA interaction at 
negative GRE or composite GRE sites, or by indirect GR and DNA interaction via 
tethering with other transcriptional factors, such as AP-1, NF-κB (Diamond, Miner et 
al. 1990; Dahlman-Wright, Wright et al. 1991). The DBD intersubunit contact was 
thought to be crucial for functional stable GR homodimer binding with DNA. By 
changing one amino acid in the DBD region of GR (GR
dim
), this intersubunit contact 
can be abolished. In this way, from both in vitro and in vivo studies, it was argued 
that that ablation of GR homodimer formation abolished the transactivation while 
maintaining the transrepression function (Heck, Kullmann et al. 1994; Reichardt, 
Kaestner et al. 1998).   
This theory has met with a number of challenges recently. First, the GR
dim
 mutant 
can still bind with GRE DNA probes and transactivation of some genes is intact in 
mice homozygous for a ‘knock-in’ GR
dim
 mutation (e.g. PNMT). From this, it is 
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reasoned that GR dimerization is necessary for transactivation of genes containing a 
simple inverted repeat GRE, such as TAT or MMTV, but is not necessary for genes 
containing different arrangement of GRE half sites such as PNMT (Liu, Wang et al. 
1996; Adams, Meijer et al. 2003).  It has been reasoned that a higher order of GR 
complex for transactivation may form between possible links over the N-terminus or 
C-terminus of GR, in addition to the well-established dimerization interface in the 
DBDs. Although most evidence suggests GR
dim/dim
 mice are less protected from 
inflammation by GC treatment, there are also studies showing a normal 
immunosuppressive response to GCs in them, for example in a model of irritative 
skin inflammation (reviewed by (Vandevyver, Dejager et al. 2013). Second, in a 
large scale genomic GR binding chip-sequencing and gene array experiment, most of 
GR binding sites were devoid of GRE sequences resembling the consensus GRE 
motif. In fact, GRE motif is present in only ~20% of both GC up-regulated and 
down-regulated genes in LPS treated macrophages (Uhlenhaut, Barish et al. 2013). 
GR is found to exclusively occupy accessible chromatin in dexamethasone treated 
hepatocytes, most of which are ‘pre-programmed sites’ occupied by liver enriched 
transcription factor, CCAAT/enhancer binding protein (C/EBP) β (Grontved, John et 
al. 2013). This suggests selective targeting of GR in other tissues is likely mediated 
by the combined action of cell-specific priming proteins and chromatin remodellers 
Third, tethering is not always associated with transrepression, according to the 
observation of the frequent proximity of GR binding sites with sites of AP-1, NF-kB, 
and/or GRIP1 binding at both induced and repressed inflammatory enhancers 
(Uhlenhaut, Barish et al. 2013). A simplified updated GR transactivation and 
transrepression model is depicted in the figure below (Figure 1-5). Other models 
explaining transrepression via prevention of transcription factor binding to DNA 
include competitive GR binding to the DNA, sequestration of GR and competitive 
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Figure 1-5 Different models of transcriptional gene control by GR.  
(A) At a ‘simple’ GRE site, the GR homodimer binds to an inverted repeat of 2 GRE half-
sites to activate gene expression. GR homodimer can bind with negative GRE to mediate 
transrepression (not depicted here). (B) In genes with multiple GRE or half GRE sites, GR 
monomer or multimers bind to an array of GRE half-sites to activate gene expression.  (C) In 
genes with composite GRE sites, GR together with other transcriptional factors bind DNA to 
activate or repress gene expression. (D) In genes without GRE or half GRE sites, GR can 
also indirectly control gene expression by tethering with other transcriptional factors to 
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1.3.7 Interaction between hedgehog signalling and 
glucocorticoid 
Hedgehog signalling was first discovered in Drosophila embryonic development, in 
which mutation of Hh gene causes the short and “spiked” phenotype of the cuticle of 
Drosophila larvae (Nusslein-Volhard and Wieschaus 1980). Genes in this pathway 
were gradually discovered and Hh ortholog genes were found in the vertebrates as 
well,  expanding to Desert Hedgehog (Dhh), Indian Hedgehog (Ihh), and Sonic 
Hedgehog (Shh) groups (Echelard, Epstein et al. 1993). Hedgehog signalling plays 
lots of functions in cell growth, survival and fate decision (reviewed by (Varjosalo 
and Taipale 2008)). One of them is to control tissue patterning in development, such 
as lung branching (Pepicelli, Lewis et al. 1998), chondrocyte differentiation 
(Kobayashi, Soegiarto et al. 2005) and neural development (reviewed by (Dessaud, 
McMahon et al. 2008)). It is also involved in lots of pathological changes, such as 
fibrosis (Philips, Chan et al. 2011; Horn, Palumbo et al. 2012), Warburg effect 
(Teperino, Amann et al. 2012)and heterotopic ossification (Ruiz-Heiland, Horn et al. 
2012; Regard, Malhotra et al. 2013).     
A schematic picture describing the signalling pathway is shown in Figure 1-6. 
Basically, when there are no hedgehog ligands, the Gli transcriptional factors are 
sequestered in the tips of primary cilium and processed for degradation. Upon 
binding of hedgehog ligands with the receptor Patched in receiving cells, 
Smoothened (SMO) translocates into the tip of primary cilium. Subsequently, Gli 
transcriptional factors are released and translocate into the nucleus to drive gene 
expressions, such as Cyclin D, Cyclin E and Myc. For detailed information, please 
refer to some review papers (Wilson and Chuang 2010; Hui and Angers 2011; 
Ingham, Nakano et al. 2011). 
In recent years, evidence showing interaction between glucocorticoid and hedgehog 
signalling emerges. Glucocorticoid may bind with Smo. Initially, it is discovered that 
select glucocorticoid compounds activate hedgehog pathway, beneficial for neural 
repair (Wang, Lu et al. 2010; Wang, Barak et al. 2011). However, a large scale 
screen shows that the effects of glucocorticoid compounds on hedgehog signalling 
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varies; some lead to hypersensitivity while others cause inhibition of hedgehog 




Figure 1-6 Schematic hedgehog signalling pathway. 
When there are no hedgehog ligands, cells are on the off-state, with Gli transcriptional 
factors sequestered in the tips of primary cilium and processed for degradation. In the on 
state, upon binding of hedgehog ligands with the receptor Patched in receiving cells, 
Smoothened (SMO) translocates into the tip of primary cilium. Subsequently, Gli 
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1.4 11β-HSD1  
1.4.1 11β-hydroxysteroid dehydrogenases 
Cortisol is the main form of GC in humans and most vertebrates, with about 5% of 
total circulating GCs being corticosterone, whose biological significance in humans 
is still under debate (Peterson 1957; Nishida, Matsumura et al. 1977; Raubenheimer, 
Young et al. 2006). The inert 11-keto derivates of cortisol and corticosterone, 
cortisone and 11dehydro-corticosterone respectively, are also present in the 
circulation. In mice and rats, there are only corticosterone and 11-
dehydrocorticosterone, which is due to the absence of 17 alpha-hydroxylase in the 
adrenal gland.  
Co-existence of these active and inactive GCs results from interconversion by 11β-
hydroxysteroid dehydrogenase enzymes (11β-HSDs), of which there are 2 isozymes: 
11β-HSD1 and 11β-HSD2 (reviewed by (Seckl and Chapman 1997; Chapman, 
Holmes et al. 2013)). In vivo and in intact cells, 11β-HSD1 mainly acts as a reductase 
catalysing the conversion of the 11-keto form of inactive GCs into the active 11-
hydroxyl form, while 11β-HSD2 catalyses the opposite reaction as a dehydrogenase. 
Therefore, 11β-HSD1 amplifies intracellular GC action whilst 11β-HSD2 diminishes 
intracellular GC action (Figure 1-7). 
11β-HSD1 is expressed in many tissues, including liver, kidney, brain, lung, adipose 
tissue, placenta, ovary and immune cells, whereas 11β-HSD2 is more restricted, with 
expression largely limited to aldosterone target tissues (eg. kidney, colon) as well as 
the developing embryo and placenta (reviewed by (Chapman, Holmes et al. 2013)). 
By inactivating intracellular GCs, 11β-HSD2 confers specificity of aldosterone 
binding to MR (Stewart, Wallace et al. 1987; Funder, Pearce et al. 1988; van Uum, 
Hermus et al. 1998). Because the adrenal glands produce little cortisone or 11-
dehydrocortocosterone (11β-HSD1 substrates), 11β-HSD1 activity is dependent on 
11β-HSD2 to generate its substrates. In the circulation, although data on the ratio of 
active and inactive GCs in large population studies are scarce, the ratio is reported in 
some studies to be about 5.4 : 1 (F:E) in humans (Vogeser, Groetzner et al. 2003) and 
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10.6:1 (B:A) in rats (Usa, Singh et al. 2007). A study in mice showed that the ratio is 
dependent on both stress and the time of the day (Harris, Kotelevtsev et al. 2001). 
This thesis is focused on 11β-HSD1, with more information provided below. 11β-
HSD1 is a 34kDa transmembrane glycosylated protein located inside the 
endoplasmic reticulum, in close association with hexose-6-phosphate dehydrogenase 
(H6PDH), which supplies the co-factor, NADP(H), to drive the reductase direction 
of 11β-HSD1 activity. In tissue homogenates and liver microsomes, without NADPH 
generation, 11β-HSD1 exhibits dehydrogenase activity in the presence of NADP 
(reviewed by (Tomlinson, Walker et al. 2004)). Apart from GCs, 7-ketocholesterol 
and 7-oxo-lithocholic acid are also substrates for 11β-HSD1 (Nashev, 
Chandsawangbhuwana et al. 2007; Odermatt, Da Cunha et al. 2011; Penno, Morgan 
et al. 2013) 
There are 3 promoters in the HSD11B1 gene, P1, P2 and P3 (reviewed by (Chapman, 
Holmes et al. 2013)), with the main one being P2. The P2 promoter contains several 
binding sites for C/EBP transcription factors. Transcription from P3 encodes a 
protein without 11β-HSD1 activity. In hepatocytes, basal expression of 11β-HSD1 is 
under the control of C/EBPα (Williams, Lyons et al. 2000). C/EBPβ and LAP:LIP 
(different translational forms of CEBPβ) ratio directly control the transcriptional 
regulation of Hsd11b1 in adipocytes and lung epithelial cells in response to pro-
inflammatory cytokines, GCs, diet, and other regulators (Williams, Lyons et al. 
2000; Sai, Esteves et al. 2008; Ignatova, Kostadinova et al. 2009; Esteves, Kelly et 
al. 2012). In mesenchyme stromal fibroblasts (which use the P2 promoter, in contrast 
to freshly isolated lung fibroblast using P1 promoter (Yang 2010)), during 
inflammatory stimulations, 11β-HSD1 expression is positively regulated via NFκB 
(p65) binding to the Hsd11b1 promoter, with a synergistic effect of GCs to further 











Figure 1-7  11β-HSDs mediate interconversion of 11-keto forms (cortisone, 11-
dehydrocorticosterone) and 11-hydroxyl forms (cortisol, corticosterone) of GCs.  
The circle indicates the hydroxyl/keto group at the 11 position. Arrows indicate the reaction 
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1.4.2 11β-HSD1 in metabolism  
Chronic GC excess, exemplified by Cushing’s syndrome in association with a low-
grade inflammation, causes metabolic disturbances (discussed in section 1.3.4), 
despite the well-known anti-inflammatory effect of GCs. 11β-HSD1 increases 
intracellular GC levels without an increase in circulating GC levels. Increased 11β-
HSD1 enzyme activity has emerged as a possible link to human obesity, diabetes and 
metabolic syndrome (Draper, Echwald et al. 2002; Walker 2006; Smit, Dekker et al. 
2007; Miyamoto, Morisaki et al. 2009; Munoz, Carvajal et al. 2009; Gambineri, 
Tomassoni et al. 2011; Moon, Lee et al. 2011; Dujic, Bego et al. 2012; Olza, Gil-
Campos et al. 2012). 
Globally 11β-HSD1 deficient mice are protected against the adverse effects of diet-
induced obesity (Kotelevtsev, Holmes et al. 1997; Morton, Paterson et al. 2004; 
Wamil, Battle et al. 2011), development of atherosclerosis in the Apoe
-/-
 genetic 
background (Garcia, Search et al. 2013; Kipari, Hadoke et al. 2013) and the normal 
cognitive loss and skin thinning associated with aging (Sandeep, Yau et al. 2004; 
Yau, Noble et al. 2011; Tiganescu, Tahrani et al. 2013). 
The following mechanisms of metabolic protection conferred by 11β-HSD1 
deficiency in mice with high fat diet induced obesity: a Microarray study of white 
adipose tissue from 11β-HSD1 deficient mice showed a profile consistent with 
higher lipid oxidation and reduced inflammatory gene expression in subcutaneous 
and mesenteric depots, respectively. This was accompanied by decreased 
macrophage and T cell infiltration in the mesenteric adipose tissue (Wamil, Battle et 
al. 2011). There is also increased angiogenesis and less fibrosis in adipose tissue of 
11β-HSD1 deficient mice after 12 weeks of high fat diet, suggesting more efficient 
adipose tissue remodeling (Michailidou, Turban et al. 2012). Inhibition of 11β-HSD1 
was shown to promote brown adipocyte differentiation (Liu, Kong et al. 2013), 
which suggests a negative role of 11β-HSD1 in brown adipocyte development.  
Conversely, tissue-specific overexpression of 11β-HSD1 in transgenic mice causes 
detrimental effects. Mice overexpressing 11β-HSD1 in adipose tissue (using the 
adipocyte Fab4 promoter) developed visceral obesity and exhibited pronounced 
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insulin-resistant diabetes, hyperlipidemia and hypertension, hyperphagia despite 
hyperleptinemia (Masuzaki, Paterson et al. 2001; Masuzaki, Yamamoto et al. 2003). 
Mice overexpressing 11β-HSD1 in liver (using the Apoe promoter/enhancer) showed 
fatty liver and dyslipidemia, impaired hepatic lipid clearance and transgene-dose-
associated hypertension paralleled by increased liver angiotensinogen expression 
(Paterson, Morton et al. 2004). Another line of mice overexpressing 11β-HSD1 in 
forebrain (using the CamIIKα promoter) exhibited premature age-associated 
cognitive decline (Holmes, Carter et al. 2010).  
Several different selective 11β-HSD1 inhibitors in mice have shown protection 
against metabolic dysfunction, particularly insulin resistance induced by high fat diet 
feeding  and atherosclerosis (Hermanowski-Vosatka, Balkovec et al. 2005; Feng, 
Huang et al. 2010; Park, Rhee et al. 2012; Wang, Liu et al. 2012; Luo, Thieringer et 
al. 2013). Clinical trials of 11β-HSD1 inhibitors showed improvements of insulin 
sensitivity in type 2 diabetes (reviewed by (Gathercole, Lavery et al. 2013; Hardy, 
Seibel et al. 2013). One of the concerns of long term 11β-HSD1 inhibitor 
administration is the possible effects on the HPA axis (reviewed by (Harno and 
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1.4.3 11β-HSD1 in the cardiovascular system and wound 
repair 
Globally 11β-HSD1 deficient mice showed increased angiogenesis in an in vivo 
assay using s.c. sponge implantation and in an in vitro aortic ring assay (Small, 
Hadoke et al. 2005). These mice also showed better recovery after myocardial 
infarction with increased angiogenesis in the infarcted area of heart accompanied by 
earlier accumulation of YM1
+
 M2 macrophages and higher Cxcl1 mRNA levels 
(Small, Hadoke et al. 2005; McSweeney, Hadoke et al. 2010).  
Protection from atherosclerosis in Apoe
-/- 
artheroslerosis-prone mice by 11β-HSD1 
inhibition was first reported by Merck researchers (Hermanowski-Vosatka, Balkovec 
et al. 2005). A recent study from Merck by 11β-HSD1 inhibition suggested 
decreased inflammatory gene expression in the vasculature as a protective 
mechanism against atherosclerosis (Luo, Thieringer et al. 2013). This has been 
further confirmed in globally 11β-HSD1 knockout mice on an Apoe
-/- 
background by 
2 independent groups, both of whom attributed this to 11β-HSD1 knockout in bone 
marrow-derived macrophages based on bone marrow transfer experiments (Garcia, 
Search et al. 2013; Kipari, Hadoke et al. 2013).  The mechanism may involve 
accumulation of cholesterol in macrophages. In one study, increased cholesterol 
efflux was reported in 11β-HSD1 deficient macrophages via up-regulation of ATP-
binding cassette transporter (ABCA) 1, ABCG1 and Apoe gene expression (Kipari, 
Hadoke et al. 2013). Consistent with this, reduced foam cell formation was found in 
the peritoneal macrophages from 11β-HSD1-deficient mice in an Apoe-/- background 
in the other study (Garcia, Search et al. 2013). Reduced circulating MCP-1 levels 
were found in all the above 4 studies, and Kipari etc. found decreased Mcp1 
expression in the mesenteric adipose tissues (Kipari, Hadoke et al. 2013). However, 
it is unknown of the tissue contributions of MCP-1 generation.  
Similar to myocardial infarction (Small, Hadoke et al. 2005), inhibition or knockout 
of 11β-HSD1 was shown to accelerate skin wound healing in several studies. Topical 
application of 11β-HSD1 inhibitor promoted skin wounding healing by increasing 
proliferation of normal epidermal keratinocytes and fibroblasts (Terao, Murota et al. 
2011). Topical 11β-HSD1 inhibition could also overcome stress or exogenous GC-
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induced delays in wound healing, with synergistic effects of liver X receptor 
activators (Youm, Park et al. 2013). 11β-HSD1 deficient mice showed reduced aging 
induced skin thinning as well as increased wound healing, pointing to a negative role 
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1.4.4 11β-HSD1 in inflammation 
11β-HSD1 is widely expressed in the immune system. In mice, expression of 11β-







 lymphocytes (Zhang, Ding et al. 2005) , mast cells (Coutinho, 
Brown et al. 2013) and neutrophils (Chapman 2011). The levels of 11β-HSD1 are 
much higher in myeloid cells than in lymphoid cells (reviewed by (Chapman, 
Coutinho et al. 2013). No HSD11B1 expression was found in healthy human blood 
cells, but it was induced upon differentiation of human blood monocytes to 
macrophages or dendritic cells (Thieringer, Le Grand et al. 2001; Freeman, Hewison 
et al. 2005) 
11β-HSD1 expression is dynamically regulated by activated state in mouse immune 
cells. 11β-HSD1 levels are very low in naïve monocytes/macrophages and tissue 
resident macrophages, but can be greatly induced by inflammatory stimuli (Gilmour, 
Coutinho et al. 2006). Phagocytosis of apoptotic neutrophils decreases human 
monocytes derived macrophage 11β-HSD1 expression (Chapman, Coutinho et al. 
2009). Expression of neutrophil 11β-HSD1 is increased during inflammation but is 
absent in apoptosis (reviewed by (Chapman, Holmes et al. 2013)). During in vitro 
polarisation of human CD14
+ 
monocytes, IL-4 has a much stronger effect to induce 
HSD11B1 expression than classic inflammatory stimuli (Thieringer, Le Grand et al. 
2001). The effect of IL4 is further potentiated by peroxisome proliferator activated 
receptor-γ (PPAR-ϒ) activation (Chinetti-Gbaguidi, Bouhlel et al. 2012). In contrast, 
immunosuppressive TGF-β2, alpha melanocyte stimulating hormone (α-MSH) and 
vasoactive intestinal peptide (VIP) are not able to induce HSD11B1 expression in 
human monocytes (Varajini Joganathan 2008). There is no information on the role of 
IL4 or TGF-β upon mouse macrophage 11β-HSD1 expression to my knowledge. 
The induction of 11β-HSD1 expression by inflammatory stimuli is generally 
conceived to be a protective mechanism to suppress inflammation (reviewed by 
(Chapman, Coutinho et al. 2013)). Exaggerated inflammation is usually found in 
situations of 11β-HSD1 deficiency or inhibition, although it is not clear to what 
extent the induction of 11β-HSD1 in activated myeloid cells contributes to this, 
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because similar induction effect happens in other cells as well, especially fibroblasts 
(Escher, Galli et al. 1997; Hardy, Filer et al. 2006; Hardy, Rabbitt et al. 2008; 
Ahasan, Hardy et al. 2012). In globally 11β-HSD1 deficient mice, there is a greater 
inflammatory response to LPS induced endotoxin inflammation, in the K/BxN serum 
transfer model of arthritis, in thioglycollate elicited peritonitis and in carrageenan-
induced pleurisy (Zhang and Daynes 2007; Coutinho, Gray et al. 2012).  In an 
arthritis study on rats, it was found that synovial 11β-HSD1 activity was increased in 
association with increased IL-1 and TNFα (Ergang, Leden et al. 2010; Sesti-Costa, 
Baccan et al. 2010). Additionally, in a human arthritis study, increased 11β-HSD1 
activity was associated with disease progression and both were decreased by 
treatment with disease modifying drugs or anti-TNFα antibodies (Hardy, Rabbitt et 
al. 2008; Beyeler, Dick et al. 2012; Nanus, Filer et al. 2013) 
A possible role for 11β-HSD1 in macrophages is suggested by changed macrophage 
functions in studies on globally 11β-HSD1 deficient mice and with selective 11β-
HSD1 inhibitor treatment, as described below. Delayed acquisition of macrophage 
phagocytic ability was first reported in globally 11β-HSD1 deficient mice in our lab 
(Gilmour, Coutinho et al. 2006). In the myocardial infarction model, there were 
earlier infiltration of YM-1
+
 (M2) macrophages and greater numbers of macrophages 
in globally 11β-HSD1 deficient mice associated with greater neutrophil influx into 
the infarcted area (McSweeney, Hadoke et al. 2010). In 11β-HSD1 deficient 
macrophages, the pro-inflammatory M1 response was found to be increased 
following in vitro LPS stimulation (Gilmour, Coutinho et al. 2006; Zhang and 
Daynes 2007). In contrast, in diet induced obesity or atherosclerosis, where the 
inflammation is widely accepted to be mediated by macrophages, 11β-HSD1 
deficient mice consistently show less inflammatory gene expression in gene arrays 
(Wamil, Battle et al. 2011; Garcia, Search et al. 2013), with similar gene array result 
in an 11β-HSD1 inhibitor study (Luo, Thieringer et al. 2013).  
Given the wide spread induction of 11β-HSD1 in different tissues by inflammatory 
stimuli, the changed disease course associated with inflammation in 11β-HSD1 
deficient mice or following 11β-HSD1 inhibitor treatment, and strong indications of 
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a regulatory effect of 11β-HSD1 on macrophage functions, it is crucial to dissect role 
of macrophage 11β-HSD1 in these inflammatory processes in order to find the target 
tissue of 11β-HSD1 inhibition. To this end, macrophage-specific Hsd11b1 knockout 
mice (LysM-Cre Hsd11b1
flox/flox
) were generated (Zhang 2011) for use in the studies 
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1.5 Hypothesis and Aims of the study 
Hypothesis:  11β-HSD1 amplification of intracellular GC levels in macrophages is 
responsible for major effects of global 11β-HSD1 deficiency during inflammation. It 
is predicted that macrophage specific 11β-HSD1 deletion would worsen 
inflammatory disease development, but protect against metabolic disease. 
Aims: 1. To examine the effects of macrophage 11β-HSD1 deficiency upon M1/M2 
polarisation and response to hypoxia to mimic tissue injury situations in vitro. 
           2. To examine whether macrophage 11β-HSD1 was efficiently deleted in 
myeloid cell-specific Hsd11b1 knockout mice (LysM-Cre Hsd11b1
flox/flox
). 
           3. To study the in vivo effects of macrophage 11β-HSD1 deficiency in 
inflammatory diseases, including inflammatory angiogenesis, arthritis and high fat 
diet induced obesity. 
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Chapter 2: Materials and Methods 
2.1 Materials and solutions 
All chemicals and reagents were purchased from Sigma-Aldrich Company Ltd, 
(Poole, UK) or Invitrogen Life Technologies (Paisley, UK), unless otherwise stated. 
To prepare buffers and solutions, double deionized water (ddH2O) was used, unless 
otherwise stated. 
 
Buffers and solutions: 
Phosphate buffered saline (PBS) solution: for 1 ⅹ PBS solution, a PBS tablet 
(Oxoid Limited, Hampshire, UK) was dissolved in 200ml ddH2O to give 8g/l NaCl, 
0.2g/L KCl, 1.15g/L Na2HPO3 and 0.2g/L NaH2PO3. 
Culture medium: Dulbeco’s modified Eagle’s medium (DMEM) with 10% heat 
inactivated fetal calf serum (FCS) and 1% penicillin/streptomycin.                    
10 ⅹ TBE buffer: 56g tris, 57.5g boric acid, 20ml 0.5M EDTA were dissovled into 
a total volume of 500ml with ddH2O and autoclaved before use. 
10 ⅹ TBS buffer: 24.4g Trizma base, 80g sodium chloride were dissolved in 1L of 
distilled water, with 0.5M HCl to adjust the final ph to 7.6. 
C buffer: 63g glycerol, 8.77g NaCl, 186mg EDTA and 3.03g tris were dissolved in 
500ml ddH2O, and the pH was adjusted to 7.7 with HCl and NaOH. 
Homogenization buffer: 100g glycerol, 300mg Tris and 186mg EDTA were 
dissolved in 500ml ddH2O, and the pH adjusted to 7.5 with HCl. The buffer was 
stored at 4℃. 7.7mg dithiothreitol (DTT) was added before use to 50ml of the buffer 
for a working solution, which was kept on ice. 
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Borate buffer: 8.25g boric acid and 7.2g NaOH were dissolved in 1L ddH2O. The 
pH was adjusted to 7.4 with HCl. Then 5g bovine serum albumin (BSA) was added 
to a final concentration of 0.5% and stored at -20℃. 
Krebs-ringer buffer: In 1L H2O, 118mM NaCl, 5mM KCl, 1.2mM MgSO4, 3mM 
NaH2PO4, 12mM Na2HPO4 and 0.9mM CaCl2 were dissolved with a final Ph of 7.4. 
The solution was filtered to satirize it before being kept at 4 C until use, when 0.1g 
glucose and 1g BSA was added. Once glucose and BSA were added, the solution 
could be kept 4 C for 1 week at maximum.  
RNase free water (DEPC-treated water): ddH2O was mixed with 
diethylpyrocarbonate (DEPC) at a proportion of 1 drop DEPC to 100ml ddH2O. The 
solution was mixed and left overnight before being autoclaved. 
Placental homogenate: 2 Wistar rat placentas were mechanically homogenied in 
1ml homogenization buffer and then 300μl aliquoted into tubes and stored at -80℃. 
Nicotinamide adenine dinucleotide phosphate (NADP): 1.1mg nicotinamide 
adenine dinucleotide sodium salt was dissolved into 1684μl C buffer to give a final 
concentration of 2mM. This solution was made freshly and kept on ice.  
Nicotinamide adenine dinucleotide (NAD): 17.1mg of NAD was dissolved in 1ml 
C buffer (25mM). This solution was made freshly and kept on ice. 
10% Thioglycollate solution: 10g of Brewer’s thioglycollate powder (DIFCO, 
Detroit, MI, USA) was dissolved in 0.1L PBS. The solution was autoclaved, then 
stored at 4℃ and “aged” for at least 3d before use. 
3
H-Corticosterone: A commercial stock solution of 
3
H-corticosterone in ethanol was 
purchased from Amersham Pharmacia Biotech, Buckingham, UK (specific activity 




H-dehydrocorticosterone was synthesized in-house 
according to the procedures described in 2.6, below.  
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2.2 Animal breeding 
Globally 11β-HSD1 deficient mice were generated by homologous recombination 
technique (Kotelevtsev, Holmes et al. 1997) and were crossed with C57Bl/6 mice for 
>10 generations. Hsd11b1
del/del 
mice were generated by Cre/loxP technique (Zhang 
2010). The latter has better deletion efficiency, especially in tissues where 11β-HSD1 
was expressed from the P1 promoter. LysM-Cre HSD11b1
flox/flox 
transgenic mice were 
generated as previously described (Zhang 2010) and crossed with HSD11b1
flox/flox 
mice. In the offspring, LysM-Cre HSD11b1
flox/flox
 mice were the conditional knockout 
mice, and HSD11b1
flox/flox 
littermates were their controls.  
All mice were bred and maintained in the Biomedical Research Facility, Little 
France, Edinburgh, UK. Mice were kept in groups of 1-8 per cage under controlled 
conditions (12h light/dark cycle, 21℃), with ad libitum access to water and standard 
rodent chow (Special Diet Services, UK). All procedures were carried out under the 
auspices of the Animal (Scientific Procedures) Act UK 1986 after prior approval by 
the local ethical committee. 
 




The line of MKO mice were maintained by breeding LysM-Cre Hsd11b1
flox/flox 
(Zhang 2010) with Hsd11b1
flox/flox 
mice. In the offsprings, LysM-Cre Hsd11b1
flox/flox 
mice were predicted to carry myeloid cell specific deletion allele of Hsd11b1, with its 
normal expression in control Hsd11b1
flox/flox 
mice. Ear and tail samples were used for 
genotyping, in which deleted allele of Hsd11b1 is predicted to be present in 
circulating myeloid cells or in the resident tissue macrophages present in the biopsies 
(e.g. skin), while other cells bearing the un-recombined floxed allele of Hsd11b1.  
Primers were designed as shown in Figure 2-1A. MKO mice were identified with 
Cre genotyping (Cre
+
, Figure 2-1B). Flox genotyping was carried out to check the 
homozygous state of the flox transgene in these mice (Figure 2-1C). And Hsd11b1 
gene genotyping was done to detect the deleted allele of Hsd11b1 (Figure 2-1D). Cre 
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genotyping was done routinely in all samples, while flox and hsd11b1 genotyping 
examined occasionally in well-established breeding lines. 
 
                     
                      
Figure 2-1 Primer design and representative gels showing genotyping results of MKO 
mice.  
(A) 2 LoxP sites (black arrow) flank exon 3. Cre mediated recombination removes exon 3. 
With flox F and flox R primers, wild-type Hsd11b1 allele (255bp) and ‘floxed’ Hsd11b1 
allele (385bp) can be distinguished. With flox R primer and deleted Hsd11b1 primer, deleted 
Hsd11b1 allele (363bp) and ‘floxed’ Hsd11b1 allele (1066bp) can be distinguished. (B) 
Genotyping for Cre transgene (465bp product) showed that mice 2, 5, 6, 7, 9, 11 and 13 
carried this gene, while the rest not. (C) Genotyping for the ‘floxed’ allele of Hsd11b1  
showed that all the mice were homozygous (flox/flox) for the ‘floxed’ allele. (D) Deleted 
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bands of Hsd11b1 (363bp product) were detected in mice 2, 6, 7, 9, 11 and 13, whose 




; ‘floxed’ band of Hsd11b1 were detected in mice 1, 




. Deleted allele in mouse 5 
was confirmed in a later repeated PCR, which carried the Cre transgene. ‘+’ indicates the 
positive control, WT wild-type and ‘-’ H2O control. 
 
2.4 PCR genotyping 
All DNA samples were extracted using Qiagen DNeasy blood & tissue kit (Qiagen, 
West Sussex, UK). Samples were either ear punch samples (for ID) or both ear and 
tail biopsies. The DNA extraction method was according to the protocol enclosed 
with the kit, except that in the last step, each sample was dissolved in 100μl instead 
of 200μl AE buffer (supplied with the kit). The PCR reaction for each sample 
composed 2.5μl MgCl2 free buffer (supplied with the Qiagen Taq kit), 2.25μl MgCl2 
(supplied with the Qiagen Taq kit), 1μl dNTP solution (10mM), 1μl forward primer 
solution (10pmol/μl), 1μl reverse primer solution (10pmol/μl), 0.2μl Taq DNA 
polymerase (Qiagen, West Sussex, UK), 15.55μl deionised H2O and 1.5μl DNA 
sample solution. Primer sequences and PCR conditions are shown in table 1. In each 
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Table 1 List of PCR primers and reaction conditions 




























94℃, 1 min 
64℃, 1 min 
72℃, 1 min  
 
95℃, 5 mins 
29  
95℃, 1min 
61℃, 1 min 





465pb Deleted band: 363bp 
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2.5 Thioglycollate-induced sterile peritonitis  
Thioglycollate (TG)-induced sterile peritonitis is a mild and self-resolving model of 
systemic inflammation, which lasts for 5 days (Gallily, Warwick et al. 1964), and 
allows for isolation of immune cells at the onset, peak and resolution stages of 
inflammation. Neutrophils are the predominant cell type recruited in the peritoneal in 
the first 24h after i.p. intraperitoneal injection of thioglycollate, whereas 
macrophages predominate at later stages, especially at 4 days (Melnicoff, Horan et 
al. 1989). 
300μl of 10% thioglycollate was injected i.p. into each mouse, with a 0.5ml syringe. 
Mice were killed by a schedule 1 method (cervical dislocation), either 24h following 
injection for isolation of total cells and/or neutrophil purification, or 96h following 
injection for macrophage enrichment. Peritoneal cells were lavaged as follows. First, 
the abdominal skin was dissected apart from the peritoneum. In this process, 
hemostatic forceps were kept ready to keep the peritoneum intact in case of cleavage 
of the peritoneum. For each mouse, 5ml cold 1 ⅹ PBS was injected (i.p.) into the 
peritoneum with a 19G needle. The peritoneum was gently massaged, and then as 
much as possible of the fluid was drawn back into the syringe. For each mouse, 
harvested solution was put in a 15ml conical tube on ice. Generally, 4ml was 
collected from each mouse. Following transfer to the laboratory, the solution was 
gently pipeted up and down for several times to suspend cells. Then the cells were 
counted using a haemocytometer (Neubauer) and centrifuged for 5 minutes at 300g, 
4℃ (Labofuge 400R Centrifuge, Heraeus, Essex, UK). After that, the supernatant 
was discarded, and the cells were resuspended in the culture medium at the required 
concentration (usually 1 ⅹ 106 cells/ml). 
Resident cells in the peritoneal cavity were harvested in the same way without 
thioglycollate injection. After returning to the laboratory, cells were resuspended in 
the culture medium and seeded in 6 well plates, 1 mouse per well. After 1-2h 
incubation at 37℃, 5% CO2, the cells were washed with PBS to remove floating cells 
and the attached macrophage cells were used for further experiment. 
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2.6 Macrophage polarisation under normal oxygen 
and hypoxia conditions 
Male 11β-HSD1 deficient and wild type (WT) mice (8-14 weeks old) were i.p. 
injected with 10% thioglycollate, 300μl/mouse. And peritoneal lavage was done after 
3 days with 5ml ice cold PBS. Cells were centrifuged and supernatants poured off. 
After another wash with PBS, cells were suspended in DMEM alone on bacteria 
degrade petri-dishes (no serum) and placed in the cell incubator for 1 or 2 hours for 
macrophage attachment. Then medium was poured off and plates washed again with 
PBS without calcium and magnesium to remove non-adhering cells. To remove 
macrophages from plates, detachment buffer (1mM glucose, 3mM EDTA in calcium 
and magnesium free PBS) was added into the plate and left in the cell incubator for 
15 minutes. Cells were centrifuged and re-suspended in PBS. With the cell number 
being counted with neucleocasstte, they were suspended in either M1 or M2 
conditioning medium (1x10
6
 cells/ml, 7ml per plate).  
M1 medium was made up with LPS and IFN-ϒ, 100ng/ml and 10U/ml respectively. 
M2 medium was made up with IL-4, 20ng/ml. Both groups were incubated for 
overnight (~20 hours) at 37 C before harvest. For hypoxia experiment, M1 
macrophages were cultured in the hypoxia chamber (COY Laboratory Inc., 
Michigan, the USA) with 1% O2. It was set up with help from Miss Kathryn Wilson 
and Professor Martin Denvir. The medium was collected and frozen at -80 C and cells 
frozen in Trizol after being washed with PBS.  
ELISA was done according to the enclosed protocols (Go-Ready ELISA, 
eBioscience, see Chapter 2 for detailed description). RNA was extracted from 
samples containing Trizol with RNeasy kit (Qiagen) according to the protocol except 
RLT buffer being replaced by Trizol here and chloroform used before samples 
transferred into columns (see Chapter 2 for detailed description). Quantitative PCR 
(qPCR) was done with gene specific primers and probe in Universal Probe Library 
(UPL) (see Chapter 2 for detailed description). 
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2.7 Tissue homogenization and protein assay 
2.5.1 Tissue homogenization 
Mice were killed by a schedule 1 method and tissues were quickly dissected and 
frozen on dry ice before being stored at -80℃ until use. Tissues were mechanically 
homogenized (Dispergierstation T8.10, IKA Instruments, Staufen, Germany) in a 
2.5ml tube containing 500-800μl homogenizing buffer, which was kept on ice as far 
as possible. The amount of tissue used varied, dependant on the protein level and the 
expected level of 11β-HSD1 in each tissue. The homogenizing time was minimized 
to avoid protein degradation. The homogenate was aliquoted: 10-30μl in one 0.5ml 
tube for protein assay (which was done on the same day) and 50-80μl in 3 ⅹ 0.5ml 
tubes for activity assay, which were kept at -80℃ until the activity assay.   
 
2.5.2 Protein assay 
Before protein assay of all the samples, a test assay was conducted to choose the 
proper dilution to use for each tissue. The concentration for each tissue that gave a 
reading within the standard curve was then used for all samples of that tissue. Then, 
in a 96 well plate, 5μl of each sample or standard solution was added to duplicate or 
triplicate wells. Protein standard solutions were made from bovine serum albumin 
(BSA, Bio-Rad Laboratories, Hertfordshire, UK) stock solution in ddH2O as 0, 0.1, 
0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4mg/ml. Then 25μl Biorad reagent A (Bio-Rad 
Laboratories, Hertfordshire, UK) and 200μl Biorad reagent B (Bio-Rad Laboratories, 
Hertfordshire, UK) were added into each well. The plate was left at room 
temperature for 15-60 minutes. Then it was read in a plate reader (OPTImax tunable 
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H-11-dehydrocorticosterone is not commercially available, it was made in-house 
from 
3





H-11-dehydrocorticosterone, as described before (Ehrchen, 
Steinmuller et al. 2007). 2 rat placentas were homogenized in 1ml of homogenizing 
buffer as described above (2.5.1, tissue homogenization) and 300µl aliquots stored at 
-80℃. 120µl stock 3H-corticosterone was dried at 60℃ under gaseous nitrogen and 
reconstituted in 50µl 100% ethanol in a glass tube or bottle. The following reagents 
were then prepared in a glass vial: 50µl reconstituted 
3
H-corticosterone, 200µl 25nM 
NAD, 300µl placental homogenate and 4.45ml C buffer. The solution was mixed by 
votexing (Rotamixer, Hook & Tucker Instruments Ltd., Croydon, UK) and split 
equally into 2 glass tubes. Both were incubated in a water bath at 37℃ for 4 h. The 
solutions in the 2 glass tubes were further divided equally into 4 glass tubes. 4ml of 
ethyl acetate was added into each tube, and after mixing in a vortex, they were 
centrifuged at 1700rpm for 10 minutes at 4℃. The top organic layer containing the 
steroids in each tube was transferred into a fresh glass vial and dried in a hot block at 
60℃ under gaseous nitrogen. When the vials were half dried, the contents of 2 glass 
vials were combined together. This step was repeated, so all the solutions were 
finally combined in one glass vial. Another 4ml ethyl acetate was added into the 
other 3 dried tubes to extract remaining steroids and the above procedures repeated. 
Finally, the dried steroids were reconstituted in 100µl ethanol and stored at -20℃. 
1µl of the solution was used for HPLC to measure the purity of 
3
H-11-
dehydrocorticosterone and another 1µl was added to 1ml scintillation solution to 
count the amount of radioactivity using a β-counter (Wallac 1450 Microbeta Plus 
liquid scintillation counter, Milton Keynes, UK).  
 
2.9 11β-HSD1 enzyme activity assay 










H-11-dehydrocorticosterone (dehydrogenase activity), 
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as described before (Low, Chapman et al. 1994). The reductase assay was carried out 
in intact cells and the dehydrogenase activity in the homogenates of tissues. The 
latter assay did not distinguish between 11β-HSD1 and 11β-HSD2, both of which 
have dehydrogenase activity in homogenates. 
2.7.1 Reductase activity assay 





were seeded into each well of a 24 well culture plate, with 0.65 µl (around 5nM) 
3
H-
11-dehydro-corticosterone only or together with 200nM non-radioactive labeled 
11dehydro-corticosterone. Samples were assayed in duplicate or triplicate. A 
negative control contained the culture medium and 
3
H-11-dehydrocorticosterone 
only, without cells. Cells were incubated at 37°C, 5% CO2 (CO2 water jacketed 
incubator, Forma Scientific, London, UK) for the duration of the experiment. 200µl 
of the culture medium was collected at each time point: 30 minutes, 1h, 2h, 4-6h, 16h 
or 24h (depending on the enzyme activity of each cell type, the time points were 
adjusted) and frozen at -20°C until analysis (see 2.73 and 2.74).  
 
2.7.2 Steroid extraction 
For steroid extraction, samples were thawed and transferred into glass tubes, each 
capable of holding 2ml (usually 10 times the sample volume, and at least 4 times the 
sample volume) ethyl acetate. The tubes were vortexed for about 10 s and left for 
about 1h to separate into organic and aqueous phases. The glass pipet was then used 
to transfer the upper organic layer to a clean glass tube. The tubes were then left to 
evaporate in the hood overnight or dried in a 65°C heat block under air or N2. When 
the tubes were dry, steroids were on the wall and in the bottom of the tube, ready to 
be reconstituted in 100% ethanol.  
 
2.7.3 TLC analysis 
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50μl of 100% ethanol was added into each tube and vortexed for about 15s. The 
reconstituted steroid was applied onto a thin layer chromatography (TLC) plate (TLC 
silica gel 60 F254, Merck, Darmstadt, Germany), 5μl at a time until there was none 
left. Then the TLC plate underwent chromatographic separation in a closed chamber 
containing 92ml chloroform and 8ml 100% ethanol. In about 45 min, when around 
80% of the plate was wet, it was taken out and dried in air. Finally, the TLC plate 
was placed in a cassette and exposed to a phosphorimager tritium image screen 
(Fujifilm, Tokyo, Japan). After 1 or 3 days, the screen was taken out and read in a 
Fujifilm FLA-2000 Image Reader (Fujifilm UK Ltd., Bedford, UK) and quantified 
by Aida Image Analyzer v.3.44 software (Raytek Scientific Ltd., Sheffield, UK). 
Enzyme activity was calculated as % conversion of substrate to product: 100 ⅹ 
[product] / ([product] + [substrate]). 
 
2.10 Western blotting 
Primary cells were collected and washed with PBS. Cell samples were then 
centrifuged at 1000rpm, 4℃ for 8 minutes. Supernatants were poured off and cell 
pellets frozen at -80 ℃. To lysis cells, RIPA cell lysis buffer (R0278, Sigma, UK) 
with 1% proteinase inhibitor cocktail (P8340, Sigma, UK) was used, 50μl for 10
7
 
cells. Protein levels were then measured by Bradford protein assay according to the 
enclosed protocol with the product (Bio-Rad Laboratories Ltd, Herts, UK), as 
described in 2.5.2. 
For each sample, 20-30μg of protein was used for western blotting. All the western 
blotting reagents were from Invitrogen (Invitrogen Ltd, Paisley, UK) and the 
experiments were done according to the manufactory’s protocols with products. 
Briefly, protein samples were mixed with sample buffer (10x) and reducing agent 
(2.5X), and heated at 70℃ for 10 minutes, then loaded onto a 4-12% Bis-Tris Gel 
(Invitrogen Ltd, Paisley, UK) with 6.5μl of rainbow full range protein ladder (GE 
Healthcare Life Sciences, Buckinghamshire, UK). The gel running time was 40-60 
min at 200v. And transferring time was 60mins at 30 voltages using wet transfer 
method. First antibodies were incubated with the membrane overnight at 4℃ or 1h at 
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room temperature. After being washed 3 X 10 min in TBST, the membrane was 
incubated with the second antibodies for 1h at room temperature. Secondary 
antibodies from Li-cor were diluted in 5% milk in 1 x TBST solution, working 
concentration at 1:10,000, and 11β-HSD1 first antibody (kindly provided by Dr. 
Scott Webster) was used at a working concentration of 1:1,000. Primary antibodies 
from Santa Cruz were usually used at 1:300-500 dilution, and STAT6 antibodies 
from Cell signalling were used at 1:1000 dilution. 
Membranes were scanned in an Odyssey® Infrared Imaging System (LI-COR 
Biotechnology - UK Ltd, Cambridge, UK) and the protein bands were quantified 
with the Odyssey V3 software. 
For western blotting of neutrophils, GAPDH was chosen as the internal control 
because of cross-reaction between antibodies. Both the 11β-HSD1 first antibody and 
the secondary antibody to β-tubulin were raised in sheep. The problem emerged that 
secondary antibody of 11β-HSD1 (anti-sheep Ig G), reacted with both antibodies 
mentioned above. First antibody of GAPDH raised in rabbit did not have this 
problem. But the band is very close to that of 11β-HSD1. So rabbit-anti-mouse Ig G 
was used as the secondary antibody for β-tubulin in later experiments.  
 
2.11 ELISA 
Ready-Set-Go!® ELISA kits (il-1β 88-7013-22, il6 88-7064-22, il12 p40 88-7120-
22, il23 88-7230-22 and tnf-α  88-7324-22) are purchased from eBioscience 
(Hatfield, UK). The experiments were performed according to the enclosed 
protocols. Briefly, 96 well plates were coated with detection antibody in 100μl 
coating buffer overnight in the cold room at 4℃. Solutions were poured off and 
plates washed with PBST for 3 times before 100μl sample buffer were added to 
block. After 1h incubation at room temperature, solutions were poured off and plates 
washed 3 times with PBST. 100μl of sample buffer containing standard or sample 
dilutions were added into each well and left to incubate at room temperature for 2h. 
It’s recommend to use 2 steps for high samples dilutions, for example, to make 1/800 
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dilution of samples, dilute first 20 times and then 40 times to reach final 1/800 
dilution. Solution were poured off and plated washed 3 times with PBST before 100μ 
sample buffer containing detection antibody was added. After 1h incubation at room 
temperature, solutions were poured off and plated washed 3 times with PBST. Then 
100μl of sample buffer containing streptavidin-HRP was added into each well for 30 
minutes incubation at room temperature. Solutions were poured off and plated 
washed 5 times before 100μl TMP solution containing HRP substrates were added 
for 15 minutes incubation at room temperature. The reaction was stopped by adding 
50μl of stopping solution. The plates were read in and data were collected by 
subtracting values in 570nm from values in 450nm with standard curve generated by 
either 4-parameter standard curve or best fit linear line. 
 
2.12 Magnetic-activated cell sorting (MACS) 
MACS is a method which uses magnetic bead-linked antibody to sort out a particular 
type of cell with the corresponding antigen, from a mixed cell population. The 
antibody used here for neutrophils was Ly6G (OGUSHI, ENDO et al. 1999). 
Immune cells were harvested by peritoneal lavage using 5ml PBS, 24h after injection 
of 300μl of 10% thioglycollate, as described above. The lavaged cells from 4 mice 
were pooled together and the cells counted using a hemocytometer. The cell density 
was adjusted to between 1 ⅹ 106 and 1 ⅹ 107 cells per ml, then 0.5μl of the 
antibody (Ly6G-PE) was added into every 200μl of sample. The samples were left to 
incubate on ice in the dark for 1h, after which cells were centrifuged at 300g for 5 
min and resuspended in 80μl the MACS running buffer (Miltenyi Biotec, Bergisch 
Gladbach, Germany) per 10
7 
cells. Then, secondary antibody (anti-PE MACS 
antibody, Miltenyi Biotec, Bergisch Gladbach, Germany) was added (20μl per 10
7 
cells) and samples were incubated in the dark at 4℃ for 15 minutes. After 
centrifuging for 10 min at 300g, 4℃, cells were resuspended in 500μl MACS running 
buffer. At this time, cells were ready to apply to the MACS column (Miltenyi Biotec, 
Bergisch Gladbach, Germany), which was kept at 4 C before use.  
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The cold column was placed in the magnet (Miltenyi Biotec, Bergisch Gladbach, 
Germany), and a 50 ml collecting tube was placed under the column. The column 
was washed with 3ml of MACS running buffer. Then the cell solution was added to 
the column and the flow through (Ly6G
- 
cells) collected. The column was washed 3 
more times, with 3 ml of the MACS running buffer each time and the flow through 
collected in the same tube as above. At this time, the column was taken off the 
magnet, and another 50 ml collecting tube placed below the column. 5 ml of PBS 
was added to the column to collect the Ly6G
+ 





cells were then counted with a hemocytometer 
and their density adjusted to 1 ⅹ 106 cells per ml. 100-200μl of the cell suspension 
was cytocentrifuged onto slides with a speed of 300rpm for 3 min. After air drying, 
the slides were stained with Diff Quick (placed in methanol for 2 minutes, 40 
seconds in the Diff Quick Red dye, 40 seconds in the Diff Quick Blue dye and 
washed in water) and mounted with DPX resin. This was used to evaluate the 
separating efficiency. 
 
2.13 Adipose stromal vascular cells (SVCs) 
separation 
Adipose tissues harvested from mice were kept in 50ml falcon tubes with about 10ml 
Krebs-ringer buffer. The tubes were kept warm in a beaker of warm water. Back in 
laboratory, lymph nodes were dissected out and tissues were weighed to make sure 
less than 3g of adipose in one sample. Collagenase type I (Worthington Biochemical 
Corporation, NJ, the USA) was dissolved in Krebs-ringer buffer at 2mg/ml. In a 
plastic bottle, 10ml of the collagenase I buffer with one adipose tissue sample were 
put in. The adipose tissue were cut into small pieces with scissors before the bottle 
was incubated in shaking water bath at 37℃ for 45 mins (swirl the bottle every 15 
mins). The reaction was stopped by adding 10-20ml Krebs-ringer buffer to dilute the 
enzyme concentration. 
The solution was passed through mesh into 50ml falcon tubes and then centrifuged at 
600g for 10 mins at room temperature. After removing adipocytes in the top layers 
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and solutions in the middle, ~500μl solution was left with SVCs inside (Optionally, 
pass the SVCs in10ml Krebs-ringer buffer through pre-wetted 100μm filters, which 
was washed with another 10ml Krebs-ringer buffer in the end). Red blood cells were 
lysed by incubating with 2ml lysis buffer (R7757, Sigma, UK) for at least 1 min at 
room temperature. The lysing was stopped by adding 10ml PBS and cells were 
recovered after centrifudge at 600g for 10 mins. The cell pellets were resuspended in 
2ml PBS buffer before being passed through a 30μm filter, which was washed with 
3ml PBS buffer. The cells were pelleted and resuspended in 1ml PBS solution. 
 
2.14 Flow cytometry 
In a 12x75 mm, 5 ml polystyrene round bottom test tube, ~10
6
cells were incubated in 
~ 100μl PBS (the volume left after gently pouring off solutions in the tube) with 10% 
mouse serum (to block non-specific binding) for 30mins on ice. Then about 3ml PBS 
were added into the tube to wash the cells. After centrifuge the tube for 5 mins at 
300-500g and pouring off the solutions, fluorescence conjugated antibodies and 
matched iso-type IgG were added into sample and iso-type control tubes 
respectively, to incubate on ice for 30min in the dark. A tube of cell sample without 
antibodies was included as well for gating and examining auto-fluorescence in the 
analysis. The volume of antibody used per test tube was 0.25-0.5μl (otherwise, 
according to the suggestions of the suppliers). All antibodies were from ebioscience 
or BD. The cells were washed in 3ml PBS and recovered by centrifugation at 300g 
for 5min prior to analysis in flow cytometry machines (FACScan or FACScalibur, 
Becton Dickinson, Oxford, UK). Usually 100μl of 10% neutral formalin solution was 
added into each tube to preserve the samples at 4 C before analysis within 1 week.  
Compensation among different fluorescence was determinded either by auto-
compensation with compensation beads (OneComp eBeads, 01-1111-42, 
eBioscience, UK) or manually set up with all the single antibody stained samples. 
Gating of cells was done in FSC (forward scatter) and SSC (side scatter) view, which 
was determined by cell size and granularity respectively. Specific and non-specific 
fluorescence was determined by processing ≥5000 cells/sample, using Cellquest 
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software (BD). Data analysis was performed using FlowJo software (Treestar, 
Oregon, USA) on cell singlets determined by gating in FSC area and FSC height 
view. 
Intracellular staining was done with FIX & PERM® Cell Fixation & Cell 
Permeabilization Kit (GAS004, Invitrogen, UK) according to the protocol enclosed 
with the product. Briefly, after surface staining, cells of a sample were fixed in 100μl 
of the fix buffer at room temperature in dark. After washing with PBS, 100μl of perm 
buffer (to make pores in cell membrane) with un-conjugated antibodies (1:50 for 
YM-1 and 1:200 for purified 11β-HSD1 antibody) was added, to incubate in room 
temperature for 15 mins in dark. Then perm buffer (00-8333-56, eBioscience) was 
used to wash samples (3ml/tube). PBS washing could lead to failure of staining as all 
intra-cellular antibodies (specific or non-specific) would be trapped inside cells when 
the cell membrane closes in PBS. A different perm buffer was used to lower the cost 
as large quantity of perm buffer used for washing. Recovered cell samples were then 
incubated with matched fluorescence conjugated secondary antibodies (1:300-500 
dilutions) in 100μl of perm buffer at room temperature for 15 mins in dark. Samples 
were washed again with perm buffer (00-8333-56, eBioscience) and analysed within 
1 day. 
Blood cell preparation for flow cytometry analysis is done as described below. Tail 
nick was done with a scalpel and 30μ of blood was collected in to an eppendorf tube 
with 30μl of 3.9% sodium citrate buffer for anti-coagulation. 30-50μl of the above 
solution was put into each test tube and antibodies were added to incubate 25 mins 
on ice in dark. No blocking step was needed as there was serum present in the blood. 
Red blood cells were lysed with 1ml 1X lysing buffer per sample (BD Pharm 
Lyse™, 555899, BD, UK) for 8 mins at room temperature in dark. After centrifuge, 
cells were preserved for flow cytometry analysis. 
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2.15 RNA extraction, reverse transcription and real-
time PCR assay 
 
Cell or samples were usually kept  in Trizol (Invitrogen Ltd., Paisley, UK, 
<107cells/ml) and stored at -80℃ for later RNA extraction. Total RNA was extracted 
using the Qiagen RNeasy mini kit according to the protocols enclosed with the 
products, except that Trizol and chloroform were used to lyse the cells instead of the 
RLT buffer. Obtained RNA was quantified in the NanoDrop ND-1000 
spectrophotometer (NanoDrop products, Wilmington, DE 19810, USA). 
To make cDNA, SuperScript® III Reverse Transcriptase (Invitrogen Ltd., Paisley, 
UK) was used according to the protocol enclosed with the product. Usually 1 μg of 
RNA was used together with 1 μl of mixed dNTPs (Promega, Southampton, United 
Kingdom), 0.5 μl of random primers (Invitrogen Ltd., Paisley, UK) in a volume of 13 
μl, which were heated at 65℃ for 5 min. Then 4 μl of the first strand buffer, 1 μl of 
the DTT solution, 1 μl of the transcriptase and 1 μl of the RNase-out (Promega, 
Southampton, United Kingdom) were added into each sample and reverse 
transcription carried out using the conditions specified in the product sheet (Samples 
were incubated at 25°C for 5min, then 50°C for 60min and 70°C for 15min). A 
control with water but no RNA was included in the reaction. 
For mRNA measurement, real-time PCR reactions were all carried out in the 
LightCycler 480 System (Roche Diagnostics Ltd., Burgess Hill, UK) with 
fluorescent probes in the Universal Probe library (Roche Diagnostics Ltd., Burgess 
Hill, UK). cDNA samples were prepared in triplicates. For each one, 2 μl of the 
diluted sample was used together with 5 μl of Roche master mix solution, 2.7 μl of 
distilled water, 0.1 μl of probes (10μM) and 0.1 μl of the primers (10-40μM) in the 
following running. The Lightcycler 480 PCR programme was as follows: pre-
incubation at 95°C, 5min, amplification for 50 cycles (95°C, 10s; 60°C, 30s; 72°C, 
1s) and cooling, 40°C for 30s. Data were calculated by the 2nd derivative maximum 
method.  This method determined the Ct (cycle of threshold) of a sample as the point 
where the sample’s fluorescence curve turns sharply upward, the maximum of the 
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second derivative of the amplification curve and the value were calculated by the 
LightCycler ® 480 Software automatically.  
SYBR green assays were used in qPCR as well with LightCycler® 480 SYBR Green 
I Master (04 707 516 001, Roche, Switzerland). In each assay, 5μl Master with 2.8μl 
water and 0.1μ of forward and reverse primer respectively were mixed with 2μl of 
cDNA. The assay was run in the same machine with a different programme 
according to the enclosed protocol. There was 1 cycle pre-incubation (95°C 10 
mins), 45 cycle amplification, 1 cycle melting cure  and 1 cycle cooling (40°C, 10s). 
In each amplification, there were denature 95°C, annealing 20s and extension 72°C 
30s. Fluorescence acquisition was done at the extension step. In the melting curve 
step, there was 95°C 10s, 65  C 1min and 97°C continuous acquisition. 
Gene concentration of samples was assigned according to the standard curve and 
then gene expression was relative to housekeeping gene expression. Usually 3 
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Table 2 List of qPCR primers and probes 
Gene Primers UPL Probe 
No. 
hprt Forward: tcctcctcagaccgctttt 
Reverse: cctggttcatcatcgctaatc 
95 
TBP Forward: gggagaatcatggaccagaa 
Reverse: gatgggaattccaggagtca 
97 
18s Forward: ctcaacacgggaaacctcac    
Reverse: cgctccaccaactaagaacg 
77 
Actb Forward: ctaaggccaaccgtgaaaag 
Reverse: accagaggcatacagggaca 
64 
Hsd11b1 Forward: tctacaaatgaagagttcagaccag 
Reverse: gccccagtgacaatcacttt 
1 
Il1a Forward: ttggttaaatgacctgcaaca 
Reverse: gagcgctcacgaacagttg 
52 
Il1b Forward: tgtaatgaaagacggcacacc 
Reverse: tcttctttgggtattgcttgg 
78 
Il6 Forward: gctaccaaactggatataatcagga 
Reverse: ccaggtagctatggtactccagaa 
6 
Il10 Forward: cagagccacatgctcctaga 41 
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Reverse: tgtccagctggtcctttgtt 
Il12b Forward: gactccaggggacaggcta 
Reverse: ggagatggttagcttctgagga 
27 
tnf Forward: tcttctcattcctgcttgtgg 
Reverse: ggtctgggccatagaactga 
49 
Nos2 Forward: ctttgccacggacgagac 
Reverse: tcattgtactctgagggctgac 
13 
Ccl5 Forward: tgcagaggactctgagacagc 
Reverse: gagtggtgtccgagccata 
110 
Cx3cl1 Forward: ccgcgttcttccatttgt 
Reverse: cacatgatttcgcatttcgt 
84 
Ifnr Forward: ggaggaactggcaaaaggat 
Reverse: ttcaagacttcaaagagtctgagg 
21 
Icam1 Forward: cccacgctacctctgctc 
Reverse: gatggatacctgagcatcacc 
81 
Vcam1 Forward: tggtgaaatggaatctgaacc 
Reverse: cccagatggtggtttcctt 
34 
Cd68 Forward: gacctacatcagagcccgagt 
Reverse: cgccatgaatgtccactg 
96 
Emr1 Forward: cctggacgaatcctgtgaag 1 
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Reverse: ggtgggaccacagagagttg 













Mrc1 Forward: ggacgagcaggtgcagtt 
Reverse: caacacatcccgcctttc 
47 
Arg1 Forward: cctgaaggaactgaaaggaaag 
Reverse: ttggcagatatgcagggagt 
2 
Ang1 Forward: ggaagatggaagcctggat 
Reverse: accagagggattcccaaaac 
12 
Ang2 Forward: cacactgaccttccccaact 
Reverse: cccacgtccatgtcacagta 
82 
Cdh5 Forward: tcatcaaacccacgaagtcc 
Reverse: ggtctgtggcctcaatgtaga 
42 




Ihh Forward: cgctgcaaggaccgtctgaa SYBR green 
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Reverse: cgtgggccttggactcgtaa assay 
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2.16 Subcutaneous sponge implantation induced 
angiogenesis and Chalkley counting of blood 
vessels 
Mice (male, 8-12 weeks old, MKO and littermates control) were anesthetized with 
halothane and a horizon wound cut behind the neck. One sterile sponge cylinder (0.5 
cmx1 cm, Caligen Foam, Accrington, Lancashire, U.K.) were implanted s.c. into 
each flank, away apart from the middle line. Wound was checked in the first 7 days 
after surgery and the sponges were harvested after 20 days. The sponges in the left 
were cut apart in the middle with half fixed in 10% formalin, the other half frozen in 
Trizol at -80  C and the sponge in the right frozen in Trizol at -80  C as well. Fixed 
sponges were embedded in paraffin after being washed in 70% ethanol. 5μm paraffin 
sections were cut and the slides were processed into H&E staining as described in 
Chapter 2. The frozen sponges were used for RNA extraction and real-time PCR to 
measure relevant gene expressions as described in Chapter 2.  
To quantify blood vessel growth in the H&E sections, Chalkley counting method was 
used as described before (Fox, Leek et al. 1995). Basically, a transparent round plate 
with 25 random dots was fitted into the field of the microscope. 3 most vascularized 
areas (usually in the surroundings of the sponges) in each section were chosen in low 
magnification (X125) and examined at high magnification power (X312.5). When a 
dot in the plate covers the position of a blood vessel, it’s counted as 1. The plate can 
be rotated and as many as possible blood vessels covered by the dots are desired to 
make the counting. Two sections from one sample were examined and the average of 
the 6 numbers is assigned as the Chalkey count value of the sample. 
 
2.17 K/BxN serum transfer induced arthritis 
In-house K/BxN serum was collected from 60 day old offspring of KRN and NOD 
breeding pairs, when the anti-G6PI antibody levels are highest (Monach, Mathis et 
al. 2008). Serum was pooled and stored in 500μl aliquots at -80 C. A single i.p. 
injection of 125μl serum per mouse (males, 7-9 weeks old) was used to induce 
arthritis on day 0. The body weight of mice was checked before injection and mice 
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weighed less than 23g were excluded from the experiments. Clinical scoring was 
carried out blind to genotype for 21 continuous days as described (Chou, Kim et al. 
2010). Briefly, a score in a range of 0-3 was given to each paw and ankle joint, with 
0 representing no inflammation (red and swelling), 1 localised inflammation, 2 
extended inflammation and 3 inflammation in the whole circumference of the joint. 
The value of the 4 scores added together is assigned as the clinical score for the 
mouse (a maximum of 12 for one mouse). Data from MKO and ‘floxed’ littermate 
control groups were assessed by repeated measurement 2 way ANOVA in Prism 
GraphPad 5.0, as well as Bonferroni post-test. Area under the curve (AUC) was 
calculated for each mouse and compared in different genotypes by unpaired t-test. 
On day 21 or day 15, mice were culled and joints fixed in 10% formalin for 1 day, 
before decalcification in 10% EDTA solution (pH 7.4) in room temperature for 2 
months or more until the bone was easy to bend. After embedding in paraffin (with 
sagittal plane of the leg parallel to the glass surface), joints were sectioned (4μm) and 
processed for H&E staining. Joint pathology was examined with help from David G. 
Brownstein (Mouse Pathology Core Lab, Queen’s Medical Research Institute) and 
Donald Salter (Pathology Department, University of Edinburgh). 
 
2.18 High fat diet feeding, glucose tolerance test 
(GTT) and plasma glucose, insulin measurement 
Male MKO and littermate control mice (8 weeks old) were put on high fat diet (58% 
mixed fat, Research Diet, U.S.A) for 14 weeks. Body weight was measured weekly 
and fasting glucose level, glucose tolerant test (GTT) was done a week before 
culling. Mice were culled by neck dislocation and blood collected in EDTA tubes for 
plasma collection. Subcutaneous (SC), epididymis (Epi), mesenteric (Mes) and 
brown adipose, liver, spleen, muscle and adrenals were harvested and weighed 
before being fixed in 10% formalin or frozen at -80 C.  
Mice were housed individually several days before GTT experiment to adjust them 
to the environment and reduce stress levels. Mice underwent a 6 hour fast to achieve 
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a ‘baseline’ blood glucose level and then glucose solution (2g glucose/kg bodyweight 
using 25% (w/v) D-glucose in PBS) was injected into the peritoneal cavity. Blood 
glucose levels were measured with a handheld glucometer (OneTouch 
Ultra,LifeScan,USA) on a drop of tail vein blood according to the protocol enclosed. 
Blood samples from each mouse were collected into EDTA coated Microvette CB 
300 tubes (Sarstedt,Leicester, UK)  at 0, 30, 60, and 120 minutes after glucose 
administration for glucose and insulin analysis.  
Glucose levels were quantified using an Infinity Glucose Hexokinase Liquid Stable 
Reagent (Thermo Electron, Pittsburgh, USA). Serial dilutions of glucose were 
prepared (50 – 400mg/dl) from the standard using distilled water, with distilled water 
used as a blank. 2μl of sample and standards was added to each well of 96-well 
plates, followed by addition of the reagent (200μl). Atfer15 min incubation in the 
dark at room temperature, the absorbance at 340nm was measured the concentration 
calculated with reference to the standard curve. 
 Plasma insulin level was measured with Mouse insulin ELISA kit (Crystal chem, 
US) according to the enclosed protocol. Briefly, an insulin standard curve (25.6, 
12.8, 6.4, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1, 0ng/ml insulin) was made by diluting 25.6ng/ml 
mouse insulin stock standard solution. In each well of a 96 well plate, 95μl of sample 
diluent buffer and 5μl of sample or standards was added to incubate for 2 hours at 
4°C. Solutions were then aspirated and the wells washed 5 times with washing buffer 
(300μl per well). 100μl of anti-insulin enzyme conjugate solution was added into 
each well. After incubation for 30mins at room temperature, solutions were aspirated 
and the wells washed 7 times as described above. Then 100μl of enzyme substrate 
solution was added into each well. After 40mins reaction at room temperature 
without exposure to light, it was stopped by adding 100μl per well of stop solution. 
The plate was read within 30 minutes using a plate reader machine 
(Spectrophotometer) at wavelengths of 450 and 630nm. The reading subtraction 
results (A450-A630) were compared to the standard curve to calculate the sample 
concentrations. 
 
Chapter 2: Materials and Methods  65 
2.19 Statistics 
All statistics analysis was conducted using Graphpad Prism 5.0, unpaired t-tests was 
often used, sometimes with Welch’s correction when the variances between groups 
are not equal. One way ANOVA and 2 way repeated measurement ANOVA were 
used as well. Significance is set at p<0.05. Data are means ± standard error of means 
(SEM). 
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Chapter 3: In vitro studies of 11β-HSD1 deficient 
macrophages 
3.1 Introduction 
Evidence is accumulating to suggest that 11β-HSD1 deficiency or inhibition 
influences macrophage functions. For example, delayed acquisition of phagocytic 
ability was observed in 11β-HSD1 deficient macrophages (Gilmour, Coutinho et al. 
2006) and YM-1 positive cells (indicative of more M2 polarised macrophages) 
accumulated earlier in the infarcted area of the heart of 11β-HSD1 deficient mice 
following coronary artery ligation (McSweeney, Hadoke et al. 2010). An increased 
inflammatory response was reported in LPS treated (M1 polarised) primary 11β-
HSD1 deficient peritoneal or spleen macrophages, but not bone marrow derived 
macrophages (BMDMs). The difference between genotypes was postulated to be 
from secondary effect of increased circulating GC levels on macrophage 
differentiation, while no influence of circulating GCs on BMDMs experiments in 
vitro (Gilmour, Coutinho et al. 2006; Zhang and Daynes 2007). In contrast, selective 
11β-HSD1 inhibitor treatment of macrophages showed decreased inflammatory 
responses by LPS, although there were no GC substrate for 11β-HSD1 added in the 
experiment (Ishii, Masuzaki et al. 2007). There are no reported direct in vitro studies 
on role of 11β-HSD1 in IL-4 induced M2 macrophage polarisation. Thus, there has 
been no conclusion so far on role of 11β-HSD1 in M1/M2 macrophage polarisation. 
The role of macrophage 11β-HSD1 in hypoxia is also worthy of study. Hypoxia is 
closely linked to macrophage-driven fibrosis and angiogenesis and both of them are 
influenced in globally 11β-HSD1 deficient mice (refer to Section 1.4). More 
angiogenesis and less fibrosis was reported in the adipose tissues of 11β-HSD1 
deficient mice following high fat diet feeding (Michailidou, Turban et al. 2012), but 
more inflammation and fibrosis were found in their lungs following bleomycin 
treatment (Yang 2010) and in livers following CCl4 treatment (Xiantong Zou 2013). 
Treatment with 11β-HSD1 inhibitor was shown to promote the proliferation of 
human dermal fibroblasts and accelerate skin wound healing (Terao, Murota et al. 
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2011). Again, there is no conclusion as to the part played by macrophage 11β-HSD1 
deficiency in these studies. 
Based on the above studies, it is important to elucidate the role of 11β-HSD1 in 
macrophage polarisation and in hypoxic response. As mentioned above, there is no 
intrinsic difference in LPS induced inflammatory responses between 11β-HSD1- 
deficient and wild-type BMDMs. So, TG elicited macrophages (differentiated from 
monocytes in vivo) were chosen for the studies reported here. 
 
3.2 Hypothesis and aims 
Hypothesis:  
1. 11β-HSD1 deficiency will favour an increased M1 and decreased M2 response in 
macrophages.  
2. The response to hypoxia will be augmented in 11β-HSD1 deficient macrophages, 
leading to greater inflammatory, angiogenic and fibrotic response. 
Aims:  
           1. To investigate whether 11β-HSD1 is differentially regulated in wild-type 
M1 and M2 macrophages. 
           2. To investigate the effects of 11β-HSD1 deficiency upon M1/M2 
macrophage polarisation in vitro. 
           3. To investigate the effects of 11β-HSD1 deficiency in the response of 
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3.3 Results 
3.3.1 Hsd11b1 mRNA levels are higher in M1 than M2 wild-
type macrophages but without change in protein levels  
To study the role of 11β-HSD1 in M1/M2 macrophage polarisation, day 3 TG 
elicited macrophages from 11β-HSD1 deficient and C57Bl/6 mice were treated with 
LPS + IFN-γ and IL4 to induce M1 and M2 polarised macrophages, respectively, as 
described in Chapter 2. 
First, 11β-HSD1 expression in M1 and M2 wild-type macrophages was examined. 
RNA sequence data from Professor Judith Allen’s group suggest down-regulation of 
Hsd11b1 in peritoneal macrophages following nematode infection (an IL4 mediated 
M2 response), compared to Hsd11b1 mRNA levels in TG elicited macrophages from 
naïve BALB/c mice. Moreover, the levels of Hsd11b1 mRNA in wild type cells were 
lower than those in Il4ra knockout mice (Thomas, Ruckerl et al. 2012). In agreement 
with this, Hsd11b1 mRNA levels are found to be higher in M1 than M2 polarised 
macrophages in this experiment (Figure 3-1A). However, surprisingly there is no 












































Figure 3-1 Higher Hsd11b1 mRNA but similar 11β-HSD1 protein levels in M1 than M2 
polarised macrophages. 
Peritoneal macrophages were elicited from C57Bl/6 mice 3 days after TG injection. LPS 
(100ng/ml) + IFN-γ (10U/ml) and IL4 (20ng/ml) were used to polarise macrophages into M1 
and M2 macrophages, respectively. After overnight treatment, RNA and proteins were 
extracted from these cells and analysed by qPCR and western blotting. (A) Hsd11b1 levels 
were measured by qPCR, relative to the levels of 18S rRNA. Data are means ± SEM and 
were analysed by un-paired t-test. N=6/group; *, p<0.05. (B) 11β-HSD1 protein levels were 
measured by western blotting. The band densities were quantified in the graph below. Each 
lane contains 20μg of protein from one mouse. N=4/group. Data are means ± SEM and were 
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3.3.2 11β-HSD1 protein levels in TG elicited macrophage are 
not increased by inflammatory stimulation  
The previous experiment addressed expression of 11β-HSD1 in M1 verse M2 
polarized macrophages but did not address whether LPS + IFNϒ increases 11β-HSD1 
levels in untreated TG elicited peritoneal macrophages. In studies on the macrophage 
cell lines, LPS induced 11β-HSD1 expression (Thieringer, Le Grand et al. 2001; 
Ishii, Masuzaki et al. 2007). Whether 11β-HSD1 protein levels can be increased by 
inflammatory stimulation of TG elicited macrophages, similar to that in macrophage 
cell lines has not been reported, although TG is known to increase 11β-HSD1 
expression in peritoneal cells, which include macrophages (Gilmour, Coutinho et al. 
2006).  
Western blotting was carried out compare 11β-HSD1 levels in untreated TG elicited 
peritoneal macrophages from C57Bl/6 mice and following treatment with LPS or 
LPS plus IFNϒ treatment groups. IFNϒ synergistically regulates LPS induced 
inflammatory response (Held, Xiao et al. 1999). 
11β-HSD1 protein levels in macrophages treated with LPS or LPS+IFN-γ did not 
differ from levels in untreated cells, although IFN-γ modestly increased 11β-HSD1 
expression in LPS treated macrophages (Figure 3-2). This reveals different 11β-
HSD1 modulation by inflammatory stimuli between primary macrophages and 
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Figure 3-2 11β-HSD1 protein levels are not higher in TG elicited macrophages 
following LPS, or LPS plus IFN-ϒ treatment compared to untreated cells.  
Western blotting of 11β-HSD1 was carried out in day 3 TG elicited peritoneal macrophages 
from C57Bl/6 mice following ex vivo treatment with LPS or LPS+IFN-γ. (A) A 
representative image of 11β-HSD1 western blotting. Each lane contained 30μg of protein 
from one mouse. (B) The bands in figure (A) were quantified and plotted into the graph. 
Data are means ± SEM and were analysed by one way ANOVA with Tukey post-test. N=4 





Chapter 3: In vitro studies of 11β-HSD1 deficient macrophages  72 
3.3.3 Levels of inflammatory gene mRNAs are increased in 
11β-HSD1 deficient macrophages, but without 
corresponding increase in protein levels. 
The next question was to test the effect of macrophage 11β-HSD1 deficiency on 
M1/M2 polarisation. To test the inflammatory M1 response, Il1b, Il6, Tnfa, Nos2 and 
Il12b mRNA levels were examined in TG elicited macrophages from 11β-HSD1 
deficient and control C57Bl/6 mice polarised ex vivo with LPS + IFNγ treatment. 
Among the examined genes, Il1b, Tnfa and Nos2 mRNA levels are significantly 
higher in 11β-HSD1 deficient (KO) macrophages compared to WT controls (Figure 
3-3).  
Other mRNAs were measured to explore the mechanism. Cox2 induction leads to 
elevated levels of prostanoids in inflammation and has been found to be GC 
regulated (Masferrer, Reddy et al. 1994). Annexin A1 (encoded by Anxa1) is a 
downstream effector of GC that supresses inflammation (Perretti and D'Acquisto 
2009). Trib1 and Cop1 are linked to control of IL12 p40 production (Yamamoto, 
Uematsu et al. 2007). There is no difference in Cox2, Anxa1, Fcgr2b, Fcgr3, 
Patched, Trib1 (tribbles pseudokinase 1) or Cop1 (constitutive photomorphogenic 1) 
expression between the 2 genotypes, but Ccl2 and Nr3c1 (encoding the GR protein) 
mRNAs are found to be lower in 11β-HSD1 deficient M1 macrophages (Figure 3-4). 






























































Figure 3-3 Levels of mRNA encoding pro-inflammatory markers are increased in 
Hsd11b1 deficient M1 macrophages. 
Day 3 TG elicited peritoneal macrophages from globally 11β-HSD1 deficient (white bar) 
and C57Bl/6 mice (black bar) were treated with 100ng/ml LPS and 10U/ml IFNγ ex vivo. 
After overnight treatment, inflammatory mRNA levels were measured by qPCR. Data are 
means ± SEM and were analysed by un-paired t-test to compare the 2 groups for each gene 
with significance set at p<0.05. *, p<0.05; **, p<0.01. N=8 in each group, except for Il12b 





























































Figure 3-4 Levels of mRNAs encoding CCL2 and GR are decreased in M1 polarised 
macrophages from 11β-HSD1 deficient mice.  
In the same experiment as shown Figure 3-3, a number of other mRNA expression levels 
were examined by qPCR to compare the two genotypes (white bar, 11β-HSD1 deficient 
macrophages; black bar, wild-type macrophages). Data are means ± SEM and were analysed 
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To check whether increased levels of inflammatory mRNAs translated into 
corresponding changes in peptide and protein levels in 11β-HSD1 deficient 
macrophages, ELISA and western blotting were carried out in the cell culture 
medium and cell homogenates, respectively. However, there was no difference in 
IL1β or IL6 cytokine levels in the medium. Instead, IL12 p40 was decreased (Figure 
3-5A). Western blotting of iNOS (encoded by Nos2) also showed no difference in its 
protein levels (Figure 3-5B), in contrast to the increased Nos2 mRNA levels in 11β-

























































Figure 3-5 Levels of the secreted cytokines IL1β, IL6 and intracellular iNOS protein 
levels in M1 macrophages were not different between the two genotypes, but IL12 p40 
secretion from 11β-HSD1 deficient macrophages was decreased.  
In the ex vivo M1 macrophage polarisation  as described in Figure 3-3, cell culture medium 
was saved for ELISA and cell homogenates for western blotting. (A) ELISA results for IL1β, 
IL6 and IL12 p40. (B) Western blotting of iNOS. Density of bands was quantified in the 
graph to the right of the western blot image. Each lane contains 30μg of protein from 1 
mouse. Data are means ± SEM and were analysed by unpaired t-test with significance set at 
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3.3.4 Increased levels of C/EBPβ protein in 11β-HSD1 
deficient M1 macrophages despite lower levels of 
encoding mRNA.  
Because C/EBPβ is a negative regulator of IL12 p40 expression (Gorgoni, Maritano 
et al. 2002) and IL12 p40 levels are decreased in 11β-HSD1 deficient M1 polarized 
macrophages, C/EBPβ was measured in M1 macrophages. C/EBPβ protein levels are 
higher in 11β-HSD1 deficient M1 macrophages (Figure 3-6A&B), possibly 
explaining the decreased IL12 p40 levels. However, the encoding Cebpb mRNA 
levels are lower in 11β-HSD1 deficient macrophages without changes in Cebpa or 






















Figure 3-6 C/EBPβ levels are higher in 11β-HSD1 deficient M1 macrophages, albeit a 
lower cebpb RNA expression.  
In the same M1 polarisation experiment described in Figure 3-3 to 3-5, C/EBPβ protein 
levels were examined by western blotting in the cell homogenates and Cebpa, Cebpb, Cebpd 
mRNA levels were measured by qPCR in the extracted RNA. (A) Image of the western blot 
of C/EBPβ and β-tubulin. All 3 isoforms of C/EBPβ (LAP*, LAP and LIP) were detected. 
Each lane contains 30μg protein from 1 mouse. (B) Density of the bands were quantified and 
plotted. Data are means ± SEM, n=6 in each group. Un-paired t-test. *, p<0.05. (C) Cebpb 
mRNA levels were lower in 11β-HSD1 deficient M1 macrophages. No differences in Cebpa 
or Cebpd were detected. Data are means ± SEM, n=6 in each group. Un-paired t-test. **, 
p<0.01. 
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3.3.5 Decreased levels of mRNA encoding M2 markers in 11β-
HSD1 deficient macrophages without change in 
phospho-STAT6 or intracellular YM1 protein levels. 
To test whether 11β-HSD1 deficiency affects M2 macrophage polarization, day 3 TG 
elicited peritoneal macrophages from globally 11β-HSD1 deficient and C57Bl/6 
mice were treated with IL4 overnight to induce M2 macrophage polarization. RNA 
and protein were harvested at the end of the experiment to study M2 markers. 
Some of the examined mRNA levels were reduced in 11β-HSD1 deficient 
macrophages such as Chi3l3, Arg1 and Il10, but no differences in Retnla, Pparg or 
Tgfb1 were detected (Figure 3-7).  
To investigate the responsible signalling pathway and confirm altered levels of M2 
markers, western blotting was carried out to detect phosphorylated STAT6 (phospho-
STAT6) and intracellular YM-1 (encoded by Chi3l3). STAT6 is the transcription 
factor that directs IL4 induced M2 gene transcription (reviewed by (Lawrence and 
Natoli 2011)). Unfortunately, no difference was found in levels of either phosphor-



































































Figure 3-7 Levels of mRNA encoding markers of  M2 polarised macrophages were 
decreased in 11β-HSD1 deficient macrophages.  
Day 3 TG elicited macrophages from 11β-HSD1 deficient and C57Bl/6 wild type mice were 
treated overnight with 20ng/ml IL4. RNA was harvested for qPCR to compare M2 marker 
mRNA levels in the 11β-HSD1 deficient macrophages (KO M2, white bar) and control wild 
type macrophages (WT M2, black bar). Data are means ± SEM and were analysed by un-
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Figure 3-8 No difference in p-STAT6 or YM-1 protein levels between 11β-HSD1 
deficient and C57Bl/6 M2 macrophages.  
In the same M2 macrophage polarisation experiment as shown in Figure 3-7, cell 
homogenates were used for western blotting. This is a representative image of a membrane, 
which was cut into 2 parts for separate first antibody staining. The left lane contains a protein 
ladder (band sizes indicated). The first 6 lanes next to the ladder are WT samples, and the 
neighbouring 6 samples in the right are 11β-HSD1 deficient samples (‘KO’).  The lane at the 
right end contains an untreated control, which showed a band of β-tubulin (50kDa), but not 
p-STAT6 (110kDa) or YM-1 (45kDa, encoded by Chi3l3). Each lane contained 30μg protein 
from 1 mouse. No difference in phospho-STAT6 or YM-1 protein levels between the 2 
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3.3.6 Decreased levels of Patched mRNA encoding the 
hedgehog ligand receptor in 11β-HSD1 deficient M2 
macrophages 
RNA sequence data on aortas of globally 11β-HSD1 deficient mice on an Apoe-/- 
genetic background showed higher Gli1 (glioma-associated oncogene homologue 1) 
and Hhip (hedgehog interacting protein) mRNA levels, compared to ApoE
-/- 
controls 
(unpublished data, Professor Karen Chapman). Both Gli1 and Hhip are in the 
hedgehog pathway. In this pathway, Gli1 is the main induced transcription factor 
after hedgehog ligands Indian hedgehog (Ihh), Sonic hedgehog (Shh) or Desert 
hedgehog (Dhh) bind to the receptor Patched (reviewed by (Kasper, Regi et al. 
2006)). The hedgehog interacting protein could sequester the hedgehog ligands 
(Bosanac, Maun et al. 2009). This pathway is emerging as an important regulator of 
inflammatory tissue remodeling underlying liver fibrosis and osteophyte formation 
(Ruiz-Heiland, Horn et al. 2012; Pereira, Xie et al. 2013).  
Therefore, related genes were examined in M1 and M2 polarized macrophage 
samples. Expression of Patched and Ihh were detected in M2 macrophages but not in 
M1 macrophages (Dhh and Shh are too low to be detected in both M1 and M2 RNA 
samples). Patched mRNA levels were decreased while there was a trend to higher 
Ihh expression levels in 11β-HSD1 deficient M2 macrophages, compared to wild 
type M2 macrophages (Figure 3-9). However, western blotting failed to detect Indian 




















































Figure 3-9 Decreased Patched and a trend to higher Ihh levels in 11β-HSD1 deficient 
M2 macrophages.  
In the M2 macrophage polarisation experiment described in Figure 3-7 and 3-8, Patched and 
Ihh mRNA levels in the macrophages were measured by qPCR. Data are means ± SEM and 
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3.3.7 The response of M1 macrophages under hypoxic 
conditions is largely unaffected by 11β-HSD1 deficiency  
Hypoxia is an important factor influencing inflammatory, fibrotic and angiogenic 
responses (Cramer, Yamanishi et al. 2003; Halberg, Khan et al. 2009; Imtiyaz, 
Williams et al. 2010). To mimic the in vivo hypoxic conditions macrophages are 
exposed to during inflammation and to investigate whether 11β-HSD1 deficiency 
alters the macrophage response to hypoxia, M1 macrophage polarization was carried 
out under hypoxic conditions (1% O2 level) in 11β-HSD1 deficient and control 
macrophages. However, neither Hif1a nor its target genes differed between 
genotypes, including the glucose transporter gene Glut1, inflammatory genes, 
angiogenesis gene Vegfa and genes related to fibrosis, such as Tgfb1, Timp1. 

































































































































Figure 3-10 Similar gene expression levels in response to hypoxia between 11β-HSD1 
deficient and wild-type M1 macrophages. 
TG elicited peritoneal macrophages from 11β-HSD1 deficient and control wild type mice 
were treated with 100ng/ml LPS and 10U/ml IFN-ϒ under hypoxic conditions (1% oxygen) 
overnight before the cells were harvested for RNA analysis by qPCR. (A) Vegf1, Hif1a, 
Tgf1a, Mmp9, 13, Timp1 and Gli1 mRNA levels are not different between genotypes, but 
Patched levels are higher in the 11β-HSD1 deficient macrophages. (B) Glut1, Ldha, Rxr1, 
Cebpa, Cebpb, Il6, Tnfa, Cox2, Nos2 and Arg1 mRNA levels are not different between the 2 
genotypes in the same experiment as in (A). Data are means ± SEM and were analysed by 
un-paired t-test for each gene. N=6-7; **, p<0.01. 
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3.4 Discussion 
Hsd11b1 mRNA is differentially expressed in M1 and M2 polarised TG elicited 
peritoneal macrophages from C57/Bl6 mice as hypothesised, with higher levels in 
M1 than M2 macrophages. But surprisingly, no difference was found in the 11β-
HSD1 protein levels, which may suggest that the protein translation is blocked or 
newly synthesised protein is quickly degraded. Equal 11β-HSD1 protein levels in M1 
and M2 polarised macrophages does not support a role for 11β-HSD1 to support one 
direction but oppose the other in M1/M2 macrophage polarisation.  
11β-HSD1 expression was induced very robustly in the J774.1 macrophage cell line 
by LPS stimulation (examined by qPCR and enzyme activity assay) (Ishii, Masuzaki 
et al. 2007; Wang, Liu et al. 2012). A dynamic 11β-HSD1 expression change is also 
seen in TG elicited peritoneal cells. 11β-HSD1 enzyme activity is increased with 
time in TG elicited peritoneal cells during the first 24h (when neutrophils and 
monocytes are dominating populations) and remains at high levels during day 1-day4 
(when monocyte differentiates into macrophages) but it returns to normal levels by 
day 5 (when macrophages are fully matured) (Gilmour, Coutinho et al. 2006). 
However, compared to untreated day 3 TG elicited peritoneal macrophages, LPS 
only or LPS+IFNϒ treatment failed to increase 11β-HSD1 expression examined by 
western blotting. This shows that TG elicited macrophages are different to the J774.1 
macrophage cell line in terms of 11β-HSD1 expression in response to inflammatory 
challenges.  
In terms of M1/M2 polarised TG elicited peritoneal macrophages, although RNA 
data showed some increased M1 markers and some decreased M2 markers in 11β-
HSD1 deficient macrophages, there were no changes in corresponding cytokine and 
protein levels. In the M1 polarisation study, Il1b, Tnfa and Nos2 mRNA levels were 
modestly increased in 11β-HSD1 deficient macrophages (less than 2 fold), but there 
were no difference in IL-1β or iNOS protein levels. A similar phenomenon was 
found in the M2 polarisation study. Chi3l3, Arg1 and Il10 mRNA levels were 
modestly higher in 11β-HSD1 deficient macrophages than wild type control 
macrophages, but YM-1 protein (encoded by Chi3l3) levels were not different 
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between the 2 groups. The M2 response is dominated by the phospho-STAT6 
transcription factor, the expression levels of which were not changed either. These 
data argue against important role of 11β-HSD1 in M1/M2 polarization of 
macrophages. Similarly, in macrophages isolated from adipose tissues of 11β-HSD1 
deficient and control wild type mice, mRNA levels of M1/M2 marker genes are 
similar, as well as cytokine levels (Wamil, Battle et al. 2011).   
In the reports based on in vitro macrophage 11β-HSD1 studies, which advocate a 
pro-inflammatory role of 11β-HSD1 (Ishii, Masuzaki et al. 2007; Wang, Liu et al. 
2012; Garcia, Search et al. 2013), 11β-HSD1 substrate concentration is a big 
concern. There is no 11β-HSD1 substrate or the substrate concentration deviates 
from the in vivo conditions. The first 2 papers used J774.1 macrophage cell line to 
study LPS induced inflammatory response with 11β-HSD1 inhibitors. In the report of 
Ishii, et al., there was no added 11β-HSD1 substrate, 11-dehydrocorticosterone, in 
the culture medium, the levels of which is very low in fetal calf serum. In the paper 
of Wang, et al., it was revealed that the pro-inflammatory role of 11β-HSD1 in 
macrophages is exhibited when 11-dehydrocorticosterone level is <0.1nM (no effects 
between 1-1000nM and anti-inflammatory effects at 10μM) in the absence of any 
active GCs. Also, the effects are very mild with about 0.25 fold change of Il6 mRNA 
levels by these treatments. Primary peritoneal macrophages elicited by TG from 11β-
HSD1 knockout mice in Apoe
-/-
 genetic background were used in the third report and 
showed a decreased inflammatory response to copper-oxidized LDL, compared to 
Apoe
-/- 
controls. The effect was produced when macrophages were incubated with 
200nM 11-DHC in culture medium for 5h and then overnight incubation with 200nM 
11-DHC and oxidized LDL.  
It is very hard to predict the levels of the 11β-HSD1 substrates in vivo, which is 
under the control of the HPA axis to generate active GCs and 11β-HSD2 to generate 
inert GCs. Inflammation induces a change in HPA axis activity and 11β-HSD2 
activity was decreased by inflammation (Chisaka, Johnstone et al. 2005). Therefore it 
is hard to judge how well these reported changes in vitro mimic what happens in 
vivo. 
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The data showing increased inflammatory cytokine levels in macrophages from 11β-
HSD1 deficient mice after LPS stimulation (Gilmour, Coutinho et al. 2006; Zhang 
and Daynes 2007) were not reproduced in the current experiments. In the second 
report, primary macrophages from 11β-HSD1 deficient mice, either TG elicited 
macrophages or spleen macrophages but not BMDMs, showed increased cytokines 
secretion upon LPS treatment, compared to wild type controls. (Zhang and Daynes 
2007). This was associated with lower Iκ Bα protein levels in 11β-HSD1 deficient 
spleen macrophages upon LPS treatment, while p-Akt, p-p38, p-ERK44/42 and 
SHIP1 were increased in them. The authors proposed higher SHIP1 expression may 
stimulate pro-inflammatory cytokine production, but this contrasts with the normally 
accepted view of SHIP1 to be a negative regulator of inflammatory cytokines (An, 
Xu et al. 2005), as the authors discussed. The increased SHIP1 levels were attributed 
to induction of TGFβ by higher circulating GC levels in the 11β-HSD1 deficient 
mice. However, the reported higher circulating GC levels in 11β-HSD1 deficient 
mice are not observed in the same line of mice measured in our centre (Carter, 
Paterson et al. 2009).  
The ELISA cytokine pattern observed here is unusual, with unchanged IL1 and IL6, 
but decreased IL12 p40 levels. However, a similar pattern was reported in 
macrophages from Trib1
-/- 
mice. After LPS stimulation of Trib1
-/- 
macrophages, the 
only difference detected was reduced IL12 p40 release associated with increased 
C/EBPβ protein expression (Yamamoto, Uematsu et al. 2007). Western blotting did 
show increased C/EBPβ expression in macrophages from Hsd11b1 deficient 
macrophages, but with lower Cebpb mRNA levels. There was no change in levels of 
Trib1 or Cop1 mRNA (encoding an E3-ubiquitin ligase, which docks on Trib1 
protein) and this does not support an influence of 11β-HSD1 deficiency on Trib1 or 
Cop1. With hindsight, it is found that selective IL12 p40 was also reported in 12/15 
lipoxygenase deficient macrophages (Zhao, Cuff et al. 2002) and IL12 p40 is also 
negatively regulated by SHIP-1 (Hadidi, Antignano et al. 2012), but these have not 
been explored in the 11β-HSD1 deficient macrophages. 
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In terms of alternative activation of macrophages, increased M2 polarisation in the 
11β-HSD1 deficient macrophages was hypothesised, as early accumulation of YM-1 
positive cells were observed in the infarcted area of the hearts of 11β-HSD1 deficient 
mice following myocardial infarction (McSweeney, Hadoke et al. 2010). However, 
the in vitro polarisation experiment does not support this. Although mRNA levels of 
most M2 gene tested are lower in the 11β-HSD1 deficient macrophages, there was no 
difference in phospho-STAT6 or YM-1 protein levels. However, there are limitations 
in the western blotting studies. YM-1 is a secreted protein and only intracellular YM-
1 is represented in western blotting. Additionally, measurement of phospho-STAT6 
at early time points would be more informative, such as 1h time point post IL4 
stimulation used in the study of ABCA1 (Pradel, Mitchell et al. 2009) rather than 20h 
in the current experiment. 
Hypoxia is a strong modulator of macrophage function. Hif1a and Hif2a were shown 
to be necessary for a macrophage inflammatory response (Cramer, Yamanishi et al. 
2003; Imtiyaz, Williams et al. 2010). In terms of hypoxic regulation of 11β-HSD1, 
HIF1α has been shown to negatively regulate 11β-HSD1 expression in adipocytes 
(Lee, Gao et al. 2013). But when 11β-HSD1 deficient and control macrophages were 
tested in the hypoxia environment, surprisingly most genes were unchanged at the 
mRNA level, including genes involved in angiogenesis, fibrosis, energy metabolism 
and inflammatory responses.  
The interest in Hedgehog signalling came from RNA-sequence data from 
atherosclerotic aortas of 11β-HSD1 deficient mice (Professor Karen Chapman, 
unpublished data). There are several reports of effects of GC on hedgehog activity 
(Heine and Rowitch 2009; Wang, Lu et al. 2010), and cortisol is reported to have a 
stronger ability than cortisone to positively sensitize cells to hedgehog ligand 
stimulation in vitro (Wang, Davidow et al. 2012). The preliminary data here on the 
effect of 11β-HSD1 deficiency in macrophages upon hedgehog signalling are not 
conclusive. The trend to higher Ihh mRNA levels with significantly lower Patched 
mRNA levels is suggestive of higher hedgehog signalling from11β-HSD1 deficient 
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M2 macrophages. However, no IHH protein was detected in M2 proteins by western 
blotting, the levels of which may be too low. 
In summary, there is little evidence to support an important role of 11β-HSD1 in 
M1/M2 macrophage polarisation or in the response to hypoxia, as least when studied 
in vitro. These in vitro experiments lack the dynamic 11β-HSD1 substrate level 
changes in vivo and are not able to explain the ‘changed’ macrophage function in 
globally 11β-HSD1 deficient mice. Therefore, macrophage specific 11β-HSD1 
knockout mice provide a good tool to examine the role of macrophage 11β-HSD1 
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Studies carried out in globally Hsd11b1 deficient mice (Kotelevtsev, Holmes et al. 
1997) have shown that 11β-HSD1 deficiency promotes angiogenesis in a model of 
subcutaneous sponge implantation (Small, Hadoke et al. 2005) and improves 
outcome of atherosclerosis and myocardial infarction (McSweeney, Hadoke et al. 
2010; Kipari, Hadoke et al. 2013). However, 11β-HSD1 deficiency increases the 
severity of acute inflammation and worsens outcome in K/BxN serum induced 
arthritis (Coutinho, Gray et al. 2012). Macrophages were suggested to play a role in 
these processes. For example, 11β-HSD1 deficient mice have more YM-1+ 
macrophage infiltration after myocardial infarction (McSweeney, Hadoke et al. 
2010), fewer macrophages in the atherosclerosis plaque area (Kipari, Hadoke et al. 
2013) and delayed acquisition of macrophage phagocytosis (Gilmour, Coutinho et al. 
2006). However, these experiments do not distinguish between cause and effect. 
Given the wide range of 11β-HSD1 expression (Whorwood, Sheppard et al. 1993; 
Tomlinson, Walker et al. 2004), it is hard to distinguish the contribution of different 
cells in a particular model. In addition, a role for changed HPA axis activity or 
regulation, shown to be dependent on mouse genetic background, in globally 11β-
HSD1 deficient mice is not ruled out (Harris, Kotelevtsev et al. 2001; Carter, 
Tworowska et al. 2006; Carter, Paterson et al. 2009).   
To avoid disturbance of HPA axis activity and dissect the function of 11β-HSD1 
function in myeloid cells, cre/loxP recombination technology was introduced. In 
LysM-Cre mice, Cre expression is under the control of the LysM (Lyz2) promoter, 
which has been shown to be highly expressed in myeloid cells; mainly neutrophils 
and monocytes/macrophages (Clausen, Burkhardt et al. 1999). By crossing LysM-




(MKO) mice were 
generated as part of a previous study (Zhang 2011), but were not characterized. In 
 
Chapter 4: Characterisation of LysM-Cre Hsd11b1
flox/flox 
mice  92 
this chapter, 11β-HSD1 deletion efficiency was examined in different sources of 
myeloid cells from MKO and control littermate mice by measuring levels of 
Hsd11b1 mRNA, 11β-HSD1 protein and enzyme activity. 
4.2 Aim 
To determine efficiency of 11β-HSD1 deletion in different populations of myeloid 
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4.3 Results 
4.3.1 Thioglycollate elicited peritoneal cells from MKO mice show reduced 
Hsd11b1 mRNA levels but no corresponding reduction in 11β-HSD1 
protein or enzyme activity levels. 
To determine whether Hsd11b1 mRNA levels were reduced as predicted in myeloid 
cells of MKO mice, peritoneal cells were lavaged 24h after intraperitoneal (i.p.) 
thioglycollate (TG) injection (when neutrophils and monocytes/macrophages are the 
majority of the population), or 96h after TG injection (when macrophages are the 
majority population, >95%). Additionally, as LysM-Cre mediated recombination is 
reported to be ~100% in neutrophils (Clausen, Burkhardt et al. 1999), neutrophils 
purified from peritoneal cells lavaged 24h after TG injection were examined as well.  
Compared to littermate control ‘floxed’ mice, MKO mice showed an 81% reduction 
in Hsd11b1 mRNA in peritoneal macrophages lavaged 96h after TG injection (Figure 
4-1A) and a 71% reduction in peritoneal cells lavaged 24h after TG injection (Figure 
4-1B). In the purified neutrophils, there was 83% reduction in Hsd11b1 mRNA levels 
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Peritoneal cells lavaged



















































Figure 4-1 Hsd11b1 mRNA levels are reduced in TG elicited myeloid cells from MKO 
mice.  
Hsd11b1mRNA levels were measured by qPCR, with TBP mRNA as internal control. (A) In 
peritoneal cell lavaged 96h after TG injection, there were lower Hsd11b1 mRNA levels in 
the MKO group than ‘floxed’ littermate controls (** p<0.01, unpaired t-test, n=4-5/group). 
(B) In peritoneal cells lavaged 24h after TG injection, there was a significant reduction in 
Hsd11b1 mRNA levels of MKO mice (p<0.01, unpaired t-test, n=6 in each group). (C) In the 
neutrophils, a reduction was also observed, although the n number in the MKO group was 2 
(n=3 in control group), too few for statistical test. Data are means ± SEM. 
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To determine whether reduced Hsd11b1 mRNA levels were associated with 
decreased 11β-HSD1 enzyme activity, enzyme activity assays were conducted in 
myeloid cells from MKO and control mice. Samples were the same as above, 
including peritoneal macrophages lavaged 96h after TG injection (Figure 4-2A), 
peritoneal cells lavaged 24h after TG injection (monocytes and neutrophils, Figure 4-
2B) and neutrophils purified from total peritoneal cells at 24h (Figure 4-2C). 
Surprisingly, there was no difference in 11β-HSD1 enzyme activity levels between 
the 2 genotypes in the macrophage and neutrophil groups. However, a modest 
decrease was observed at one time point of the assay in the mixed cell population 
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Figure 4-2 11β-HSD1 reductase activity did not differ between TG elicited myeloid cells 
from MKO and control mice.  
11β-HSD1 activity was measured by the conversion of 
3
H-11-dehydrocorticosterone (B) to 
3
H-corticosterone (A) in the medium by intact cells. (A) In peritoneal macrophages lavaged 
96h after TG injection, there was no significant difference in 11β-HSD1 reductase activity 
levels between MKO and control mice (p=0.43, unpaired t-test, n=4 in the control group and 
n=8 in the MKO group). (B) In repeated samplings of the culture medium during the enzyme 
activity assay of peritoneal cells lavaged 24h after TG injection, 2 way repeated 
measurement ANOVA showed a significant interaction between genotypes and time. 
Bonferroni post-test showed significant difference at the 4h time point, but not at the 2h time 
point. (n=4 in each group). (C) In the purified neutrophils, there was no significant difference 
in 11β-HSD1 reductase activity levels (p=0.72, unpaired t-test, n=3/group). Data are means ± 
SEM. 
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To address the discrepancy between reduced Hsd11b1 mRNA levels and nearly 
normal 11β-HSD1 enzyme activity levels in TG elicited myeloid cells form MKO 
mice, the encoded 11β-HSD1 protein levels were measured. Western blotting of 11β-
HSD1 showed 33% reduction in peritoneal macrophages lavaged 96h after TG 
injection (Figure 4-3A), 31% reduction in cells lavaged 24h after TG injection 
(Figure 4-3B) and 38% reduction in purified neutrophils (Figure 4-3C), although the 
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Figure 4-3 11β-HSD1 protein levels were decreased modestly in TG elicited myeloid 
cells of MKO mice.  
Western blotting was used to measure 11β-HSD1 protein levels, relative to β-tubulin or 
GAPDH. (A) 11β-HSD1 protein levels were reduced in peritoneal macrophages lavaged 96h 
after TG injection in MKO mice, compared to controls (* p<0.05, unpaired t-test, n=4 in 
each group). (B) 11β-HSD1 protein levels were reduced in peritoneal cells lavaged 24h after 
TG injection in MKO mice, compared to controls (*** p<0.001, unpaired t-test, n=4 in each 
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from MKO mice, but did not achieve significance (p=0.19, unpaired t-test, n=3 in each 
group). Data shown are means ± SEM. 
 
4.3.2 Cre protein is expressed in peritoneal cells lavaged 24h 
after TG injection  
The modest reduction in 11β-HSD1 protein levels of myeloid cells from MKO group 
was disappointing. To make sure that Cre protein is expressed in myeloid cells 
lavaged from MKO mice, western blotting of Cre protein was conducted. In a 
separate experiment, peritoneal cells lavaged 24h after TG injection were harvested 
from MKO and control mice. Although several bands appeared, a band unique to the 
MKO group of the correct size of Cre protein (38kDa) was present in the MKO 
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Figure 4-4 Cre protein is expressed in MKO peritoneal myeloid cells lavaged 24h after 
TG injection in MKO group.  
Western blotting was done to detect Cre protein. Each lane contains 20μg protein from one 
mouse. The left lane (‘L’) contains a protein ladder with 3 sizes marked. Arrow indicates a 
band of the right size for Cre, which is present in the MKO group, but not in the control 
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4.3.3 Moderate deletion efficiency in day 7 bone marrow derived macrophages 
from MKO mice 
The absence of the expected reduction in 11β-HSD1 enzyme activity in TG elicited 
myeloid cells from MKO mice was puzzling. Therefore, another population of 
macrophages was examined: bone marrow derived macrophages (BMDM, day 7). 
BMDMs from MKO mice showed a trend for a 45% reduction in Hsd11b1 mRNA 
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Figure 4-5 11β-HSD1 activity was reduced in BMDMs from MKO mice, compared to 
Cre
-
 littermate controls.   
Level of Hsd11b1 mRNA was measured by qPCR and 11β-HSD1 enzyme activity was 
measured by conversion of 
3
H-11-dehydrocorticosterone (B) to 
3
H-corticosterone (A) in the 
medium by intact cells. (A) Hsd11b1 mRNA showed a trend of 45% reduction in the MKO 
group (n=5-6, no significant difference, unpaired t-test with Welch’s correction). (B) 11β-
HSD1 enzyme activity was reduced by 54% in BMDMs from MKO group (n=5-6, ** 
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4.3.4 11β-HSD1 protein is reduced by ~50% in TG elicited 
macrophages from LysM-Cre Hsd11b1del/flox (MKO/Δ) 
mice 
The poor deletion efficiency observed in the above experiments may be due to 
insufficient Cre-mediated recombination. To try to improve this, LysM-Cre 
Hsd11b1
del/flox 
(MKO/Δ) mice (with one ‘floxed’ and one null allele of Hsd11b1) 
were generated by crossing LysM-Cre Hsd11b1
flox/flox
 mice with Hsd11b1
del/del
 mice. 
However, western blotting on peritoneal macrophages lavaged 96h after TG injection 
showed that there was still ~50% 11β-HSD1 protein expression remaining in 
macrophages from MKO mice compared to controls (Figure 4-6). The experiment 
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Figure 4-6 11β-HSD1 protein levels in MKO/Δ mice were reduced by ~50% in 
peritoneal macrophages lavaged 96h after TG injection.  
Western blotting was done to detect 11β-HSD1 protein in macrophage homogenates. In the 
picture, 11β-HSD1 protein is clearly visible in MKO/Δ mouse samples. Each lane contained 
30μg of protein from one mouse. Data shown are the mean of the control group and mean ± 
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To address whether the observed ~50% reduction in MKO/Δ mice simply reflects 
loss of an allele of Hsd11b1, 11β-HSD1 protein and Hsd11b1 mRNA levels were 
measured in Hsd11b1
del/+ 
heterozygous mice and control ‘floxed’ mice. In peritoneal 
cells lavaged from Hsd11b1
del/+ 
heterozygous mice 24h after TG injection, there was 
~50% reduction in Hsd11b1 mRNA levels and 11β-HSD1 protein levels (data not 
shown). This confirms the lack of efficient LysM-Cre mediated deletion of 11β-
HSD1 protein and rules out post-translational regulation of 11β-HSD1 protein to 
increase 11β-HSD1 protein expression in myeloid cells as the source of discrepancy 
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4.3.5 11β-HSD1 enzyme activity is markedly reduced in resident peritoneal 
macrophages from MKO mice.  
Previous studies using siRNA to reduce Hsd11b1 expression in vitro (Bujalska, 
Draper et al. 2005; Aubry and Odermatt 2009) showed a similar discrepancy between 
mRNA and 11β-HSD1 protein expression to that observed here, in TG-elicited 
myeloid cells from MKO mice. A long half-life of 11β-HSD1 protein was suggested 
to account for this (Aubry and Odermatt 2009). It was reasoned that the discrepancy 
between Hsd11b1 mRNA and 11β-HSD1 protein in the current study was because of 
a recent Cre-mediated recombination of Hsd11b1 gene, sufficient to decrease mRNA, 
but not the long-lived 11β-HSD1 protein in short-living circulating myeloid cells. 
Therefore, the long-lived resident peritoneal macrophage population was chosen to 
measure 11β-HSD1 protein and enzyme activity in MKO mice.  
In a pilot experiment, it was found that 11β-HSD1 protein was undetectable in 
resident peritoneal macrophages from a single MKO mouse (Figure 4-7A). The 
limited cell number (about 1 million) obtained from each mouse and the method of 
collecting macrophages (which attach firmly in the tissue culture plate during the 
purification process) constrained amount of concentrated proteins for western 
blotting study. Instead, 11β-HSD1 enzyme activity was examined in these cells. As 
11β-HSD1 activity in resident macrophages is much lower than in TG elicited 
myeloid cells, a 20h assay time was used. It was evident that 11β-HSD1 enzyme 
activity was greatly reduced in MKO mice, compared to the littermate controls 
(Figure 4-7B and C). 
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Figure 4-7 11β-HSD1 enzyme activity is markedly reduced in resident peritoneal 
macrophages from MKO mice.   
(A)  Western blotting showed a lack of immuno-reactive 11β-HSD1 in resident peritoneal 
macrophages from a naïve MKO mouse. Each lane contains ~10µg protein from one mouse. 
Only the 3 labelled lanes were loaded. (Because the maximum volume was loaded into the 
wells, sample overload caused spillage into neighbouring wells.) (B) Image of the 
phosphorimager tritium image screen showed little or no conversion of 11-
dehydrocorticosterone (A) to corticosterone (B) by resident peritoneal macrophages from 
MKO mice.  ‘C’, control; ‘-’, no cells. Each lane represents one mouse except for the lane 
marked as ‘-’. (C) Quantification of 11β-HSD1 activity shown in (B) showed 82% reduction 
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To examine other tissue resident macrophages, 11β-HSD1 western blotting was 
carried out in alveolar macrophages and adipose stromal vascular cells (SVCs) from 
naïve mice. However, no 11β-HSD1 protein was detectable in alveolar macrophages, 
even in control mice (Figure 4-8A). In macrophages harvested from adipose SVCs 
(CD11b
+
 population), there did not appear to be an obvious decrease in 11β-HSD1 
protein levels (Figure 4-8B). Limited cell number constrained protein harvest in both 

















Chapter 4: Characterisation of LysM-Cre Hsd11b1
flox/flox 




Figure 4-8 11β-HSD1 protein was undetectable in alveolar macrophages from either 
control or MKO mice and the expression levels in macrophages in the adipose SVCs of 
MKO mice were not obviously different to those controls.  
(A) Comparison to the positive control (wild-type lung total protein sample; ‘+’) and 
negative control (Hsd11b1
del/del 
lung total protein sample; ‘-’) showed that 11β-HSD1 was 
undetectable in alveolar macrophages from either MKO or control mice. Each lane contains 
~10μg of protein and represents one mouse. Arrows indicate the bands of target proteins. For 
11β-HSD1, there are 2 bands detected with the lower band as glycosylated form of 11β-




 cells isolated from adipose SVCs, 11β-HSD1 
protein levels were obviously decreased in MKO mice. However, failure to detect β-tubulin 
confounded the interpretation of this experiment. Each sample was obtained by pooling 
SVCs from 2 or 3 mice of the same genotype. 
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4.4 Discussion 
In this line of MKO mice, it is likely that there is good Cre-mediated Hsd11b1 
recombination at the genomic level in target cells, reflected by ~80% reduction in 
Hsd11b1 mRNA levels in macrophages lavaged 96h after TG injection, as well as 
total peritoneal cells lavaged 24h after TG injection and in purified neutrophils. 
However, 11β-HSD1 protein and enzyme activity were reduced by less than 50% at 
best in these cells. In contrast, substantial reduction in 11β-HSD1 protein and 
enzyme activity levels was observed in resident peritoneal macrophages. 
The possible discrepancy between Hsd11b1 mRNA and encoded protein expression 
in the TG-elicited myeloid cells was first attributed to a post-transcriptional 
regulation mechanism, to maintain normal levels of 11β-HSD1 protein in response to 
reduced Hsd11b1 mRNA levels. However, the fact that myeloid cells from 
heterozygous Hsd11b1 globally knockout mice (Hsd11b1
del/+
) contain approximately 
half the levels of Hsd11b1 mRNA and encoded protein of the control ‘floxed’ mice 
does not support this.  
An alternative explanation for the discrepancy between Hsd11b1 mRNA and 11β-
HSD1 protein levels in TG elicited myeloid cells is the long half-life of 11β-HSD1 
protein. A similar persistence in 11β-HSD1 enzyme activity was described in mouse 
C2C12 myotubes, following down-regulation of Hsd11b1 mRNA by incubation with 
retinoic acid (Aubry and Odermatt 2009). Similarly, when siRNA was used to knock 
down HSD11B1 in HEK 293T1 cells, despite >52% reduction in HSD11B1 mRNA, 
85% of 11β-HSD1 enzyme activity remained (Bujalska, Draper et al. 2005). The 
half-life of Hsd11b1 mRNA in 3T3-L1 adipocytes is reported to be 21h under basal 
conditions (Balachandran, Guan et al. 2008), but so far, little information about 11β-
HSD1 protein half-life is available to my knowledge. In a proteomics study after 6 
month of protein labelling with N
15
 (Toyama, Savas et al. 2013), 11β-HSD1 scored 
the top 5% in terms of being “exceptionally long lived” (personal communication, 
Dr. Jeffrey N. Savas, Lab of John Yates, Scripps Institute, the US). The half-life of 
myeloid cells in vivo is another factor to consider. For TG elicited myeloid cells and 
circulating myeloid cells, the rapid clearance in vivo probably constrains the 
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observation of protein decrease. For example, the half-life of circulating neutrophils 
is reported to be about 6-8 hours in one report (Summers, Rankin et al. 2010).  
It is puzzling that there was little reduction in 11β-HSD1 enzyme activity levels in 
neutrophils and macrophages from MKO mice than control mice, albeit ~30% 
decrease in 11β-HSD1 protein levels. Moreover, enzyme activity was modestly 
reduced in peritoneal cells lavaged 24h after TG injection at 4h of the assay but not 
at 2h. In the case of cells lavaged 24h after TG injection, monocytes and neutrophils 
are in the majority, it is likely that during the assay, 11β-HSD1 expression was 
synthesised de novo in the control but not the MKO group. It is known that 
monocytes up-regulate 11β-HSD1 expression during differentiation into 
macrophages (Thieringer, Le Grand et al. 2001; Gilmour, Coutinho et al. 2006). This 
could be the reason for the difference of activity assay at 4h but not at 2h. 
Alternatively, the ‘missed’ difference in enzyme activity assay may be due to limited 
n number (n=3 -8) and big intra-group variance. With hindsight, it is realised that 
small n number usually used in the literature is enough for detecting the expected big 
difference (>80%, for example) but has limited power to uncover small differences. 
However, even if there was a 30% difference in enzyme activity levels between 
MKO and controls, this small decrease probably would not produce a phenotype in 
the macrophages. 
The poor deletion efficiency of target genes by LysM-Cre has been described 
previously. The original paper described very high deletion efficiency in the LysM-
Cre mice, but it is of note that the method they used to detect target gene expression 
change was only southern blotting. For the 2 tested target genes, deletion efficiency 
was lower for one than the other.  An on-going deletion process was found in bone 
marrow derived macrophages (Clausen, Burkhardt et al. 1999). This may explain the 
observation of about 50% deletion of Hsd11b1 mRNA and11β-HSD1 protein in 
BMDMs from MKO mice. Other researchers have noted varying efficiency of LysM-
Cre mediated gene ‘knock-out’ in different monocyte/macrophage populations. By 
examining LysM-Cre ROSA26-GFP  mice, it was found that there was 80% deletion 
of the target gene in resident peritoneal macrophages but only about 50% in TG 
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elicited ones (day 3) and BMDMs ( from day 1 and day 7) by flow cytometry 
examination ((Osterreicher, Penz-Osterreicher et al. 2011)). In another study, 
researchers crossed LysM-Cre mice with ROSA26STOP*DTR (DTR, diphtheria-
toxin receptor) mice, aiming to specifically deplete macrophages after DT 
administration. When DT was administered to the LysM-Cre/DTR mice, it was only 
the resident macrophages (such as those in the skin and liver) that were markedly 
reduced, not the circulating monocytes (Goren, Allmann et al. 2009). Comparison of 









 monocyte precursors. This suggests that 
LysM-Cre expression increases with the maturation of monocytes and macrophages.  
Why is good deletion efficiency achieved in resident peritoneal macrophages? In a 
recent study, resident macrophages from different anatomical sites (brain, liver, lung 
and peritoneal cavity) were examined by microarray. Interestingly, Lyz2 (LysM) is 
found to be expressed at markedly higher levels in resident peritoneal macrophages 
than in all the other tissue resident macrophages (Gautier, Shay et al. 2012). This 
may explain the high deletion efficiency of 11β-HSD1 activity in resident peritoneal 
macrophages.  
It remains to be investigated whether other tissue resident macrophages have good 
11β-HSD1 deletion in MKO mice or whether some of them do not express 11β-
HSD1. 11β-HSD1 seems to be expressed in different levels among different 
populations of tissue resident macrophages. There is no 11β-HSD1 protein detected 
from alveolar macrophages in the current study, although low levels of Hsd11b1 
mRNA have been detected previously, which may be due higher sensitivity of qPCR 
(Yang 2010). Immunohistology staining only detect very low 11β-HSD1 expression 
in adipose tissue macrophages (De Sousa Peixoto, Turban et al. 2008) or in 
microglial cells (personal communication, Miss Mei Xuan Lye, University of 
Edinburgh). Weak enzyme activity in peritoneal resident macrophages found in this 
study is similar to what was reported in a previous study (Gilmour, Coutinho et al. 
2006). Whether adipose tissue SVC macrophages are tissue resident macrophage or 
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bone marrow derived macrophages are not defined yet (personal communication, 
Frederic Geissman, King’s College of London). 
Different to tissue resident macrophages, TG-elicited peritoneal macrophages are 
bone marrow derived macrophages (Van Furth, Diesselhoff-den Dulk et al. 1973). 
Peritoneal macrophages lavaged after TG injection are generally thought to be not 
fully activated in the first instance. Accordingly, they are usually further stimulated 
with LPS, etc. to study macrophage polarisation (Usher, Duan et al. 2010).  
The attempt to achieve better deletion in LysM-Cre Hsd11b1l
flox/Δ 
mice is not 
successful, although this method was shown to work well for other target genes 
(Huang, Perlman et al. 2010). With hind sight, Cre deletion efficiency does not 
appear to be the problem in the MKO mice; instead, it is likely to be owing to that 
11β-HSD1 protein has a long half-life, relative to that of the circulating myeloid 
cells. 
In summary, macrophage-specific 11β-HSD1 knockout is achieved in peritoneal 
resident macrophages, but not in TG-elicited myeloid cells in MKO mice. These 
mice will be therefore suitable to assess the role of 11β-HSD1 in certain tissue 
resident macrophages in inflammation, but may not be suitable for the investigation 
of 11β-HSD1 in inflammatory cells recruited from bone marrow during acute 
inflammation. Moreover, in inflammatory models such as wound healing, diet 
induced obesity, atherosclerosis and K/BxN serum induced arthritis, inflammation 
evolves in a much longer time period with possible involvement of resident 
macrophages and thus these models may be suitable to study the effect of 11β-HSD1 
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Chapter 5: Increased angiogenesis in 
macrophage-specific 11β-HSD1 knockout MKO 
mice 
5.1 Introduction 
Angiogenesis is a process of capillary branching formation from big blood vessels. It 
is important in both embryo development and tissue remodelling to ensure an 
appropriate supply of oxygen and nutrition. It is a rigorously regulated process, as 
either inadequate (as in ischemic diseases) or excess (as in tumour growth) blood 
vessel growth poses a threat to the body. Glucocorticoids (GCs) have been shown to 
effectively inhibit angiogenesis (Folkman, Langer et al. 1983). Local amplification of 
GC action by 11β-HSD1 is also demonstrated to assert a negative role on 
angiogenesis, demonstrated in globally 11β-HSD1 deficient mice (Small, Hadoke et 
al. 2005). 
The cell type responsible for increased angiogenesis in globally 11β-HSD1 deficient 
mice has not been identified. By qPCR in different parts of the mouse aorta, 
Hsd11b1 was shown to be localised in the smooth muscles and the adventitial tissues 
(where macrophages and other cells resides), but not in endothelial cells (Christy, 
Hadoke et al. 2003). Later, immunohistology staining showed that 11β-HSD1 was in 
endothelial cells (Gong, Morris et al. 2008; Luo, Thieringer et al. 2013). But the 
existence of 11β-HSD1 in endothelial cells is still controversial, as 11β-HSD2 is 
expressed there and 11β-HSD1 and 11β-HSD2 rarely co-localise (Hadoke, 
Macdonald et al. 2006; Hadoke, Kipari et al. 2013).  Specificity of 11β-HSD1 
antibodies for immunohistology is another concern (Coutinho 2009; Liu, Srikant et 
al. 2011). 
As mentioned in the Section 1.1.3 and 1.4.3, inflammation is closely associated with 
angiogenesis and changed macrophage polarisation was indicated in previous 
angiogenesis studies on globally 11β-HSD1 deficient mice (McSweeney, Hadoke et 
al. 2010). To dissect the contribution of resident macrophage 11β-HSD1 deficiency 
to the increased angiogenesis phenotype in globally Hsd11b1 deficient mice, 
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angiogenesis was studied in MKO mice using a model of subcutaneous (s.c.) sponge 
implantation.  
5.2 Hypothesis 
Myeloid cell 11β-HSD1 ablation increases angiogenesis in vivo. 
 
5.3 Results 
5.3.1 Blood vessel formation in the sponge implantation 
model on MKO and control mice. 
To investigate the role of myeloid cell 11β-HSD1 in angiogenesis, MKO and control 
mice were subjected to s.c. sponge implantation. In the experiment, one piece of 
sponge was inserted subcutaneously in each flank. After 21 days, sponges were 
removed for analysis, one for histology and the other for RNA extraction. The colour 
of sponges is indicative of haemoglobin content and thus blood vessel number 
(Yoshida, Amano et al. 2003). Although images of fresh sponges were not taken, 
Figure 5-1 shows images of sponges in the paraffin blocks. The gross appearance of 
the sponge shows that those from MKO mice display a darker colour than those from 
control mice. One globally 11β-HSD1 knockout mouse (‘Del I’) was included in the 
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Figure 5-1 Representative images of sponges from MKO and control mice in paraffin 
blocks.  




 row from control 
mice (except the one within a red box). Each block shows one sponge from one mouse. ‘Del 
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5.3.2 Increased angiogenesis in sponges from MKO mice.  
To visualise blood vessels in the sponges, H&E staining was carried out on paraffin 
sections. Circle or tube-like shaped structures usually with red blood cells inside 
were considered to be blood vessels. Chalkley counting was performed to count the 
number of blood vessels, blind to genotype, as described in Section 2.16. As shown 
in Figure 5-2A, blood vessel numbers are higher in MKO mice than in littermate 
controls. This was confirmed by measuring an endothelial cell specific marker, Cdh5 
(encoding VE-cadherin) (Figure 5-2B). Examples of H&E stained section are shown 
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Figure 5-2 MKO mice show more angiogensesis than littermate controls.  
(A) Chalkley counting on H&E stained sections of day 21 sponges showed more blood 
vessel formation in MKO mice than controls. Scoring was carried out blind to genotype and 
the average number of 6 fields from 2 sections was assigned to each sample. (B) Cdh5 
mRNA (encoding VE-Cadherin) levels were higher in sponges from MKO mice than 
controls. (C) Representive images of H&E stained sections of sponges from MKO and 
control mice, with blood vessels indicated by arrows. Data are means ± SEM and analysed 
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5.3.3 No difference in the cell proliferation marker Ki67 or the 
angiogenic factor Vegfa between MKO and control mice  
Increased cell proliferation (especially endothelial cells) may underline the increased 
blood vessel growth phenotype. However, measurement of mRNA encoding cell 
proliferation marker Ki67 did not support this (Figure 5-3A).  
VEGF and angiopoietin are crucial regulators of endothelial cell proliferation and 
migration, and thus angiogenesis (Welti, Loges et al. 2013). The presence of both 
was examined by qPCR on RNA from the sponges. There was no difference in Vegfa 
mRNA levels between MKO and control groups (Figure 5-3B), although with a trend 
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Figure 5-3  qPCR measurement of ki67, Vegfa and Angpt1, 2 and 4 gene expression in 
MKO and control mice.  
Expression of cell proliferation maker Ki67 (A) and angiogenesis factors Vegfa (B) were 
similar between MKO and control mice. There was a trend to higher Angpt1 mRNA levels in 
MKO mice, but not significant, the same as Angpt2 and Angpt4. Data are means ± SEM, 
n=7-11 in each group. Data were analysed by unpaired t-test, or un-paired t-test with 
Welch’s correction in case of Angpt1. 
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5.3.4 Higher Il1b and lower Icam1 mRNA levels in sponge 
from MKO. 
 Because the sponge implantation model is usually considered to be an inflammation-
driven model of angiogenesis (Zhang, Modi et al. 2012), inflammatory and other 
relevant gene expressions were examined. Of the inflammatory genes examined, 
only Il1b expression levels are significantly higher in the MKO group, and no 
difference is detected in Il6, Ifng, Tnfa or Ccl5 expression levels (Figure 5-4A). No 
Il12b gene expression is detected. There is little difference in the relevant gene 
expression levels, such as hedgehog receptor Patched, anti-inflammatory Tgfb1, etc., 
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Figure 5-4 Increased Il1b and decreased Icam1 mRNA levels in the sponges from MKO 
mice.   
(A) qPCR measurement of Il1b, Il6, Ifng, Tnfa and Ccl5 gene expression. (B) qPCR 
measurement of Ho1, Tgfb1, Patched, Icam1, Vcam1 and Grp78 expression.  Data are means 
± SEM, n=7-11. Each gene expression data are analysed by unpaired t-test individually to 
compare MKO and control groups with significance set at p<0.05; *, p<0.05. When the 
intergroup variance is not equal, un-paired t-test with Welch correction is used to analyse the 
data in the case of Il1b and Ho1.  
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5.3.5 Evidence for similar recruitment and alternative 
polarization state of macrophages in the sponges from 
MKO and control mice.  
Inflammation is accompanied by immune cell infiltration. Given the previous 
evidence of changed inflammatory state in MKO mice (higher Il1b expression), 
macrophage number and polarisation were investigated by qPCR in the sponges from 
MKO and control mice. However, levels of macrophage marker Cd68 mRNA was 
not different between genotypes (Figure 5-5), nor was expression of macrophage 
alternative polarisation status marker Retnla (Figure 5-5). Ym1 mRNA was 
undetectable (data not shown). 
Myeloid cell 11β-HSD1 ablation may result in decreased total Hsd11b1 mRNA 
levels in the sponges from MKO mice. However, total Hsd11b1 mRNA levels in the 
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Figure 5-5 Macrophage markers are not different in mRNA levels between genotypes. 
The pan-macrophage marker CD68 (A), alternative polarisation state maker Retnla (B) and 
Hsd11b1 mRNA levels (C) in the sponges were measured by qPCR. Data are means ± SEM, 
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5.4 Discussion 
The s.c. sponge implantation experiment offered an in vivo insight into the role of 
macrophages in the increased angiogenic response of globally 11β-HSD1 deficient 
mice. As hypothesised, MKO mice showed increased angiogenesis in the sponge 
implantation model. These data highlight the important function of macrophage 11β-
HSD1 in limiting angiogenesis. It contrasts with little effect of smooth muscle 
specific 11β-HSD1 ablation on angiogenesis in the same model (personal 
communication, Dr. Patrick Hadoke, University of Edinburgh).  
The angiogenesis of sponge implantation is considered to be an ‘inflammatory’ 
model. It is a chronic granulomatous response accompanied by angiogenesis and 
infiltration of inflammatory cells. Molecules involved include VEGF, PDGF, IL-1β, 
TNF-α, TGF-β, fibroblast growth factor 2, NO, COX2 and angiotensin-converting 
enzyme, many of which are from macrophages (Alam 2008). Endogenous GCs 
generated by 11β-HSD1 inhibit this angiogenesis process (Small, Hadoke et al. 
2005). When synthetic dexamethasone-loaded polyurethane implants were inserted 
in the sponge, reductions neovascularization, macrophage recruitment and collagen 
deposition were observed, with no change in neutrophil infiltration (Moura, Lima et 
al. 2011). Lack of GC signalling within macrophages of MKO mice may worsen 
acute inflammation. Higher Il1 mRNA levels of MKO mice support this. However, 
there is no indication of a general difference in inflammation, as other inflammatory 
genes such as Il6, Ifna and Tnfa were not differently expressed.  Validation of this at 
the protein level, using ELISA or western blotting would enhance this conclusion. 
However, attempts to do western blotting on whole sponge homogenates failed. 
Western blotting on cells isolated by collagenase digestion of the sponges may be 
helpful.  
Study of the angiogenesis in more time windows, especially at earlier times, may 
help reveal possible gene expression differences. In an in vivo nemotade infection 
model, there are more alternative polarised macrophages in globally 11β-HSD1 
deficient mice on day 8, but not later time points. Angiogenesis is controlled in a 
coordinated way. The early step of invasive capillary sprouting is induced by 
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VEGF/VEGF receptor and Notch/Notch ligand pathways. Subsequently, 
neurovascular guidance molecules (ephrins, slits, netrins, semaphorins) induce 3D 
vessel assembly and lumen formation. Maturation and vascular remodelling in the 
final stage of angiogenesis is controlled by angiopoietins, PDGF, and TGF-β families 
(Felcht, Luck et al. 2012). In past studies on globally 11β-HSD1 deficient mice, 
Vegfa mRNA levels were shown to be increased in the s.c. adipose tissues after high 
fat diet feeding (Michailidou, Turban et al. 2012), but this was not found in hearts 7 
days post myocardial infarction (McSweeney, Hadoke et al. 2010) or in the 
angiogenesis of sponge implantation model (personal communication, Dr. Patrick 
Hadoke).  In the current study, neither Vegfa nor the proliferation maker Ki67 was 
differently expressed between genotypes, but the day 21 data represent only a 
snapshot of the late stage of the whole angiogenesis process. On day 21, angiogenic 
activity is likely to have switched from sprouting of new blood vessel formation to 
maturation of blood vessels in MKO mice. The trend to higher Angpt1 expression 
levels is likely to reflect enhanced angiogenesis. It would be worth examining gene 
expressions at earlier time points, when the angiogenic activity is just initiated. 
In the s.c. environment where the sponges are implanted, resident macrophage 
number may be very limited. And other infiltrating cells of the sponges, such as 
fibroblasts and neutrophils could highly express 11β-HSD1. This may explain why 
the total Hsd11b1 mRNA in the sponge is not different between the 2 groups. But 
there is no direct evidence to show the deletion efficiency in sponge macrophages of 
the MKO mice anyway.  
In summary, the data from MKO mice in the angiogenesis model of s.c. sponge 
implantation show that generation of active GCs by myeloid cell 11β-HSD1 
suppresses angiogenesis, by regulating Il-1β and possibly angiopoietin-1 expression. 
This indicates that endocrine and immune systems work closely to regulate 
angiogenesis.
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Chapter 6: Impaired resolution of K/BxN serum 
transfer induced arthritis in MKO mice 
6.1 Introduction 
Synthetic GCs have been used in arthritis treatment for over 60 years and remain 
widely used in clinics to suppress a wide range of inflammatory diseases. However, 
the role of endogenous GCs in inflammatory responses remains eclusive.  
11β-HSD1 expression is usually increased in joints of arthritic subjects, a possible 
mechanism to suppress inflammation. A study in RA patients demonstrated a 
positive correlation between donor erythrocyte sedimentation rate (SER) and 11β-
HSD1 enzyme activity in the synovium (Hardy, Rabbitt et al. 2008). A rat study in 
adjuvant arthritis showed increased synovial Hsd11b1 mRNA and 11β-HSD1 
reductase activity, which was decreased by treatment with TNF-α and IL-1β 
antagonists (Ergang, Leden et al. 2010). A human study of urine steroid metabolites 
revealed higher 11β-HSD1 enzyme activity during RA progression, which was 
decreased after treatment with disease modifying drugs (Beyeler, Dick et al. 2012).  
The protective role of endogenous GCs was confirmed in studies of globally 11β-
HSD1 deficient mice. A previous study in the lab on these mice revealed a more 
severe onset and delayed resolution of K/BxN serum transfer induced arthritis 
(Coutinho, Gray et al. 2012). To further dissect contributions of different cell 
populations to this phenotype, myeloid cell specific Hsd11b1 KO mice (LysM-Cre 
Hsd11b1
flox/flox
, MKO) and their littermate controls (Hsd11b1
flox/flox
, Control) were 
studied in this model. 
K/BxN serum induced arthritis was chosen because this model is reported to be 
lymphoid cell independent (Ji, Ohmura et al. 2002). As K/BxN serum contains 
autoantibody against glucose-6-phosphate isomerase, arthritis is initiated by immune 
complex formation, eliciting myeloid cells without T cell activation or B cell 
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producing antibodies (Ditzel 2004). In this way, myeloid cell functions in 
inflammation can be studied separately from lymphocytes. Moreover, globally 11β-
HSD1 deficient mice are maintained on the C57Bl/6 strain genetic background, in 
which the K/BxN serum transfer induced arthritis (K/BxN arthritis) model works 
well (in contrast to other arthritis models, such as collagen induced arthritis) 
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6.2 Results 
6.2.1 11β-HSD1 expression is modestly decreased in 
circulating neutrophils and monocytes of MKO mice 
during K/BxN serum transfer induced arthritis 
Increased LysM-Cre mediated gene deletion efficiency with inflammation 
development has been reported (Cho, Hong et al. 2008). It was predicted that in the 
K/BxN serum induced arthritis model, 11β-HSD1 deletion efficiency would be 
boosted by development of inflammation. This was tested by flow cytometry to 
measure levels of 11β-HSD1 in blood neutrophils and monocytes.  
K/BxN serum transfer induced arthritis (abbreviated as K/BxN arthritis below) was 
induced as described in Section 2.17. In a pilot experiment, on day 3, 6, 9 and 12 
after K/BxN serum injection, blood was collected by a tail nick from 2 mice in each 
group; C57/BL6 (‘WT’), Hsd11b1
del/del 
(‘Del’), MKO and ‘floxed’ littermate 
(‘Control’). Blood cells were stained with CD45, CD11B and Ly6G antibodies 
before intracellular staining of 11β-HSD1 as described in Section 2.14 
An in-house sheep anti-11β-HSD1 antibody was kindly provided by Dr. Scott 
Webster. Staining with this antibody was specific as shown, by comparing the 
staining in Hsd11b1
del/del 
(‘Del’) samples (negative control for 11β-HSD1 
expression), isotype sheep IgG staining and unstained samples (Figure 6-1A). 
Examples of myeloid cell 11β-HSD1 staining in ‘floxed’ control and MKO mice are 
shown in Figure 6-1B and 6-1C, respectively.  
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Figure 6-1 Flow cytometry measurement of blood myeloid cell 11β-HSD1.  
Levels of 11β-HSD1 in the blood myeloid cells were measured by flow cytometry following 
induction of K/BxN arthritis. Total leukocytes were stained with anti-CD45 antibody, 





. (A) 11β-HSD1 flow cytometry staining in unstained cells (red), 
negative control Hsd11b1
del/del 
cells (brown) and isotype IgG staining (blue) in ‘floxed’ 
control mice. (B) An example of neutrophil (red) and monocyte (brown) 11β-HSD1 staining 
in a ‘floxed’ mouse, compared to isotype control staining (blue). (C) An example of 
neutrophil (red) and monocyte (brown) 11β-HSD1 staining in a MKO mouse, compared to 
isotype control staining (blue). 
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This pilot experiment to measure 11β-HSD1 levels showed that there was no 
improvement in 11β-HSD1 deletion efficiency in circulating neutrophils or 
monocytes of MKO mice during the study period, with about 50% reduction in 
neutrophils and monocytes (Figure 6-2). Peak expression of 11β-HSD1 on day 6 













Chapter 6: Impaired resolution of K/BxN serum transfer induced arthritis in MKO 



























































































Figure 6-2 No increase in 11β-HSD1 deletion efficiency in circulating neutrophils and 
monocytes from MKO mice during K/BxN arthritis. 
Levels of 11β-HSD1 in blood myeloid cells were measured by flow cytometry on day 3, 6, 9 
and 12 following induction of K/BxN arthritis. Geometric means of 11β-HSD1 staining were 
used to plot the figure, which reflected average levels of 11β-HSD1 in the cells. Day 3-12 
blood neutrophil (A) and monocyte (B) 11β-HSD1 staining in C57/BL6 (‘WT’, black 
squares), Hsd11b1
del/del 
(‘Del’, circles), MKO (filled triangles) and ‘floxed’ littermate control 
s(empty triangles) mice were plotted into the lines. N=2/group. Data are means. No data of 
day 12 in WT mice were obtained. 
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The low deletion efficiency in circulating myeloid cells was subsequently confirmed 
in a larger group of mice on day 9 after i.p. K/BxN serum injection. As shown in 
Figure 6-3, about 50% reduction in 11β-HSD1 staining was found in neutrophils of 
MKO mice with little change in monocytes. These data suggests a limited 
contribution of 11β-HSD1 deletion in circulating myeloid cells to the effects of 
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Figure 6-3 11β-HSD1 staining was modestly reduced in circulating myeloid cells of 
MKO mice on day 9 following K/BxN serum injection.  
MKO and littermate ‘floxed’ control mice were injected with 125μl K/BxN serum and 9d 
later, 11β-HSD1 levels in the circulating neutrophils and monocytes were measured. 
Geometric means of 11β-HSD1 staining were calculated for each sample after deduction of 
background staining (the average value of the staining in Hsd11b1
del/del
 samples). (A) There 
was a significant reduction in 11β-HSD1 staining in neutrophils from the MKO group. (B) 
There was no significant difference in blood monocyte 11β-HSD1 staining between MKO 
and control groups. Data are means ± SEM and were analyzed by un-paired t-test with 
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6.2.2 Resolution of arthritis was impaired in the MKO mice, 
indistinguishable from that of Hsd11b1del/del mice 
Despite the lack of efficient deletion of 11β-HSD1 in circulating myeloid cells, 11β-
HSD1 is successfully deleted in resident peritoneal macrophages and possibly other 
resident macrophages in MKO mice. To investigate whether deletion of 11β-HSD1 
in tissue macrophages alter the course of K/BxN serum induced arthritis, young adult 
male MKO, ‘floxed’ littermate controls and Hsd11b1
del/del 
mice (with ‘null’ alleles of 
Hsd11b1, see Section 2.2) were i.p. injected with 125μl K/BxN serum per mouse. 
Clinical scoring was used to assess joint inflammation in the following 21 days. 
Ankle joints were harvested for histopathological examination at the end of the 
experiment. 
As shown in Figure 6-4, during the arthritis onset, clinical scores were similar 
between MKO and ‘floxed’ control mice. However, from day 9 onwards, MKO mice 
exhibited a trend to higher clinical scores than ‘floxed’ control mice, which was 




The experiment was repeated in another cohort of mice using a slightly higher dose 
of serum (150μl/mouse), which showed a very similar pattern of arthritis 
development (data not shown). 
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Figure 6-4 Worse inflammation resolution reflected by higher clinical scores in MKO 
compared to control littermate mice during the resolution phase of K/BxN arthritis. 
MKO (n=7), ‘floxed’ control (n=6) and Hsd11b1
del/del 
(n=3) mice were injected with 125μl 
K/BxN serum and joint inflammation was assessed by clinical scoring for 21 continual days, 
blind to genotype. (A) Clinical scores over 21 days. Data in the MKO and control groups are 
means ± SEM and were analysed by repeated measurement 2 way ANOVA with Bonferroni 
post-test. The p value for interaction between time and genotype is p<0.0001. Post-test 
shows a significant difference between MKO and ‘floxed’ control mice from day 13 to day 
18(except day 16). *, p<0.05, **, p<0.01, ***, p<0.001. Only the mean is shown for the 
Hsd11b1
del/del 
group. (B) There was no significant difference in the AUC of clinical scores in 
the MKO and control mice from day 1 to day 21 or (C) from day 1 to day 8. (D) There was a 
higher AUC of clinical scores in MKO mice from day 9 to day 21 compared to controls. 
AUC was calculated when input data were in XY form, then the calculated total area was 
plotted and data were analysed by unpaired t-test. Data are means ± SEM. N=6-7/group; *, 
p<0.05. 
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6.2.3 More advanced fibroplasia in the mesenchymal tissue 
around the joints of MKO mice 
Ankle joints were collected on day 21 after K/BxN serum injection, processed for H 
& E staining and examined for pathological changes with help from Professor 
Donald Salter. More severe pathological changes were found in MKO and 
Hsd11b1
del/del
 mice than in ‘floxed’ controls. There was more advanced fibroplasia in 
the mesenchymal tissue surrounding the joint and tendon sheath in MKO and 
Hsd11b1
del/del
 mice than in controls, with new bone (exostosis) and blood vessel 
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Figure 6-5 Worse fibroplasia and new bone formation in ankle joints of MKO mice.  
In the experiment described in Figure 6-4, ankle joints after 21 days of K/BxN serum 
injection were harvested and processed for H & E staining. The top 2 pictures are 
representative images of joints in one MKO mouse and the bottom 2 are from a control 
mouse. The pictures in the left are taken at 2x magnification and those in the right are taken 
from the boxed area in the left pictures at 20x magnification. Fibroplasia and new bone 
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6.2.4 Synovial fluid leukocyte populations do not differ 
between MKO and control mice 
Synovial fluid leukocyte infiltration dominates the development of K/BxN arthritis, 
with neutrophils and monocytes/macrophages in particular (Ji, Ohmura et al. 2002; 
Chou, Kim et al. 2010; Alexander V. Misharin 2012). A pilot study of synovial fluid 
leukocytes on day 12 following K/BxN serum injection showed that the percentage 
of CD11b
+
 cells (mainly neutrophils and monocytes/macrophages) decreased from 
about 90% of total leukocytes in Hsd11b1
del/del 
and 60% in MKO mice, to about 30% 
in littermate ‘floxed’ controls (each sample was pooled from 2 mice) (Figure 6-6). 
This suggested that high synovial fluid leukocyte count was associated with higher 
clinical scores. 
Therefore, a larger cohort was used to investigate synovial fluid leukocytes in MKO, 
Hsd11b1
del/del 
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Figure 6-6 Higher CD11b
+ 
cell ratios in total synovial fluid leukocytes from 
Hsd11b1
del/del 
(Del I) and MKO mice than ‘floxed’ control mice. 
Synovial fluid leukocytes were harvested 12 days after K/BxN serum injection. The 
percentage of CD11b
+
 cells of total single cells in the synovial fluid is shown for (A) 
Hsd11b1
del/del 
(Del I), (B) MKO and (C) ‘floxed’ control mice. In each graph, a single sample 
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Figure 6-7 No difference in percentage of myeloid cell populations in synovial fluid 
from control, MKO and Hsd11b1
del/del 
mice (‘Del’) on day 11 after K/BxN serum 
injection.  
Synovial fluid leukocytes harvested 11 days after K/BxN serum injection were analysised  






) and 2 














 cells as a percenatge of all the single cells. (B) Ly6g
+
 neutrophils 
as a percentage of all the CD11b
+
 cells. (C) Ratios of  Ly6c
high





). (D) Ratios of Ly6c
low 
cells  in the total monocytes. No differences were 
detected by one way ANNOVA in any of the cell populations except in Figure 6-7A (but no 
difference between any 2 genotypes was found in by Tukey post test). Data are means ± 
SEM. N=6-9 in each group; *, p<0.05. 
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6.3 Discussion 
Neutrophils and macrophages are the main effector cells in the K/BxN serum transfer 
induced arthritis model with arthritis induction dependant on neutrophil expression 
of FcRϒ, C5aR and CD11a/LFA-1 (Monach, Nigrovic et al. 2010). In this model, 
neutrophils are recruited by the lipid mediator LTB4, the cytokine IL-1, and CCR1 
and CXCR2 chemokine ligands (Chou, Kim et al. 2010). The importance of 
monocytes and macrophages in the initiation and resolution of K/BxN arthritis was 
revealed by in vivo cell depletion studies, including studies on CD11b-DTR mice 
(Rajasekaran 2005; Solomon, Rajasekaran et al. 2005; Alexander V. Misharin 2012). 
Although mast cells were initially thought to be important for arthritis initiation from 
studies in mast cell deficient c-kit
W/Wv 
mice (Nigrovic, Binstadt et al. 2007),  mast 
cells were later revealed to be redundant in this model, using mast cell deficient c-
kit
Sh/Sh
 mice (Elliott, Van Ziffle et al. 2011). The initial findings of impaired arthritis 
initiation in mast cell deficient c-kit
W/Wv 
mice were subsequently attributed to 
impaired neutrophil function in the former line of mice. 
There was a trend for lower clinical scores during the onset phase of arthritis in 
MKO mice, although there was no significant difference detected by post-test of 
repeated measurement 2 way ANOVA or by t-test to examine the AUC. This may 
reflect low levels of 11β-HSD1 expression or poor 11β-HSD1 deletion efficiency in 
circulating myeloid cells from MKO mice at the early time of arthritis development, 
or little effect of resident macrophage 11β-HSD1 deletion on the arthritis initiation.  
In the K/BxN arthritis model, resolution of inflammation is less studied than the 
initiation of the disease. Most studies aim to decrease the peak of inflammation 
during arthritis development. Given that failed resolution often causes chronic 
disease, it is important to elucidate the mechanisms of inflammation resolution. In 
the resolution phase of inflammation, phagocytosis of apoptotic cells by 
macrophages is essential for inflammation resolution (Uderhardt, Herrmann et al. 
2012). A previous study demonstrated delayed acquisition of macrophage phagocytic 
ability in globally 11β-HSD1 deficient mice (Gilmour, Coutinho et al. 2006). This 
may be due to decreased GC signalling within macrophages, which promotes 
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macrophage phagocytosis (Giles, Ross et al. 2001). As shown here, impaired 
resolution without higher inflammatory altitude in MKO mice resulted in worse 
pathological fibroplasia, more new bone formation and greater angiogenesis. This 
may reflect deficient phagocytic ability of 11β-HSD1 deficient macrophages in 
clearing inflammatory neutrophils in MKO mice and it is possible that 11β-HSD1 
deficiency in tissue resident macrophages contributes to this phenotype. So far, 
evidence supports good deletion of 11β-HSD1 protein in tissue resident macrophages 
(as shown in Chapter 4), while there is only about 50% deletion of 11β-HSD1 in 
circulating neutrophils and little deletion in monocytes. In a previous bone marrow 
transfer experiment between globally 11β-HSD1 deficient and C57Bl/6 mice, a trend 
of impaired arthritis resolution was seen in globally 11β-HSD1 deficient mice re-
constituted with wild type bone marrow cells, compared to C57Bl/6  recipient mice 
receiving 11β-HSD1 deficient bone marrow cells (Coutinho 2009). 
Similar results were found in another inflammatory model in globally 11β-HSD1 
knockout mice. In a study of LPS induced lung inflammation, there was no 
difference in the peak inflammation between global 11β-HSD1 knockout and control 





 monocytes was found in the lungs of the knockout 
mice, indicative of failed inflammation resolution (Lax, Wilson et al. 2012).  
The lack of change in myeloid cell populations in the synovial fluid between MKO 
and control mice awaits further investigation. There were some problems in the 




 neutrophil population 
was plotted in the side scatter channel (SSC) and forward scatter channel (FSC), 
there were 2 distinct populations of cells, which was not observed in the pilot 
experiment and puzzling. The reason was not clear. Cytospin examination of 
synovial fluid leukocytes may help clarify this. In addition, there was also likely 
some contamination with blood, as red cells were observed after centrifugation. 
In a human RA study, 11β-HSD1 enzyme activity was positively correlated with 
erythrocyte sedimentation rate, a marker of disease activity (Hardy, Rabbitt et al. 
2008). Increased 11β-HSD1 may be a protective mechanism to suppress 
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inflammation by generating more active GC. However, in that study, 11β-HSD1 
expression was shown by immunofluorescence staining, to be located in fibroblasts 
rather than macrophages, whilst 11β-HSD2 was localised in macrophages. Up-
regulation of Hsd11b2 mRNA in the blood monocytes was reported in early RA 
patients (Olsen, Sokka et al. 2004). This is an interesting phenomenon, as mouse 
macrophages usually express 11β-HSD1 but not 11β-HSD2 (Gilmour, Coutinho et 
al. 2006; Usher, Duan et al. 2010) and human monocytes from healthy donors 
expressed 11β-HSD1 during in vitro differentiation into macrophages (Thieringer, Le 
Grand et al. 2001; Chinetti-Gbaguidi, Bouhlel et al. 2012). The presence of 11β-
HSD2 but not 11β-HSD1 in synovial macrophages of RA patients may be a result of 
disease modification or drug treatment. However, it is possible that immunostaining 
is not sensitive enough to pick up the lower 11β-HSD1 levels in macrophages than 
those in fibroblasts. The study here indicates that the anti-inflammatory effects of 
11β-HSD1 in K/BxN arthritis should be attributed to macrophages, rather than 
fibroblasts, although there is a chance that induction of fibroblast 11β-HSD1 is 
impaired by macrophage 11β-HSD1 deficiency in the current study.  
Without a clear aetiology of RA, all current animal models have drawbacks in 
mimicking the human disease, including the K/BxN serum induced arthritis model 
(reviewed by (Wekerle, Flugel et al. 2012)). Therefore, a possible role of fibroblast 
11β-HSD1 in other types of arthritis models is not excluded. First, the auto-antibody 
is not generated de novo in mice, but administered artificially. The disease 
development is self-limited and highly depends on the titration of the antibody. 
Second, the inflammation mainly depends on neutrophils and macrophages, not T or 
B cells. This is more like self-resolving arthritis and other none-RA arthritis in 
humans rather than RA. Last, but not least, is that fibroplasia in K/BxN arthritis is 
wide-spread and extends beyond the joint, involving the mesenchymal tissue along 
the bones and tendon sheath. Indeed, the damage in this area is more pronounced 
than in the joint itself (personal communication, Dr. David Brownstein and Professor 
Donald Salter).   
 
Chapter 6: Impaired resolution of K/BxN serum transfer induced arthritis in MKO 
mice  145 
A limitation of this study is that circulating neutrophils showed about 50% deletion 
of 11β-HSD1. Actually the current study cannot dissect the roles of macrophages and 
neutrophils. What’s more, it is not entirely clear that the phenotype is down to an 
altered GC signalling pathway, although this is the putative pathway altered by 11β-
HSD1. A study on LysM-Cre GR
flox/flox 
mice in adjuvant induced arthritis showed no 
difference in arthritis development (both initiation and resolution) compared to 
control ‘floxed’ mice (Baschant, Frappart et al. 2011). This suggests that in arthritis 
models involving both innate and adaptive immune cells, the influence of 
endogenous GC action in myeloid cells is limited. To test whether this phenotype is 
because of GC signalling in macrophages, in addition to a K/BxN arthritis study in 
LysM-Cre GR
flox/flox 
mice, macrophage specific delivery of GCs by liposome 
encapsulation could be administered into MKO mice during arthritis resolution to 
test whether this would promote arthritis resolution. 
In summary, clinical scoring indicated impaired resolution of K/BxN arthritis in 
MKO mice with advanced histopathological changes in the joint with pronounced 
fibroplasia in the mesenchymal tissues surrounding the joints, possibly due to tissue 
resident macrophage 11β-HSD1 deficiency. It suggests that impaired resolution 
alone, without increased peak inflammation, could result in a poor prognosis and that 
GC signalling in tissue resident macrophages can boost the ability of macrophages to 
dampen inflammation.
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Chapter 7: Less subcutaneous adipose fibrosis 
in high fat fed MKO mice  
7.1 Introduction 
Increased adipose tissue 11β-HSD1 activity has been implicated in the pathogenesis 
of metabolic syndrome (Engeli, Bohnke et al. 2004). The predominant theory to 
explain the link between high 11β-HSD1 enzyme activity and metabolic diseases, 
supported by evidence from transgenic mice overexpressing Hsd11b1 in adipose 
tissue, is that elevated 11β-HSD1 activity increases GC signalling in adipocytes, 
which in turn antagonizes insulin signalling, leading to dysregulated glucose and 
lipid homeostasis and accumulation of visceral adipose tissue (Morton and Seckl 
2008). As several clinical trials of 11β-HSD1 inhibitors are on-going for treatment of 
metabolic diseases, it is crucial to gain more understanding of the underlying 
mechanisms through basic research, for example, identification of the target tissue to 
inhibit 11β-HSD1 to generate beneficial effects upon metabolism. 
The liver gained attention as a target in studies related to glucose homoeostasis and 
type 2 diabetes, as 11β-HSD1 is most highly expressed in the liver and the original 
paper describing the globally 11β-HSD1 deficient mice showed lower fasting 
glucose levels with decreased liver glucose 6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK) activity, key enzymes in 
gluconeogenesis (Kotelevtsev, Holmes et al. 1997). However, liver specific Hsd11b1 
KO mice failed to recapitulate these phenotypes (Lavery, Zielinska et al. 2012), 
although they were protected against 11-dehydrocorticosterone induced insulin 
resistance (Harno, Cottrell et al. 2013). 
Several ‘metabolically protective’ mechanisms conferred by 11β-HSD1 deficiency in 
high fat fed mice have been uncovered in the white adipose tissue, including more 
lipid oxidation and less inflammation (Wamil, Battle et al. 2011), more angiogenesis 
and less fibrosis (Michailidou, Turban et al. 2012). However, it is unknown whether 
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this reflects an effect in adipocytes themselves or in the residing immune cells, 
especially macrophages.  
Adipose tissue macrophages are important to maintain of normal insulin sensitivity, 
with a protective role for alternatively activated macrophages (M2) and a harmful 
role for classically activated macrophages (M1) (Wu, Molofsky et al. 2011; 
Molofsky, Nussbaum et al. 2013). Secreted inflammatory cytokines from 
accumulated inflammatory macrophages activate NFκB signalling in adipocytes, 
which is possible to blunt the insulin signalling pathway (Olefsky and Glass 2010; 
Tabas and Glass 2013).  
To dissect the in vivo effect of macrophage 11β-HSD1 deficiency upon metabolic 
disease, a high fat diet (HFD) induced obesity experiment was carried out in MKO 
and control mice. Male MKO and littermate control ‘floxed’ mice (8-10 weeks old) 
were subject to 14 week HFD feeding. Body weight was measured weekly from the 
first week until week 14. A glucose tolerance test (GTT) was carried out in week 13 
before the mice were culled for tissue collection in week 14. 
 
7.2 Hypothesis 
Myeloid cell 11β-HSD1 deficiency partly or fully accounts for the metabolic 
protective effects of global 11β-HSD1 deficiency, such as improved insulin 
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7.3 Results 
7.3.1 Similar body weight and tissue weight between MKO 
and control mice 
There was no difference in body weight between MKO and control mice through the 
HFD experiment. Tissues were collected and weighed before being fixed or frozen at 
the end of the experiment. There was no difference in tissue to body weight ratios 
between MKO and control groups in any of the tissues examined: subcutaneous 
adipose tissue (Figure 7-2A), epididymal adipose tissue (Figure 7-2B), mesenteric 
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Figure 7-1 Similar body weight between MKO and control mice during 14 weeks of 
high fat diet feeding.  
Body weight was monitored weekly during 14 week high fat diet feeding. Red square 
symbols show MKO mice and black round symbols show control mice. Data are means ± 
SEM, n=5-7. Data were analysed by repeated measurement 2-way ANOVA. There was no 
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Figure 7-2 Similar tissue and organ weights in MKO and control mice.  
At the end of the 14 week HFD experiment, tissues were harvested from the mice and 
weighted. There was no difference in (A) subcutaneous (SC), (B) epididymal (Epi) or (C) 
mesenteric adipose tissue (MES), (D) liver or (E) spleen tissue to body weight ratios between 
genotypes. Data are means ± SEM, n=5-7. Data were analysed by unpaired t-test with 
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7.3.2 Similar circulating glucose and insulin levels during 
GTT in MKO and control mice 
A GTT was carried out in week 13 of the experiment. Tail bleeding was carried out 
at each time point to collect blood for plasma glucose and insulin measurement in the 
lab, in addition to the onsite measurement of whole blood glucose levels with a 
glucose meter. Plasma glucose and insulin measurements were carried out by Dr. 
Sophie Turban. 
The limited detection range of the glucose meter resulted in some readings of ‘HI’ 
without a numerical value, whereas in the plasma glucose ELISA assay, 
haemoglobin contamination in some samples caused artificially high glucose levels. 
For these situations, the relevant data were excluded from the analysis. As some data 
points were missing, no statistical tests were performed in the glucose measurements. 
There did not appear to be any difference in glucose levels between MKO and 
control mice (Figure 7-3), but the missing data may alter the current judgement. 
Insulin levels in plasma samples from each time point were measured and there was 
no difference between MKO and control groups by repeated measurement 2 way 
ANOVA (7-4A) or by comparing the area under the curve (AUC, Figure 7-4B). 
 








































































Figure 7-3 Similar blood and plasma glucose levels during GTT between MKO and 
control mice.  
Young male MKO and control littermate mice were subject to a 14 week HFD experiment 
with GTT carried out in week 13. Circulating glucose levels were measured by glucose 
meter in blood (A) and by ELISA in the plasma (B). There are 3 out of 25 and 35 readings in 
the MKO and control groups unavailable in (A), respectively. There are 6-8 out of 25 and 35 
readings unavailable in the MKO and control groups in (B), respectively. Data are means ± 
SEM, n=5-7/group. 
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Figure 7-4 Similar plasma insulin levels during GTT between MKO and control mice.  
During the experiment described in Figure 7-3, plasma insulin levels were measured by 
GTT. (A) There was no significant difference between genotypes by repeated measurement 
2-way ANOVA. (B) The AUC of insulin levels between MKO and control mice during GTT 
was not different by unpaired t-test. Data are means ± SEM, n=4-6/group. There was 1out of 
25 and 35 readings unavailable in the MKO and control groups, respectively and thus all the 
readings from the same mouse are not included in the graph. 
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7.3.3 No difference in macrophage related gene expression in 
mesenteric adipose tissue between MKO and control 
mice  
Mesenteric adipose tissue was chosen for RNA analysis because inflammation is 
considered to be more pronounced here than in subcutaneous adipose tissue (Wamil, 
Battle et al. 2011). Between MKO and control mice, there was no difference in levels 
of the macrophage marker Cd68, the hypoxia response marker Hif1a, the angiogenic 
factor Vegfa, or in inflammatory M1 makers Tnfa or Nos2 (Il6 expression was too 
low to measure). There was no difference in alternative M2 markers Mrc1 (mannose 






































































Figure 7-5 No difference in macrophage related gene expression levels in mesenteric 
adipose tissues from MKO and control mice.   
At the end of the 14 week HFD experiment, tissues were harvested for analysis with 
mensentric adipose tissue gene expression examined by qPCR. There was no difference in 
levels of Cd68, Hif1a, Vegfa, Tnfa, Nos2, Mrc1 or Fizz1 mRNA between genotypes. Data 
are means ± SEM, N=5-7/group. Data were analysed by un-paired t-test for each individual 
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7.3.4 Subcutaneous adipose tissue from MKO mice shows 
decreased fibrosis but similar cell size to control mice. 
To further study adipose tissue remodeling, picrosirius red staining was carried out 
on sections from subcutaneous inguinal depots to visualize collagen deposition, a key 
feature of fibrosis. In addition, cell size was also measured in these sections. The 
quantification of the staining was done by Mr. Oliver Brown, an undergraduate 
project student. There was less collagen deposition in adipose tissue from MKO 
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Figure 7-6 Reduced collagen content but similar adipocyte size in the subcutaneous 
adipose tissues from MKO mice, compared to littermate controls.   
Picrosirius red staining was performed on sections of subcutaneous adipose tissues collected 
after 14 week HFD and collagen content and adipocyte size were analysed by ImageJ. (A) 
There was reduced collagen content in MKO mice compared to controls. Data were analysed 
by unpaired t-test, with significance set at p<0.05. Data are means ± SEM, n=3-5/group. **, 
p<0.01. (B) There was no difference in adipocyte sizes between genotypes. Data are means ± 
SEM, n=3/group. Data were analysed by unpaired t-test, with significance set at p<0.05. (C 




Chapter 7: Less subcutaneous adipose fibrosis in high fat fed MKO mice  159 
7.4 Discussion 
MKO mice showed a similar body weight to their littermate controls during the 14 
week HFD experiment. This was associated with similar organ and tissue weights at 
the end of the experiment. The results differed from previous data in  globally 11β-
HSD1 deficient mice which showed reduced body weight gain and reduced 
mesenteric adipose tissue weight after HFD, compared to wild type controls (Morton, 
Paterson et al. 2004; Wamil, Battle et al. 2011). However, both the original 11β-
HSD1 deficient mice and Hsd11b1
del/del 
mice (with null alleles of Hsd11b1) failed to 
show the previous difference in an HFD experiment in parallel to this one (data not 
shown). In terms of glucose metabolism, the GTT data are not conclusive in MKO 
mice but there is no suggestion that their glucose or insulin levels differed from 
control littermates. This again contrasts with globally 11β-HSD1 deficient mice 
which showed lower glucose levels during both GTT and insulin tolerance test (ITT) 
(Morton, Paterson et al. 2004). 
In the gene analysis of mesenteric adipose tissues, there were no differences found 
between genotypes, whereas higher Vegfa and lower Hif1a were reported in the 
white adipose tissues of HFD fed globally 11β-HSD1 deficient mice compared to 
wild type controls (Michailidou, Turban et al. 2012). Although a gene array from a 
previous study concluded that inflammation was reduced in mesenteric adipose of 
11β-HSD1 deficient mice after HFD feeding, the reported changes were not in the 
familiar immune genes examined in the current study, such as Tnfa, Mcp1, Il6, Il10 
or Arg (Wamil, Battle et al. 2011). It awaits future examination whether the reported 
decreased levels of Marco, Stat4 and L-sel mRNA occurred in the MKO adipose 
tissues. Decreased macrophage infiltration was reported in the same paper, but again 
this is not suggested by Cd68 mRNA measurement in the current study on MKO 
mice. It is of note that CD11b as a marker for adipose macrophages in the report is 
likely to be unspecific, as neutrophils are also evident in the cytospins of separated 
CD11b
+
 cells (data not shown here). However, the reduction in tissue fibrosis in 
subcutaneous adipose tissue of MKO mice is similar to that previously described in 
globally 11β-HSD1 deficient mice (Michailidou, Turban et al. 2012). These results 
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suggest that macrophage 11β-HSD1 deficiency contributes to only part of the 
adipose tissue phenotype of globally 11β-HSD1 deficient mice.  
There are several suggestions that macrophage 11β-HSD1 may not play an important 
role in HFD induced obesity. Inflammation in the adipose tissue of 11β-HSD1 
deficient mice was found to be reduced in the microarray study with reduced 
infiltration of cytotoxic T cells and macrophages. But in separated macrophages from 
the adipose tissue, there were no differences in levels of inflammatory mRNA or 
cytokine release (Wamil, Battle et al. 2011). In terms of 11β-HSD1 expression in 
adipose tissue stromal cells, a previous immunofluorescence staining study from the 
lab has shown that 11β-HSD1 co-localises with p27kip1 positive pre-adipocytes with 
little 11β-HSD1 expression in  the F4/80 positive macrophage population (De Sousa 
Peixoto, Turban et al. 2008).  These studies do not support an important role of 
adipose macrophage 11β-HSD1 to reduce inflammation in globally 11β-HSD1 
deficient mice.  
However, the experiment is restricted in some ways and does not allow a final 
conclusion. First, the n number in each group is low. There were only 5 MKO mice 
and 7 littermate controls and some data were missing in the GTT results. Second, in a 
parallel HFD experiment to the study, no reported improved insulin signalling was 
found in the globally 11β-HSD1 deficient mice (data not shown here). Third, most 
infiltrated macrophages in the adipose tissue arise from bone marrow derived 
monocytes (Koh, Kang et al. 2007) and 11β-HSD1 deletion efficiency is not likely to 
be high in these macrophages.  
Searching for the target tissue which confers the beneficial metabolic effect in 
globally 11β-HSD1 deficiency has turned out to be a challenging task. So far, brain, 
adipose, liver and macrophage specific 11β-HSD1 deficient mice have failed to 
replicate the phenotype (Lavery, Zielinska et al. 2012; Erika Harno 2013) 
(unpublished data from our lab). Given the recent discovery that osteocalcin from 
osteoblasts underlies the protection from GC induced glucose intolerance in Col2.3-
11β-HSD2 Tg mice (Brennan-Speranza, Henneicke et al. 2012), it is reasonable to 
 
Chapter 7: Less subcutaneous adipose fibrosis in high fat fed MKO mice  161 
propose a role for bone 11β-HSD1 in glucose metabolism. Another possible target is 
skeletal muscle. Previous studies showed a role for muscle 11β-HSD1 in insulin 
signalling and protein degradation (Morgan, Sherlock et al. 2009; Biedasek, Andres 
et al. 2011). Combined deletion of 11β-HSD1 in liver and adipose tissue may be 
needed to recapitulate the phenotype of globally 11β-HSD1 deficient mice, as 11β-
HSD1 is highly expressed in both places and there is a possible cross-talk between 
liver and adipose tissue 11β-HSD1 (unpublished data, Professor Karen Chapman).  
In summary, the preliminary data from MKO mice on 14 week HFD experiment do 
not show differences in body or tissue weights, or GTT results compared to controls. 
Thus myeloid cell 11β-HSD1 deficiency does not contribute to improved insulin 
signalling in globally 11β-HSD1 deficient mice. However, the study does reveal 
reduced fibrosis in subcutaneous adipose of MKO mice after HFD feeding, which 
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Chapter 8: Summary and Discussion 
8.1 Summary 
In this thesis, the role of 11β-HSD1 in macrophages was first studied during in vitro 
M1/M2 macrophage polarisation and hypoxic conditioning experiments, to compare 
day 3 TG elicited macrophages from 11β-HSD1 deficient and control C57Bl/6 mice. 
In control macrophages, levels of 11β-HSD1 protein were found to be similar 
between M1 and M2 polarised macrophages, despite higher Hsd11b1 mRNA levels 
in M1 than M2 polarised macrophages. It is also surprising that although expression 
of some M1 genes was increased and that of some M2 genes decreased in 11β-HSD1 
deficient macrophages, compared to controls, no evidence of changed M1/M2 
polarisation was found in ELISA or western blotting measurements (except for 
decreased IL-12 p40). Upon inflammatory stimulation under hypoxic conditions, 
11β-HSD1 deficient and control macrophages showed similar expression levels of 
genes related to inflammatory, angiogenic, fibrotic and metabolic responses.  
To directly study macrophage 11β-HSD1 in vivo, macrophage specific Hsd11b1 
knockout mice (MKO) were introduced. The deletion efficiency of 11β-HSD1 was 
examined in different macrophage populations. There was no effective deletion 
(>50%) at 11β-HSD1 protein or enzyme activity levels in TG elicited myeloid cells 
from MKO mice, albeit decreased Hsd11b1 mRNA levels (>80%). A modest 
decrease was found in bone marrow derived macrophages of MKO mice (~50% in 
both enzyme activity and mRNA levels). However, resident peritoneal macrophages 
from MKO mice exhibited >80% reduction in 11β-HSD1 enzyme activity and 
protein levels. Other tissue resident macrophage populations were studied as well, 
but there was no detectable 11β-HSD1 protein in alveolar macrophages and no 
evidence of high deletion efficiency in adipose macrophages. 
The inflammatory angiogenesis response was studied in MKO and control ‘floxed’ 
littermate mice using subcutaneous implanted sponges. In the sponges harvested 21 
days later, evidence of increased angiogenesis was found in the MKO mice by both 
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Chakley counting of blood vessels and qPCR measurement of the endothelial marker 
Cdh5. In qPCR measurements, no difference in Vegfa levels was found, nor was 
there a difference in levels of mRNA encoding the macrophage marker Cd68 or other 
inflammatory genes with the notable exception of higher pro-angiogenic Il1b mRNA 
in MKO mice. 
The role of macrophage 11β-HSD1 in an inflammatory response was studied using 
the K/BxN serum transfer induced arthritis model. A longitudinal blood flow 
cytometry study to measure levels of myeloid cell 11β-HSD1 failed to show 
increased 11β-HSD1 deletion with arthritis development in MKO mice, with a 
consistent ~50% deletion in neutrophils and much less in monocytes of MKO mice. 
Using clinical scoring to access joint inflammation, it was found that arthritis 
resolution is impaired in MKO mice. Histopathological examination of ankle joints 
confirmed this and pointed out more advanced fibroplasia in the mesenchymal 
tissues around the joints. Examination of joint RNA showed higher levels of yhr 
endothelial cell marker Cdh5, suggesting increased angiogenesis activity. However, a 
flow cytometry study of day 11 joint synovial fluid leukocytes did not detect the 
expected increase in composition of myeloid cells in MKO. 
To study metabolic diseases associated with chronic GC excess, MKO and control 
littermate ‘floxed’ mice were subjected to high fat diet feeding to generate obesity. 
After 14 weeks of high fat diet feeding, there was no difference in body weight or 
organ weight between genotypes, nor was there a difference in blood glucose or 
insulin levels in a GTT. There was no change in levels of mRNA encoding 
inflammatory markers in the mesenteric adipose tissue between genotypes either. 
The only phenotype related to protection from metabolic diseases found in obese 
MKO mice was reduced fibrosis in the subcutaneous adipose tissue, with no change 
in adipocyte size. 
 
 
Chapter 8: Summary and Discussion  164 
8.2 Macrophage 11β-HSD1 in inflammatory signalling 
study 
The lack of difference during in vitro macrophage studies on TG elicited peritoneal 
11β-HSD1 deficient and wild type macrophages is not able to explain the changed 
inflammatory disease course in the MKO mice. The effects of macrophage 11β-
HSD1 deficiency would be more interpretable if studied in vivo with simpler 
inflammatory models, such as LPS or zymosan induced peritonitis. For example, the 
inflammation onset and resolution phases of both zymosan induced peritonitis have 
been well characterised, with macrophage phenotypes similar to M1 and M2 
(Bystrom, Evans et al. 2008). Poor 11β-HSD1 deletion efficiency in recruited 
macrophages of MKO mice hindered such studies. However, resident peritoneal 
macrophages were suggested to be involved in zymosan induced peritonitis, in which 
macrophages showed the characteristic proliferation behaviour of resident 
macrophages (Davies, Rosas et al. 2011); this model would be worthy of study. 
Alternatively, effective 11β-HSD1 deficiency restricted to immune cells (including 
macrophages) can be achieved with bone marrow transfer experiment between 11β-
HSD1 deficient and wild type mice. However, bone marrow radiation is not specific 
to deplete bone marrow derived monocytes/macrophages. In addition, irradiation 
may have its own effect and tissue resident macrophages may also be affected.  
The active GC generated by 11β-HSD1 in macrophages may act through GR or MR 
to modulate inflammation development. It was shown in an in vitro study that a low 
dose of corticosterone (<1nM) increases inflammation and high dose of 
corticosterone (>10nM) suppresses inflammation, both effects of which are elicited 
by GR, not MR (Lim, Muller et al. 2007). Given the fact of basal circulating active 
GC levels in vivo, it is likely that MR is saturated and GR exerts anti-inflammatory 
effects in physiological situations. Therefore, 11β-HSD1 generated active GC in 
macrophages is likely to bind with GR to suppress inflammation, but this awaits 
examination. As 11β-HSD1 can also metabolise cholesterol and bile acids, apart 
from GR and MR, LXR and FXR are also possible affected targets in 11β-HSD1 
deficient macrophages. More information on this topic will be discussed in Section 
8.4. 
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The hedgehog pathway in macrophages is worth further study. In addition to the 
hedgehog ligands (IHH, SHH and DHH) and receptor patched measurement, it is 
important to measure the induced transcription factor Gli1 at target cells. In tissues in 
vivo, macrophages are more likely to be a source of the hedgehog ligands to act on 
the surrounding cells, such as endothelial cells, pericytes or fibroblasts. Co-culture of 
macrophages and target cells or using the macrophage culture medium to stimulate 
target cells is a way to further study influence of macrophage 11β-HSD1 deficiency 
on this signalling pathway. 
 
8.3 Macrophage 11β-HSD1 in cardiovascular study 
It was surprising that increased angiogenesis was observed in the MKO mice in the 
angiogenesis assay of sponge implantation. Hsd11b1 mRNA is expressed in smooth 
muscle cells of the aorta (Christy, Hadoke et al. 2003), but angiogenesis experiments 
carried out in Sm22-Cre Hsd11b1
flox/flox 
mice did not show a difference in either in 
vivo (hind leg ischaemic model) or in vitro models (aorta ring assay) (personal 
communication, Dr. Patrick Hadoke, University of Edinburgh). The results from 
MKO mice highlighted the importance of macrophage 11β-HSD1 in regulation of 
angiogenesis. However, the extent of increased angiogenesis in MKO mice is likely 
to be smaller than globally 11β-HSD1 deficient mice, by comparing with the 
reported day 21 Chalkley counting data (Small, Hadoke et al. 2005). What’s more, in 
a myocardial infarction experiment carried out in MKO mice by Dr. Gillian Gray’s 
group, there was no improvement in cardiac performance of MKO mice, in contrast 
to globally 11β-HSD1 deficient mice. It is unknown whether incomplete macrophage 
11β-HSD1 deficiency in MKO mice or 11β-HSD1 deficiency in other places in 
globally 11β-HSD1 deficient mice is responsible for the differences. Role of 
endothelial cell 11β-HSD1 awaits future examination, the expression of which was 
confirmed by immunohistochemical staining in blood vessels (Luo, Thieringer et al. 
2013). 
In terms of atherosclerosis, a bone marrow transfer experiment between 11β-HSD1 
KO and wild type mice revealed protection against atherosclerosis by 11β-HSD1 KO 
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bone marrow cells, suggesting macrophages are involved in atherosclerosis with 11β-
HSD1 deficiency (Garcia, Search et al. 2013; Kipari, Hadoke et al. 2013). Other 
candidates include liver and adipose tissue, which are important places for lipid and 
cholesterol metabolism and highly enriched for 11β-HSD1. However, myeloid cell, 
but not liver or adipose specific 11β-HSD1 knockout mice (using LysM-Cre, 
Albumin-Cre and Ap2-Cre, respectively) in the Apoe
-/-
 genetic background were 
protected from atherosclerosis development (unpublished data, Professor Karen 
Chapman). Whether macrophage 11β-HSD1 has a direct role in cholesterol 
metabolism can be investigated by lipomics analysis of the atherosclerosis plaque or 
foam macrophages from 11β-HSD1 deficient and wild type mice, but data from 
Kipari et al support increased cholesterol efflux in 11β-HSD1 deficient macrophages.  
 
8.4 Macrophage 11β-HSD1 in arthritis 
The impaired resolution of K/BxN serum transfer induced arthritis found in MKO 
mice appear to be in contrast to a previous report of lack of difference with LysM-
Cre mediated GR knockout during glucose-6-phosphate isomerase antigen induced 
arthritis (Baschant, Frappart et al. 2011), although the latter involves not only innate 
but also adaptive immune cells. It raised the question that whether endogenous GCs 
are important in some type of arthritis (inflammatory arthritis) but not others 
(rheumatoid arthritis). This was similar to findings in an atherosclerosis study, where 





 bone marrow cells but with reduced blood vessel calcification 
(Preusch, Rattazzi et al. 2008). Protection from atherosclerosis in LysM-Cre 
Hsd11b1
flox/flox 
mice suggests that the effect of 11β-HSD1 in macrophages may not be 
via the classic substrate 11-DHC, or 11β-HSD1 generated GCs in macrophages bind 
to MR rather than GR. In addition, the drawback of the experiment is bone marrow 
transfer method is inclusive on role of resident macrophage GR. 
Study on myeloid cell MR or GR knockout mice in the K/BxN arthritis model will 
give help clarify the target of 11β-HSD1. Myeloid cell MR knockout mice are 
protected from several types of inflammation associated-adverse tissue remodelling 
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(Rickard, Morgan et al. 2009; Frieler, Meng et al. 2011; Frieler, Ray et al. 2012). 
Studies of neural inflammation in brain of LysM-Cre Nr3c1
flox/flox 
 mice yielded 
conflicting results on role of macrophage GR expression. In studies from Sheela 
Vyasa’ group, these mice suffered from more dopaminergic neuron loss following 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication treatment (Ros-Bernal, 
Hunot et al. 2011) and worse inflammation following LPS treatment (Carrillo-de 
Sauvage, Maatouk et al. 2013), whereas studies from Robert M. Sapolsky’s group 
showed little or even protective effect of myeloid cell GR deletion in kainic acid 
induced excitotoxic injury model and focal cerebral ischemia model (Sorrells, Caso 
et al. 2013). 
It is also worth noting that although very successful in relieving the inflammatory 
symptoms for a short time period, they have limited long term efficacy on disease 
progression (Townsend and Saag 2004). This is different to rodent studies, where 
disease progression is usually dramatically regressed associated with reduced 
inflammation following GC treatment. An understanding of the underlying 
mechanism behind the difference of GC’s effects on animal and human arthritis 
would be helpful in clinics. Although there may be simple explanations such as more 
complex pathological activities in human arthritis, it is also possible that repeated 
administration of GCs in humans causes GC to lose properties required to modify 
disease progression but retain the ability to suppress inflammation.  
 
8.5 Macrophage specific 11β-HSD1 deficiency in 
metabolism  
Although preliminary data did not suggest a difference in GTT between MKO and 
control mice, it would be good to repeat the experiment with a larger group of mice. 
Based on the increased ‘inflammatory’ angiogenesis and impaired resolution of 
K/BxN arthritis, more inflammation and possible worse glucose metabolism would 
be expected in MKO mice on high fat diet feeding. However, less subcutaneous 
adipose fibrosis in MKO mice after HFD feeding is an indication of better adipose 
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remodelling, similar to that reported in the globally 11β-HSD1 deficient mice 
(Michailidou, Turban et al. 2012).   
There is some evidence supporting that some degree of inflammation can be 
beneficial for glucose metabolism, although inflammation is generally believed to 
disrupt insulin sensitivity. For example, overexpression of NF-kB p65 (RelA) in 
adipose tissue in aP2-p65 transgenic mice or global inactivation of NF-kB p50 (NF-
kB1) are both protective against insulin resistance with HFD feeding, despite 
elevated inflammatory cytokines (TNFα and IL6) in adipose tissues and serum 
(Tang, Zhang et al. 2010). Conversely, Il6
-/-
 mice develop obesity, hepatosteatosis, 
liver inflammation and insulin resistance (Matthews, Allen et al. 2010) and IL6 was 
shown to be able to stimulate glucagon-like peptide-1 secretion (Ellingsgaard, 
Hauselmann et al. 2011). The IL6 secretion from adipocytes of globally 11β-HSD1 
deficient mice was lower in chow fat diet feeding than the controls, but increased 
after HFD feeding, in contrast to the decrease in controls (Wamil, Battle et al. 2011). 
 
8.6 Future studies 
Increased 11β-HSD1 by various cytokines in leukocytes, especially in macrophages, 
is a possible endogenous brake to limit inflammation development. One of the likely 
mechanisms is that amplified GC action in macrophages would enhance the ability of 
macrophage phagocytosis to clear inflammatory cells. A better understanding of 
human monocyte/macrophage 11β-HSD1 expression in physiological and 
pathological conditions would help to exploit this for inflammatory disease 
treatment.  
Healthy human monocytes can be induced to express 11β-HSD1 by in vitro 
treatment with IL4, TNFα, etc. and don’t express 11β-HSD2 (Thieringer, Le Grand 
et al. 2001; Chinetti-Gbaguidi, Bouhlel et al. 2012).  In human rheumatoid arthritis 
patients, blood monocyte 11β-HSD2 is transiently up-expressed in the early disease 
development (Olsen, Sokka et al. 2004) and synovial macrophages are found to co-
express 11β-HSD1 and 11β-HSD2 (Schmidt, Weidler et al. 2005) or only 11β-HSD2 
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(Hardy, Rabbitt et al. 2008). This shift from 11β-HSD1 to 11β-HSD2 expression in 
macrophages between healthy and rheumatoid arthritis donors may be due to disease 
modification or drug treatment. And reduced ability to generate active GCs would 
perpetuate inflammation development. Ways of reversing this expression pattern, for 
example large dose of GC administration may benefit patients, as it reduces 11β-
HSD2 but increases 11β-HSD1 expression (reviewed by (Chapman, Holmes et al. 
2013)). It would be interesting to examine leukocyte, especially macrophage 11β-
HSD1/11β-HSD2 expression in other inflammatory diseases such as systemic lupus 
erythematosus.  
As evidence for high induction of 11β-HSD1 by inflammation in activated 
neutrophils is emerging (Chapman 2011), another area worthy of study is neutrophil 
11β-HSD1 function. Neutrophil specific gene deletion can be achieved using Mrp8-
Cre mice (Elliott, Van Ziffle et al. 2011). Although cortisone is showing little effect 
in delaying healthy human neutrophil apoptosis after overnight incubation (my data, 
not shown here), it appears possible that during inflammatory disease settings, 11β-
HSD1 activity would be induced in neutrophils as happened at the RNA level after 
LPS stimulation (my data, not shown here).  
From a translational point of view, one of the important implications from the study 
is that macrophages represent good targets for GCs. Macrophage targeted GC 
administration such as liposome encapsulated GC (which is already on the way 
(Crielaard, Lammers et al. 2011)), could provide lots of similar benefits to that of 
systemic GC use such as anti-inflammation and suppression of angiogenesis. In this 
way, metabolic side effects of GC use in clinics may be avoided. Regarding the use 
of 11β-HSD1 inhibitors to treat metabolic disease, this study raises caution of their 
possible side effects to delay recovery from inflammatory diseases. 
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Flow cytometry gating method 
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Blood myeloid cell gating method 
Singlet cells were gated in the samples before CD45
+ 
population was gated. Myeloid 
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Synovial fluid leukocytes gating method 



























Synovial fluid leukocytes gating method 
Singlet cells were first gated from total cells. CD11b antibody was then used to gate 
myeloid cells. In the CD11b
+
 myeloid cells, Ly6g antibody was used to gate 








cells assigned as 
monocytes/macrophages. This monocyte/macrophage population is further stained 
with F4/80 and Ly6c. 
 
